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SUMMARY
The epoxyeicosatrienoic acids (EETs) are a group of 
four regio-isomeric cytochrome P4 so metabolites of 
arachidonic acid. Since their first isolation and 
identification in rabbit hepatic microsomal incubation 
medium in 1982, investigations into their biological 
functions have been limited.
Following the successful synthesis of the EETs, 
separation by TLC and identification by GC-MS, all four
isomers were tested for biological activity in rat
thoracic aortic strips, guinea-pig tracheal rings and rat 
washed platelets.
All four EETs were found to relax phenylephrine 
pre-contracted aortic strips in a dose-dependent manner. 
5(6)-EET was observed to be significantly more potent 
than the other three isomers especially in aortic strips 
with an intact endothelial lining. Removal of the
endothelium was found to reduce the potency of 5(6)-EET 
whilst having no effect on the relaxations induced by the 
other EETs. Inhibition of eyelo-oxygenase activity with 
indomethacin also inhibited 5(6)-EET-induced relaxations, 
whereas NDGA, a lipoxygenase inhibitor, had no effect on 
any of the EET-induced responses. Inhibition of
cGMP-phosphodiesterase by M&B 22,948 increased the 
potency of 8(9)-, 11(12)- and 14(15)-EET.
The EET-induced relaxatory responses induced in 
guinea-pig tracheal rings were similar to those in rat
iv
aortic strips. Again the 5(6)-isomer was more potent than 
the other EETs. Indomethacin attenuated the potency of 
5(6)-EET whilst augmenting the maximal response, however, 
NDGA did not effect EET-induced relaxant responses. M&B 
22,948, in an analogous manner to that observed in the 
aorta, increased the potency of 8(9)- 11(12)- and
14(15)-EET in guinea-pig tracheal rings.
Platelet aggregation induced by both ADP and thrombin 
was inhibited by the EETs, 5(6)-EET being the most potent 
of the EETs. However, in platelets, neither indomethacin 
or NDGA had any significant effect on the inhibition 
induced by any of the EETs. Papaverine was observed to 
augment the inhibition induced by all four EETs, whilst 
M&B 22,948 did not alter the anti-aggregatory responses.
v
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CHAPTER 1; INTRODUCTION
The metabolism of arachidonic acid (AA), a 20-carbon 
polyunsaturated essential fatty acid (EFA), to 
prostaglandins (PGs), thromboxanes (TXs) and leukotrienes 
(LTs), and the biological importance of these compounds 
has been the centre of intense pharmacological 
investigation.
The importance of the EFAs for normal body function 
was recognised in the 1930's by Burr & Burr (1930) whilst 
working on vitamin E and ovulation in rats. Around the 
same time, the biological actions of PGs were described 
by U.S. von Euler and by M.W. Goldblatt (Bergstrom & 
Sjovall, 1957), however their structures were 
undetermined. It was nearly thirty years later that PGEX 
and PGFX« were isolated (Bergstrom & Sjovall, 1957). The 
link between EFAs and PGs was soon revealed and the 
synthesis of PGE= achieved by Bergstrom et a l . (1964) and
Van Dorp et al. (1964). Thromboxane Aa (TXAa ), a potent 
aggregator of platelets and its breakdown product 
thromboxane B2 (TXB= ) were isolated ten years later 
(Hamberg et a l ., 1975). Shortly afterwards Moncada and
colleagues (1976) identified prostacyclin (PGI= ), a 
labile two eyelo-pentane ring structure with 
anti-aggregatory activity. A second pathway for AA 
metabolism, via 5-lipoxygenase producing the leukotrienes 
(LTs) was later described (Bray, 1983; Piper, 1983; 
Taylor & Morris, 1983).
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In the early 80's, a third pathway of AA metabolism 
via cytochrome P*»o mono-oxygenase was described (Oliw et 
al., 1981). The products of this pathway include a series 
of epoxides together with their respective diols and some 
w- and (w-1)-hydroxylated compounds. During the mid 
1980's reports of biological activity of the epoxides 
started to appear.
The purpose of this project is therefore to 
consolidate some previous investigations into epoxy- 
eicosatrienoic acid-induced biological effects and to 
extend investigations to other tissues. Furthermore the 
mechanism of action of these products will be examined 
with the aim of setting foundations for the clinical 
manipulation of the mono-oxygenase pathway.
The starting point for the biological synthesis of the 
epoxyeicosatrienoates (EETs), as for other eicosanoids is 
arachidonic acid. The opening sections of this 
introduction will therefore endeavour to familiarise the 
reader with the biological processes involved in the 
storage, release and subsequent metabolism of AA. 
Subsequently the biological distribution and
physiological role of the EETs will be discussed.
|
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1.1: Arachidonic Acid Storage and Release
Under normal physiological conditions AA is found 
predominantly bound to the membrane phospholipids 
phosphatidylethanolamine, phosphatidylcholine, phospha- 
tidylserine and phosphatidyl inositol. The enzyme 
responsible for incorporating AA into the phospholipids 
is an acyl transferase. The free acid is firstly bound to 
coenzyme-A (Co-A) by the action of acyl-CoA synthetase. 
Acyl-CoA synthetase does not appear to have any 
selectivity as to which fatty acids it utilises (Normann 
et al., 1981). AA can then be transferred to a 
lysophospholipid by lyso-phospholipid acyl transferase 
which has a high affinity selectively for AA-CoA (Jezky 
& Lands, 1968; Hasegawa-Sakai & Ohno, 1980), which 
increases further when lysophosphatidy1 inositol is the 
receptor (Baker & Thompson, 1973; Holub, 1976) (Fig. 
1.1). The phosphatidyl inositols are therefore a major 
source of arachidonic acid. AA-CoA specificity may be due 
to a separate enzyme (Hasegawa-Sakai & Ohno, 1980) and 
could explain the disproportionately large quantities of 
AA esterified to the inositol phosphates (Irvine, 1982).
Under resting conditions there is a small release of 
AA setting up a dynamic equilibrium, with the uptake 
mechanism, which controls the actual amount of free AA in 
cells at any given time (Irvine, 1982). The free levels 
of AA have been shown to be of paramount importance in 
controlling the formation of any AA-metabolites (Flower &
-3-
R" I GURE ± - J.
Incorporation and hydrolytic cleavage of AA from membrane 
phospholipid stores. Abbreviations: AA, arachidonic acid; 
CoA, coenzyme-A; PL, phospholipid; PLA= , phospholipase 
A= ; PLC, phospholipase C; InsP, inositol trisphosphate; 
DAG, diacylglycerol; MAG, monoacylglyecrol.
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Acyl-CoA
synthetase
LysoPL 
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Blackwell, 1976; Irvine, 1982). On stimulation of the 
cell membrane the balance is shifted in favour of AA 
release (Broekman et al ., 1981; Rittenhouse-Simmons,
1981; Billah & Lapetina, 1982a; Emilsson & Sundler, 
1986), however the phospholipase involved is still 
controversial . Possible pathways of AA release from the 
phospholipid stores include:
i) phosphol ipase A x (PLAj.)/lyso phosphol ipase (PLB),
ii) phospholipase A= (PLA2 ),
iii) phospholipase C (PLC)/diacylglycerol (DAG) lipase,
iv) PLC/DAG kinase/PLA2 .
(Fig. 1.2).
After cell activation, the release of AA is limited by 
an increase in acyl transferase activity (Schrey & Rubin, 
1979).
1.1.1: PLAi/PLB
The Ca2'4‘-independent, lysosomal enzyme, PLAx was found 
to have a pH optimum of 4.8, whilst PLB was optimum at pH 
8.5. At the low pH conditions required for PLAx > PLB was 
virtually inactive, in addition to which the activity of 
PLAx was still only one quarter that of PLA2 . As a 
consequence, little time has been spent investigating
this enzyme system as a possible release mechanism for
AA.
1.1.2: PLA=
As the majority of arachidonate is stored in the
2-acyl position of phospholipids the involvement of PLA= 
in its release was suggested by Lands & Samuelsson
-5-
F" I G U R E  JL . 2
Points of phospholipase attack on membrane lipids. PLB 
hydrolysis of lyso-phospholipids follows PLAx or PLA2 
hyrolysis of parent phospholipid. Abbreviations: PLAx, 
phospholipase Ax; PLA= , phospholipase A= ; PLB, lyso 
phospholipase; PLC, phospholipase C; PLD, phospholipase 
D.
PL A,
PLB
FATTY ACID
PLA
FATTY ACID
PLC PLD
(1968). When phosphatidylcholine and phosphatidyl- 
ethanolamine are substrates it is now widely accepted 
that AA is liberated by the action of phospholipase A= 
(PLAss). There is also evidence that PLA= is, at least in 
part, responsible for the liberation of AA from 
phosphatidyl inositol (Flower & Blackwell, 1976; Blackwell 
et a l ., 1977; Hong & Deykin, 1981; Billah & Lapetina,
1982a).
1.1.3s PLC/ DAG lipase
A calcium-independent phosphodiesterase, PLC, attacks 
phosphatidyl inositol 4,5-bisphosphate (PtdIns4,5P= ) at 
the sn-3 position to release 1,2-DAG and inositol
1,4,5-trisphosphate (InsP3 ) (Berridge, 1983). The 
breakdown of PtdIns4,5P= precedes the disappearance of 
phosphatidyl inositol (Ptdlns) and phosphatidyl
4-monophosphate (PtdIns4P) (Rebecchi & Gershengorn, 
1983). 1,2-DAG can then be metabolised by 1,2-DAG lipase
to 2-monoacylglycerol (2-MAG), the 2-MAG liberating AA 
and glycerol due to the action of 2-MAG lipase (Bell et 
al., 1979; Prescott & Majerus, 1983). (Fig. 1.3).
The AA liberation from phosphatidyl inositol alone is 
not enough to account for all the AA released following 
cell stimulation, however it does precede and possibly 
triggers AA release by other phospholipases from other 
phospholipids (e.g. phosphatidycholine).
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R  I G U R E  1 - 3
Inositol phosphate cycle. Abbreviations: Ptdlns,
phosphatidyl inositol; PtdIns4P, phosphatidyl inositol
4-monophosphate; Ptd Ins4, 5Ps*, phosphatidyl inositol
4,5-bisphosphate; ATP, adenosine triphosphate; PLC, 
phospholipase C; Insi,4Pz , inositol 1,4-bisphosphate; 
InslP, inositol phosphate; Ins, inositol; DAG, 
diacylglycerol; PA, phosphatidic acid; CDP, cytosine 
diphosphate; MAG, monoacylglycerol; AA, arachidonic acid.
phospturtidyfinositol
synthase
Ins Ptdlns CDP-DAG
ATP
CDP; 
sypt 
CTP—1 *phosphatase
Ptdlns4P
phosphatase
Ptdlns
kinaseInsIP
PA
Ptdlns4P
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ATP ATP4-phosphatase
DAG
lns1,4P Ptdlns4P
kinase
Ptdlns4,5P MAG
5-phosphatase
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1.1.4s PLC/ DAG kinase & PLA3
As above, the activity of PLC would liberate DAG. DAG 
could alternatively be phosphorylated by DAG kinase to 
phospatidic acid. Appearance of phosphatidic acid before 
the liberation of AA has been reported (Lapetina & 
Cuatrecasas, 1979). Liberated phosphatidic acid and InsP3 
may open calcium gates allowing the activation of PLA= 
which would release AA from phosphatidic acid or any of 
the phospholipids (Lapetina et al., 1981).
-9-
1.2 : Arachidonic acid metabolism
Once cellular levels of free AA have increased, free
AA is rapidly converted by several different enzyme
systems to many physiologically active metabolites. The 
more commonly known and widely investigated AA 
metabolites are the eicosanoids. Indeed the rate 
determining step in the production of the eicosanoids is 
the liberation of free AA (Flower & Blackwell, 1976). The 
eicosanoids include the prostaglandins (PGs), 
prostacyclin (PGIS ), thromboxanes (TXAs) and leukotrienes 
(LTs) (Hamberg & Samuelsson, 1974; Hamberg et al., 1975; 
Moncada et al., 1976), alternatively AA can be
metabolised by the cytochrome P4oo pathway (see later).
1.2.1: Cyclo-oxygenase Pathway
The first step in the 'cyclic pathway' is the 
oxidation of AA under the control of fatty acid 
cyclo-oxygenase (Lands, 1979). The resulting
prostaglandin endoperoxide, PGGa , is then reduced by 
peroxidase activity to a second endoperoxide, PGH= 
(Hamberg et al., 1974; Nugteren & Hazelhof, 1973). 
Further conversion of the endoperoxides can proceed
either non-enzymatica1ly or enzymatically as a result of 
isomerase activity. The resulting products, the 'primary 
prostaglandins', consist of PGD= , PGEat and PGF=«. The 
conversion of PGE2 to PGF2-l by 9-oxoprostag landin
reductase and of PGFa* to PGE= by 9-hydroxyprostaglandin
dehydrogenase has been demonstrated (Lands, 1979;
-10-
Pace-Asciak, 1975), but the biological relevance is
unknown. Other prostaglandins, namely PGAje and B= are 
breakdown products of PGEa formed during chemical
isolation, PGCs being enzymatically derived from PGA2 . 
Two other important products of the endoperoxides are 
prostacyclin (PGI= ) and thromboxane A2 (TBA2 ). Their
formation is governed by prostacyclin synthetase and 
thromboxane synthetase respectively (Hamberg & 
Samuelsson, 1974; Hamberg et a l ., 1975) . Both compounds
are unstable, PGI2 hydrolyses non-enzymatically to 
6-o x o -PGFjl* whilst TXA2 breaks down non-enzymatical ly to 
TXBa. The relative proportions of PGs produced varies 
between tissues, furthermore the resultant mixture may 
even vary within a tissue depending upon the level of 
available substrate. One further eyelo-oxygenase product 
is 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT), a 
17-carbon hydroxy fatty acid, together with
malondialdehyde (MDA). HHT and MDA are formed 
non-enzymatically from PGH= . (Fig. 1.4).
-11-
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Cyclo-oxygenase pathway. Abbreviations; AA, arachidonic 
acid; PG, prostaglandin; T X , thromboxane; HHT,
heptadecatrienoic acid; MDA, malondialdehyde.
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1.2.2: Lipoxygenase Pathway
The 'linear pathway' is initiated by 12-lipoxygenase 
or 5-lipoxygenase which may metabolise, amongst other 
fatty acids, AA. The essential structural requirement for 
the hydroperoxidation is a penta-1,4-cis-diene system 
(Taylor & Morris, 1983). 12— 1ipoxygenase converts AA to 
12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid (12-HPETE) 
(Nugteren, 1975), the reduction of which gives
12-hydroxyeicosa-5,8,10,14-tetraenoic acid (12-HETE).
5-lipoxygenase produces 5-hydroperoxyeicosa-6,8,11,14- 
tetraenoic acid (5-HPETE) (Borgeat et al., 1976), the 
reduction of which is catalysed by glutathione peroxidase 
(Bryant & Bailey, 1980) resulting in the hydroxy acid,
5-hydroxyeicosa-6,8,11,14-tetraenoic acid (5-HETE).
Removal of water from 5-HPETE by dehydrase results in the 
formation of a 5,6-epoxide, leukotriene A* (LTA*). 
Rehydrolysis of LTA* by hydrolase produces 
5,12-dihydroxyeicosatetraenoic acid (leukotriene B*,
LTB*). Alternatively LTA* may be conjugated with 
glutathione to form leukotriene C* (LTC*), the enzyme 
responsible being glutathione-S-transferase. Subsequent 
cleavage of glutamic acid followed by glycine from LTC* 
leaves leukotriene D* (LTD*) and leukotriene E* (LTE*) 
respectively. Finally, re-incorporation of y-glutamic 
acid into LTE* produces leukotriene F* (LTF*). (Fig. 
1.5).
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F" I G U R E  1 - 5
Lipoxygenase pathway. Abbreviations: AA, arachidonic
acid; HPETE, hydroperoxyeicosatetraenoic acid; HETE, 
hydroxyeicosatetraenoic acid; LT, leukatriene.
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1.3s Cytochrome PA gg> ■
In addition to its metabolism by eyelo-oxygenase and 
lipoxygenase enzymes, unesterified AA may undergo 
oxidation by the cytochrome P^»o mono-oxygenase system. 
Before describing the AA-products so formed, it is 
necessary to briefly describe the P4so mono-oxygenase 
pathway.
Cytochrome P 4 B0  is a primary component of the 
oxidative enzyme system found in the microsomal fraction 
of cells. Responsible for the metabolism of both 
endogenous and exogenous compounds it is located 
predominantly in the hepatocytes. However cytochrome P4so 
activity has also been described in lung, kidney, small 
intestine, placenta, skin and vascular tissue (Bond et 
al., 1979, 1980; Ullrich et al., 1981; Dees et al.,
1982). Although cytochrome P*»© has many isozymic forms, 
they all have molecular weights of 48-55 Kdaltons and 
possess a haem group ionically bound to an amino acid 
residue in the protein. Carbon monoxide (CO) binds avidly 
with cytochrome P4So causing enzyme inhibition, the 
resultant complex absorbing light of wavelength 450nm 
(hence cytochrome P <*»©). Cyanide on the other hand has no 
effect on microsomal oxidations, differentiating them 
from mitochondrial transformations. When the enzyme is 
isolated from the membrane (using surfactants), its UV 
absorption maximum drops to 420nm, the spectral 
properties altering again on association with a substrate
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suggesting a conformational change on binding. Despite 
the large range of substrates (e.g. benzene derivatives 
and polycyclic aromatic hydrocarbons, alkyl and alkene 
chains, amines) metabolised by cytochrome P 4 so> they are 
all lipophilic, a physical property of paramount 
importance if they are to cross the cell membrane.
The oxidation process can be split into five stages 
starting with the binding of the substrate to oxidised 
P48o . The enzyme-substrate complex is reduced (the single 
electron donated by NADPH, via a f1avoprotein) then bound 
with molecular oxygen (0= ). A second reduction takes 
place when two hydrogen atoms together with an electron 
are inserted resulting in the subsequent release of 
oxidised substrate together with water. The oxidised 
enzyme is also regenerated (Fig. 1.6).
Recently the Committee of Standardized Nomenclature of 
the P4so Genes was set up to oversee the naming of P4eo 
isozymes. The agreed system involves the division of the 
P4So gene superfamily into families, subfamilies and 
genes. Gene families were designated Roman numerals, 
subfamilies designated capital letters and the individual 
genes were labelled using Arabic numerals e.g. rat 
P^ooPBl is P 4 9 0 IIC6  (Nebert et al., 1987).
-16-
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Cytochrome P 4 8 0  pathway. Abbreviations: NADPH, reduced 
nicotinamide adenine dinucleotide phosphate; NADP"*', 
icotinamide adenine dinucleotide phosphet; S, substrate; 
s ot cytochrome P4so monooxygenase.
oxidised flavoproteinNADPH
cytochrome P450 reductase
NADP reduced flavoprotein
2H+ +
1.4: Cytochrome P4so Synthesis of the Epoxvarachidonates
The first work identifying NADPH-dependent cytochrome 
P 4 so metabolites of AA was described by Oliw et al.
(1981). Both w- and (w-1)-hydroxylation products were 
identified following the incubation of AA with
NADPH-fortified renal cortical microsomes. Previous work 
with medium chain (C8-C18) fatty acids had revealed
similar compounds (Navarro et al., 1978). An unexpected
result was the appearance of 11,12- and 14,15-dihydroxy- 
eicosatrienoic acids (DHETs). Oliw et a l . (1981) proposed
that these 1 ,2 -diols were formed via their respective 
epoxides. Inhibition by carbon monoxide of the
production of the diols confirmed their synthesis by 
cytochrome P4»© mono-oxygenase activity.
Further work with hepatic microsomes showed that the 
two 1 ,2 -diols could be further metabolised to their w- 
and (w-1)-hydroxylated products (Oliw and Oates, 1981). 
Furthermore the (w-1)-hydroxylated products could be 
converted to epoxyderivatives. In the same work Oliw and 
Oates confirmed that the two 1,2-diols were formed via 
their respective epoxyeicosatrienoic acids.
The 5(6)- and 8(9)-EETs were later isolated from 
hepatic microsomal incubations of AA in the presence of 
NADPH (Oliw et al., 1982). In order to isolate the four 
EETs rather than their corresponding 1,2-diols from 
microsomal incubations, it was necessary to use 
1 ,2-epoxy-3,3,3-trichloropropane to inhibit epoxide
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hydrolase, or to use purified cytochrome P*»o, which 
proved more effective. It was speculated that the EETs 
were hydrolysed to the 1 ,2 -diols by the action of 
microsomal epoxide hydrolase (Oliw et a l ., 1982). Ferrous 
iron or ADP were not important in the synthesis (Oliw et 
al., 1982). The 'epoxygenase' pathway is summarised in 
F i g . 1.7.
Work by Chacos et al., 1983 disputed the role of
microsomal epoxide hydrolase in the hydration of
epoxyeicosatrienoic acids as proposed by Oliw et a l .
(1981). The newly discovered cytosolic epoxide hydrolase 
was found to be far more active than its microsomal 
counterpart at hydrating the 8(9)-, 11(12)- and
14(15)—EETs, however the 5(6)-EET had a much lower 
reactivity to the cytosolic form. The poor metabolism of 
5(6)-EET by epoxide hydrolase would therefore leave this 
cytochrome P*»o product available to act on other 
physiological systems (see later). It was noted however 
that a tightly bound microsomal epoxide hydolase was 
present which possessed many of the cytosolic enzyme's 
properties and could be responsible for the
misinterpretation of results obtained by Oliw et al.
(1982).
Synthesis of the EETs by oxygen radical attack of AA 
was shown not to be involved by Capdevila et al. (1981a). 
The addition of mannitol, catalase or superoxide 
dismutase (SOD) had no effect on the turnover of AA in 
microsomal incubations. If oxygen reduction products were
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F “ I G U R E  ±  m ~Z
Epoxygenase pathway. Abbreviations: AA, arachidonic acid 
EET, epoxyeicosatrienoic acid; DHET, dihydroxy 
eicosatrienoic acid.
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involved then a reduction in AA turnover would have been 
observed. Furthermore benzphetamine, a P4so substrate 
known to uncouple cytochrome P4SO whilst increasing the 
production of oxygenated products by hydrogen peroxide, 
was found to reduce the turnover of AA, consolidating the 
view that oxygen radical attack was not involved.
The rate of AA metabolism by both kidney and liver 
microsomal P-q.»o was increased 2 to 3 fold by the presence 
of cytochrome bs (Capdevila et al., 1981b). NADPH- 
fortified cytochrome ba alone was unable to metabolise AA 
indicating a separate metabolic path for b» was not 
responsible for the increase. The liver microsomal enzyme 
appeared to be more efficient at producing the EETs than 
did the kidney microsomal enzyme.
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1.5; Metabolism of Cytochrome -,o Metabolites of
Arachidonic Acid
As 5(6)-EET possesses three cis double bonds (a 
structural requirement of substrates for fatty acid 
cyclo-oxygenase) Oliw investigated the further epoxide 
metabolism by cyclo-oxygenase. Initial work utilising ram 
seminal vesicles (RSVs) indeed found 5(6)-EET to be 
converted to several polar products, the two major 
metabolites being identified as 5-hydroxy-prostag1andin 
Ii« and 5-hydroxy-prostag landin Ij.to (Oliw, 1984a). 
Production of these two metabolites was postulated to be 
via 5(6 )-epoxyprostaglandin endoperoxides, 5(6)-epoxy-
prostaglandin F ia or both. Isolation of the two 
epoxyprostaglandin endoperoxides was later achieved 
following further arachidonic acid incubations with RSVs 
(Oliw, 1984d). 5(6 )-epoxy-PGFi* was also isolated from
RSV incubations with 5(6)-EET, which was increased 
several fold in the presence of dithiothreitol (Oliw & 
Benthin, 1985), a compound known to increase the 
production of PGF compounds. In the presence of 
glutathione the major fatty acid cyclo-oxygenase 
metabolites of 5(6)-EET were found to be 
5(6 )-epoxyprostaglandin E*, 5,6-dihydroxyprostaglandin Ei 
and its d5-lactone (Oliw, 1984b). The enzyme 
endoperoxidase E isomerase with glutathione as a cofactor 
was probably responsible for this conversion as 
non-enzymatic breakdown of the epoxyprostaglandin
endoperoxides only occurs in the absence of cofactor 
(Oliw, 1984b). The epoxyendoperoxides were also found to 
be transformed into 5( 6 )-epoxy- 8 ,1 1 -heptadecadienoic acid 
(5(6 )-epoxy-HHD) in small amounts (Oliw, 1984d).
5,6 -DHET, the hydration product of 5(6)EET, has a 
metabolic fate parallel to 5(6)-EET. Fatty acid 
cyclo-oxygenase converted the 1 ,2 -diol to
5,6-dihydroxyprostaglandin G x and 5 ,6 -dihydroxy- 
prostaglandin Hx (Oliw, 1984c). The 5,6 -dihydroxy- 
prostag 1 andin endoperoxides may either undergo further 
enzymatic conversion to 5,6 -dihydroxyprostag1andin E x by 
prostaglandin E isomerase or breakdown non-enzymatically 
to 5,6 -dihydroxyprostaglandin F x« (Oliw, 1984c). However 
the conversion to prostaglandin E compounds was found to 
be slower for 5,6 -DHET than for 5(6)-EET or AA. Possible 
conversion of 5,6 -DHET by either thromboxane or 
prostacyclin synthetase was not investigated.
In addition there is evidence that at least one of the 
isomers, the 8(9)-EET, is a substrate for soyabean 
15-lipoxygenase, however this report has not been 
confirmed.
As with the LTs, the EETs are substrates for 
glutathione conjugation, 14(15)-EET proved to be by far 
the best substrate (Spearman et a l ., 1985). The
physiological relevance of such conversions remains 
unsure. The products so formed may have additional 
biological roles or alternatively GSH-conj'ugation may 
simply act as a deactivation pathway.
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Lipid epoxides may be found esterified in cellular 
stores. Sevanian et a l ., (1978) demonstrated the presence
of epoxides esterified to trig 1 ycerides, cholesterol and 
phospholipids of rat lung. However the appearance of 
these epoxides was believed to be through autoxidation, 
although the phospholipid fraction was not increased by 
exposure to N0= .
GC-MS analysis of tissue samples from rat liver 
identified the epoxyeicosatrienoates as components of 
cellular phospholipids (Capdevila at al., 1984). Whether 
the EETs were derived from free AA and later esterified 
with membrane phospholipids or the AA was epoxygenated 
whilst esterified to the phospholipids was not 
determined.
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1.6s Biological activities of the epoxvarachidonates
The EETs have been reported to induce a range of 
biological responses including inhibition of platelet 
aggregation and cyclo-oxygenase activity (Fitzpatrick et 
al., 1986, 1987; Oliw & Benthin, 1985), alteration of
hormone release (Negro-Vilar et a l . , 1985; Capdevila et 
al., 1983; Turk et al., 1985; Falck et a l ., 1983; 
Grandsaert et a l ., 1986; Cashman et a l ., 1987; Snyder et 
al . , 1983) and mobilization of Ca2*^ (Snyder et al . , 1986; 
Kutsky et al., 1983). The EETs have also been shown to 
inhibit (Na^+K^)ATPase (Schwartzman et al., 1985) and 
reduce vasular resistance in the rat intestinal 
microcirculation (Procter et a l ., 1987).
Whilst investigating the fatty acid cyclo-oxygenase 
metabolism of 5(6)-EET, Oliw and Benthin (1985) noted 
that 14(15)-EET actually inhibited the enzyme. Although 
the potency of 14(15)-EET was equal to that of ETYA, 
endogenous levels of the EET would not be sufficient to 
act as an inhibitor. Fitzpatrick and co-workers (1986, 
1987) later reported that in addition to 5(6)-EET being a 
substrate for fatty acid cyclo-oxygenase, 8(9)-EET and 
14(15)-EET were inhibitors of the purified enzyme at 
micromolar concentrations. 11(12)—EET was shown to be
inactive both as a substrate and an inhibitor. More 
detailed investigation of the inhibitory effects of the 
14(15)-EET uncovered a stereospecificity. As with many 
other naturally occuring enantiomeric pairs the
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dextrorotatory isomer (14R,15S-cis-EET) was the more
potent. The inhibition of cyclo-oxygenase was also 
evident for the enzyme within intact platelets. 
Inhibition of platelet aggregation however differed in 
profile to cyclo-oxygenase inhibition. 8(9)-, 11(12)- and 
14(15)-EETs were all found to inhibit platelet 
aggregation at micromolar concentrations. In contrast to 
enzyme inhibition results the inhibitory activity was not 
stereospecific. The anti-aggregatory activity of 5(6)-EET 
was not investigated.
A series of papers from the University of Texas Health 
Science Centre described the effects of EETs on the 
release of hormones. EET involvement in luteinizing
hormone-releasing hormone (LHRH) stimulated luteinizing 
hormone (LH) release from anterior pituitary cells was 
described by Snyder et al., (1983). Cyclo-oxygenase and 
lipoxygenase enzyme inhibition by indomethacin and
nordihydroguaiaretic acid (NDGA) respectively had no 
effect on LHRH-stimulated LH release whilst 5,8,11,14- 
eicosatetraynoic acid (ETYA) produced inhibition. ETYA 
effectively inhibits AA metabolism by the three pathways 
presently identified. In addition, the exposure of
anterior pituitary cells to any of the four EETs induced 
LH release, the 5(6)-EET being the most potent. 
5(6 )-EET-induced LH release was shown to be greater than 
that induced by lOnM LHRH, however the concentration of 
5(6)-EET utilised was greater than would be found in 
vivo. Although the EETs were capable of inducing LH
-26-
release the actual mechanism and indeed the final AA 
metabolite involved was not elucidated in the reported 
work.
In addition to stimulating LH release, 5(6)-EET was 
later reported to simultaneously induce Ca3_H efflux in 
anterior pituitary cells (Snyder et a l ., 1986). Indeed
5(6)-EET was found to mimic LHRH in stimulating LH 
release and the efflux of Ca2 + . However it was not 
verified whether the Ca3-*- was mobilised from internal 
stores or simply leaked in through the cellular membrane 
as a result of some non-specific 5(6)-EET effect.
5( 6 )-EET-induced loss of Ca2+ from rat aortic smooth 
muscle microsomes and from rat liver microsomes was
reported by Kutsky et al., (1983). In addition 14(15)-EET 
was found to decrease active Ca3"" uptake whilst passive 
Ca3*” binding was unaffected. The DHETs were inactive at 
uM concen trations. Furthermore, Ca3"" loss by canine 
aortic microsomes was increased by micromolar 
concentration of 5(6)- and ll(12)-EETs. No effect on Ca3-" 
release was observed for the DHETs and 8(9)-EET in aortic 
microsomes.
A report by Fishman et a l ., (1976) indicating a
cytochrome P4»o mono-oxygenase activity in the
hypothalamus and the discovery of AA-metabolism by P4»o
enzymes (Oliw et al., 1981, 1982; Capdevila et a l .,
1981a) provoked an investigation by Capdevila et al.,
(1983) on the possible role of such AA-metabolites in 
somatostatin (SRIF) release. Absolute evidence that the
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hypothalamic cytochrome P4»o mono-oxygenase synthesised 
the EETs in vivo eluded examinations by Capdevila and his 
colleagues. However incubation of cells from the median 
eminence (ME) with AA induced SRIF release which was 
attenuated in the presence of ETYA but not indomethacin. 
Indeed the addition of indomethacin to the incubation
medium produced a small increase in SRIF release.
Furthermore hypothalamic microsomal fractions when
incubated with AA in the presence of NADPH produced
several polar compounds including 5(6)-EET and its
corresponding diol. Both 5(6)-EET and 5(6)-DHET
stimulated the release of SRIF from the ME in vitro, the 
epoxide being the more potent. Synthetic 14(15)-EET and 
its corresponding diol were ineffective in stimulating
SRIF release in the same preparation. From their results 
Capdevila et a l . proposed that AA metabolites by 
different pathways may be involved in the regulation of 
hypothalamic hormonal release.
Previous reports by Gillespie et a l ., (1972) and by
Desai and Raghavan (1982) indicated an in vivo
stimulation by PGs of oxytocin release from the pituitary 
gland. Arginine vasopressin (AVP) release from the
pituitary had also been shown to be stimulated by PGs 
(Vilhardt & Hedqvist, 1970; Yamamoto et a l ., 1976).
Negro-Vilar et al., (1985) therefore investigated the 
possible role of the EETs and HETEs as well as the PGs in 
the release of oxytocin and AVP. The inhibition of 
AA-stimulated hormone release by ETYA indicated
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AA-metabolites were exerting an influence rather than the 
parent AA. The production of the EETs by microsomal 
fractions from the neural lobe of the rat pituitary was 
demonstrated. 8(9)-, 11(12)- and 14(15)-EETs were
primarily produced, 5(6)-EET only appearing in trace 
amounts. Stimulation of oxytocin and AVP release from the 
neural lobe by the EETs followed the same pattern as
their synthesis; 8(9)-, 11(12)- and 14(15)-EET being
active whilst 5(6)—EET was only weakly stimulatory.
Furthermore 11(12)-EET was found to favour stimulation of 
AVP release whilst 8(9)-EET favoured the stimulation of 
oxytocin release. The effect of the EETs however was
found to be of less importance than that of the PG tested 
(PGEa). Of the lipoxygenase products tested, 5-HETE was 
found to be without effect and 12-HETE only stimulated 
AVP release.
The EETs have also been shown to be active in isolated 
rat pancreatic islets in vitro (Falck et a l ., 1983).
Arginine-induced stimulation of glucagon and insulin
release was found to be inhibited by both metyrapone and 
ETYA. Similar results were obtained with glucose-induced 
stimulation of insulin release. The incubation of AA with 
isolated pancreatic islets increased the release of 
insulin and to a much lesser extent the release of 
glucagon. Both effects were again inhibited by ETYA. 
Incubation of the individual EETs with islet cells
disclosed that only 5(6)-EET significantly stimulated 
insulin release whilst 8(9)-, 11(12)- and 14(15)-EET
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stimulated glucagon release to increasing amounts. The 
stimulatory effects of the EETs were also found to be 
dose-dependent in the concentration range 1 0 “e to 1 0 “Bfi. 
Incubation of 5-HETE or 12-HETE with isolated islet
produced an increase in glucagon secretion only. 
Unfortunately Falck et al. were unable to demonstrate
epoxygenation of AA by the isolated rat pancreatic
islets.
A later report by Turk et al., (1985) however gave a 
contrasting opinion as to the actions of the EETs on 
pancreatic islet cells. ETYA and NDGA, both lipoxygenase 
inhibitors, were found to inhibit glucose-induced insulin 
secretion from islet cells whilst not inhibiting the
mono-oxygenase enzyme. Furthermore Turk et a l . failed to 
detect any EET stimulation of insulin secretion or indeed 
any synthesis of the EETs by isolated islets or 
microsomal fractions of islets. Although a significant 
5(6)-EET stimulation of pancreatic islet cells had been 
shown by Falck and colleagues the final insulin 
production was still only small in comparison to that 
during glucose stimulation. A role for 12-HETE was 
favoured by Turk et a l . in the glucose-induced 
stimulation of pancreatic islet cells. The inhibition 
seen with 12-HETE by Falck et a l . was questioned in their 
report.
Grandsaert et a l . (1986) described 5(6)-EET
stimulation of prolactin release from rat GH 3  anterior 
pituitary tumor cells. This work was later confirmed by
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Cashman et a l . (1987). Utilising rat anterior pituitary
tumour cells (GH3 cells) the authors demonstrated a 3 to 
4-fold increase in secretion stimulated by 5(6)-EET. 
Although 14(15)-EET and 5-HETE also stimulated prolactin 
secretion it was to a lesser degree than 5(6)-EET. 
Unfortunately a response to AA was not obtained.
Schwartzman et al., (1985) reported the presence of a 
cytochrome P4 so mono-oxygenase system in the medullary 
thick ascending loop of Henle (mTALH). The two main 
metabolites of this enzyme were 5(6)-EET and 11(12)-DHET, 
both of which were found to be biologically active. The 
formation of the metabolites was stimulated by arginine 
vasopressin and salmon calcitonin. 5(6)-EET proved to be 
a potent relaxant of rabbit pulmonary artery rings 
precontracted with phenylephrine. 11(12)-DHET was active 
as an inhibitor of (Na^+K-*-)ATPase.
Of the four cytochrome P*»o_AA metabolites the 
5(6)-EET proved to be the most potent vasodilator of the 
intestinal microcirculation in rats (Procter et a l ., 
1987). Whilst 8(9)- and 11(12)-EET also demonstrated 
vasodilator activity, but to a lesser extent than 
5(6)-EET, 14(15)-EET failed to evoke a response. Although 
the EETs had vasoactivity, in vivo synthesis could not be 
demonstrated. Application of AA to the serosa did induce 
vasodilation but this could be almost completely 
inhibited by cyclo-oxygenase inhibitors. However AA 
application to the mucosal surface in the presence of 
bile induced vasodilation that was predominantly blocked
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by mono-oxygenase inhibitors. The response achieved by 
mucosal application of AA was smaller than that observed 
with serosal application.
The biological activities of the EETs are summarized 
in table 1 .1 .
1.7: Objectives
The primary objectives of this project were to 
establish a reliable EET synthesis and test the products 
for pharmacological activity in cardiovascular and 
respiratory preparations. In addition, all four 
EET-isomers were to be tested for biological activity in 
isolated platelets. Attention would then be turned 
towards determining a mechanism of action for the EETs 
and finally demonstrating their synthesis in the systems 
examined.
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T A B L E  JL - JL
Summary of the biological effects of the 
epoxyeicosatrienoic acids.
Source Reference 
Tissue 5(6)-EET
Tissue
8(9)-EET
Response 
11 (12)-EET 14(15)-EET
Capdevila et al. 1983 
somatostatin release stisulation inactive
Falck et al. 1983 
insulin release 
glucagon release
stimulation
inactive
inactive
stimulation
inactive
stimulation
inactive
stimulation
Snyder et al. 1983 
LH release stimulation stimulation stimulation stimulation
Kutsky et al. 1983 
active Ca2* uptake 
passive Ca2+ binding 
Ca2+ release increased no effect increased
reduction 
no effect 
increased
01iw and Benthin 1985 
cyclo-oxygenase inhibition
Negro-Vilar et al. 1985 
oxytocin and AVP release
meak
stimulation
oxytocin
stimulation
AVP
stimulation stimulation
Turk et al. 1985 
insulin release inactive
Schmartzman et al. 1985 
pulmonary artery relaxation
Fitzpatrick et a l .'86/7
platelets
cyclo-oxygenase substrate
anti­
aggregatory
inhibition
anti­
aggregatory
inactive
anti­
aggregatory
inhibition
Snyder et al. 1986 
Ca2* efflux (ant. pit.) stimulation
6randsaert et al., 1986 
prolactin release stimulation
Cashman et al. 1987 
prolactin release stimulation stimulation
Procter et al. 1987 
intestinal vasculature relaxation relaxation relaxation no effect
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CHAPTER 2; EPOXIDE SYNTHESIS AND SEPARATION
2.1: INTRODUCTION
Several methods of selective and non-selective EET 
synthesis have been reported. Non-selective epoxidation 
of AA yielding a mixture of all four EET-isomers has been 
described by Oliw et al. (1982), based on the oxidation 
of polyunsaturated fatty acids by m-chloroperoxybenzoic 
acid (Chung & Scott, 1974). Selective methods of 
synthesising the different regio-isomers have also been 
described. 5(6)-EET and 14(15)-EET were synthesised from 
the parent fatty acid, AA (Corey et al., 1979). 8(9)-EET 
was sythesised from the 5(6)-isomer (Falck & Manna, 1982) 
and 11(12)-EET was synthesised from the 14(15)-isomer 
Corey et al., 1980).
The well established method described by Oliw et a l .
(1982) was initially adopted for the non-selective 
synthesis of all four EETs. Separation of the individual 
EETs from the reaction mixture was accomplished using 
thin layer chromatography (Chung & Scott, 1974). Routine 
HPLC separation of the EETs as described by Oliw et al.
(1982) was also evaluated.
The poor yield of 5(6)-isomer obtained by 
non-selective epoxidation necessitated the evaluation of 
selective 5(6)-EET synthesis according to the method of 
Corey et a l . (1979).
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2.2: METHODS
2.2.1: Synthesis & Separation of the EETs
Non-selective epoxidation of l-i4C radio-labelled AA 
by m-chloroperoxybenzoic acid (m-CPBA) in dichlorcmethane 
was achieved utilising a modification of the protocol 
described by Oliw et al. (1982). AA and m-CPBA were 
reacted in molar ratios of 1:1, 1:1.5, 1:2, 1:5 and 1:10. 
The products were separated by TLC using a solvent of 
ethylacetate/hexane/acetic acid 35:65:0.1 (Oliw et a l ., 
1982) and visualised by iodine staining. The reaction 
mixture ratio (AA:mCPBA) giving optimum AA epoxidation 
without excessive product breakdown was adopted for 
routine EET synthesis.
Other TLC solvent systems were evaluated due to poor 
resolution of the four epoxide isomers obtained using the 
system described by Oliw et a l . (1982). Normal phase
silica gel TLC plates (plate thickness 0.25mm, particle 
size 0.25mm, pore size 60A) were used throughout for the 
separation of the EETs. Solvent systems investigated 
included ethy1acetate/hexane/acetic acid 40:20:1,
hexane/ether 4:1 (Corey et a l ., 1979), ethylacetate/
hexane/acetic acid 30:70:0.1, ethylacetate/hexane/acetic 
acid 35:65:0.1 (Oliw et al., 1982) and ether/hexane/ 
acetic acid 30:70:1 (Chung & Scott 1974). The solvent 
system giving greatest resolution of the four EETs and 
any unchanged AA or breakdown products was adopted for
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routine EET separation.
SOOmg of AA was oxidised by 1.5 molar equivalents of 
mCPBA in a final reaction volume of 25ml of dichloro- 
methane for 17hrs at 20°C under nitrogen.
Using the chosen solvent system of ether/hexane/acetic 
acid (30:70:1), TLC plates (loaded with 0.2mg of reaction 
mixture per lane) were developed twice to 17cm. After 
drying, the EETs on the end two lanes on each plate were 
visualised using iodine. Corresponding epoxide bands were 
removed from the plates by scraping and the EETs eluted 
from the silica with three serial 1 0 ml aliquots of dry 
ether. Once eluted the epoxides were stored in liquid 
nitrogen, the pooled eluates evaporated to dryness under 
vacuum using a Gyro-Vac centrifugal evaporator before 
being reconstituted in 0.4ml of dry methanol. Methanolic 
solutions of the EETs were stored under nitrogen until 
required.
The final yields of the four EETs were assessed by 
liquid scintillation counting using an LKB Rackbeta 1215 
counter, the count being converted to EET content by 
comparison to the initial reaction mixture count.
-36-
2.2.2: Identification of the EETs
The identities of the four EETs was confirmed using 
GC-MS and 2D-TLC. For GC-MS analysis, aliquots of the 
four epoxides were methylated at the carboxylic acid 
group using an ethereal solution of diazomethane (see 
below). The methylated EETs were then evaporated to 
dryness and reconstituted in HPLC-grade ethylacetate. 
Positive identification was obtained by GC-MS using a 
Hewlett-Packard 59770C MS ChemStation. 2ul samples were 
injected onto an OV-1, 12m capillary column. The column
temperature was ramped from 55°C to 270°C increasing by 
30°C/minute. Eluates were ionised by electron impact 
using an electron energy of 70eV, the search parameters 
set between 50 and 400 atomic mass units. In the case of 
2D-TLC a mixture of non-methylated EETs was loaded onto a 
plain silica gel plate (20cm2 , plate thickness 0.25mm, 
particle size 0.25mm, pore size 60A) and developed over 
17cm in the first dimension using a solvent of 
ether/hexane/acetic acid (30s70:l). After drying the 
plate was developed over the second dimension with a 
solvent of ethylacetate/hexane/acetic acid (35:65:0.1). 
The position of the EETs was visualised by iodine 
staining.
Synthesis of diazomethane
6 g of potassium hydroxide in 1 0 ml of water was placed 
in a 100ml distilling flask together with 35ml of
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diethylether and 10ml of water. The flask was fitted with 
a dropping funnel and a downward condenser which emptied 
into a collecting flask cooled on ice. The solution was 
warmed to a temperature of 70 to 75°C in a water bath. At 
the first sign of ether being distilled a solution of 
21. 5g of /V-methyl-/V/-nitrosotoluene-p-sul phonamide in 
125ml of ether, already in the dropping funnel, was 
introduced to the distillation flask dropwise. The rate 
of addition of the nitrosoamide was adjusted to equal the 
rate of distillation. Once all the nitrosoamide had 
passed into the distillation flask, further aliquots of 
ether were added through the dropping funnel until the 
distillate became colourless.
Using a blunt pasteur pipette, the ethereal solution 
of diazomethane was transferred in molar excess to the 
epoxide solutions. Excess diazomethane was neutralised by 
the dropwise addition of glacial acetic acid until no 
further effervescence was observed.
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2.2.5: Selective 5(6)-EET synthesis
The method of selective epoxidation of AA at the 5,6 
position as described by Corey et a l . (1979) was
considered. Briefly, arachidonic acid in tetrahydrofuran 
water (A A :THF-water, 1.7:1) was reacted with 5 molar
equivalents of potassium bicarbonate and 8  molar 
equivalents of potassium triiodide for 3 days at 4°C. 
Following extraction the products were further reacted in 
THF-water (3:2) with excess 0.2N lithium hydroxide for 3 
hours at 25°C. Extraction and evaporation yielded the
final product which could be reconstituted in dry
methanol.
Potassium triiodide was synthesised as described by 
Foote & Chalker (1908). Briefly, a stoichiometric amount 
of iodine was slowly added to a solution of potassium 
diiodide with constant stirring at 60°C. The final 
solution was then cooled to 0°C.
2.2.4: HPLC Separation
Reverse-phase HPLC separation of the EETs was 
performed using an analytical column (150mm length x 7mm 
internal diameter) packed with Lichroprep RP18 ODS, 
25-40um. O.lmg samples underwent separation using a 
mobile phase of 737. methanol in water with 0.27. acetic 
acid (Oliw et al., 1982) at a flow rate of 2ml/minute 
driven by an LDC Constametric III pump. Elution of
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conjugated products was monitored using an LDC 
Spectromonitor III measuring UV absorbance at 320nm. The 
eluate was collected in 2ml fractions using an LKB 
Helirac 2212, and the position of the peaks determined by 
liquid scintillation counting.
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2.3; RESULTS
2.3.1: Synthesis & Separation of the EETs
The optimal molar ratio of AA:mCPBA was found to be 
1:1.5. At this ratio some AA remained with only slight 
product oxidation taking place. Lower ratios gave only 
poor yields of EETs whilst higher ratios showed excessive 
subsequent oxidation of the products (Figure 2.1).
Of the solvent systems evaluated for routine EET 
separation only ether/hexane/acetic acid (30:70:1) gave 
complete separation of the four EETs. Using ethylacetate/ 
hexane/acetic acid (35:65:0.1) or ethy1acetate/hexane/ 
acetic acid (30:70:0.1), the 5(6)- and B(9)-EETs were 
unresolved. With ethy1acetate/hexane/acetic acid 
(40:20:1) as solvent, all the products migrated with AA 
at the solvent front. In the non-acidified solvent, 
hexane/ ether (4:1) all the products and AA were retained 
by the silica at the origin (Figure 2.2).
A representative set of Rf values for the EETs, 
relative to AA (solvent ether/hexane/acetic acid 
30:70:1), from one separation were 0.854, 0.797, 0.577
and 0.707 for the 14(15)-, 11(12)-, 8(9)- and 5(6)-EETs 
respectively. The final ratio following extractive 
isolation of 14(15)-, 11(12)-, 8(9)- and 5(6)-EET was
79:37:33:4 respectively. Of the AA initially reacted with 
mCPBA approximately 40/C was recovered as EET.
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F- I BURE 2.1
Thin-layer chromatographic separation (solvent:
ethylacetate/hexane/acetic acid 35:65:0.1) of EETs and AA 
following epoxidation of AA with increasing molar ratios 
of m-chloroperoxybenzoic acid (m-CPBA:AA). A ratio of 
1.5:1 gave the best yield with least breakdown of the 
EETs. Abbreviations: AA, arachidonic acid; EETs, epoxy- 
eicosatrienoic acids.
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Separation of AA and EETs by different solvent systems 
using thin layer chromatography. 0 .2 mg of radio­
labelled reaction mixture was separated using different 
solvents. A solvent of ether/hexane/acetic acid (30:70:1) 
gave the best separation. Abbreviations: EtOAc,
ethylacetate; Hex, hexane; GAA, glacial acetic acid; AA, 
arachidonic acid; EET, epoxyeicosatrienoic acid.
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2.3.2; Identification of the EETs
Mass spectrographic analysis of the four methylated 
compounds, together with 2D-TLC of the separated compound 
substantiated the identities as the 5(6)-, 8(9)-, 11(12)- 
and 14(15)-EETs. The GC retention times of the methylated 
EETs were 8.93, 8.90, 8.83 and 8.85 minutes for the
14(15)-, 11(12)-, 8(9)- and 5(6)-isomers respectively.
The more important mass ions indicative of the EETs 
present in the MS traces have mass/charge values of 303, 
263*, 245, 235, 234 and 220 for 14(15)-EET (Fig. 2.3),
and 303, 290, 263, 245, 223*, 207 and 205 for 11(12)-EET
(Fig. 2.4). Important mass ions for 8(9)-EET were 
detected at mass/charge values of 245, 193*, 175 and 165 
(Fig. 2.5), and important mass ions for 5(6)-EET were 
detected at 245, 233*, 215 and 143* (Fig. 2.6). The mass 
ions resulting from cleavage around the epoxide bridge 
are superscripted with an asterisk. Table A3.1 shows the 
mass/charge values of all the ions detected for each EET 
together with their abundances. The M"* ion (mass/charge 
334) was not detected in any of the EET spectra.
The identities of the EET bands following separation 
using ether/hexane/acetic acid (30:70:1) were confirmed 
by the second development using ethyacetate/hexane/acetic 
acid (35:65:0.1). The relative positions of the EETs 
using the second solvent are known from the work of Oliw 
et al., (1981). From these the relative positions of the 
bands following separation with ether/hexane/acetic acid
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were determined. As the 5(6)- and B(9)-EETs were not 
resolved utilising ethylacetate/hexane/acetic acid the 
final identification of these two EETs was achieved by 
GC-MS.
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Methyl -5(6)-epoxyeicosa-8,11,14-trienolc acid
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MS of methyl-5( 6 )-EET. Mass ion 233 results from the 
cleavage of the C4-C5 bond and mass ion 143 results from 
the cleavage of C6-C7 bond around the epoxide bridge.
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Methyh8(9)-epoxyeicosa-5,11,14-trienoic acid
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MS of methy1-8 (9)-EET. Mass ion 193 results from the 
cleavage of the C7-C8 bond.
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Methyl-11(12)-epoxyeicosa-5>8,14-trienoic acid
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MS of methy1—11(12)—EET. Mass ion 223 results from the 
cleavage of the C12-C13 bond.
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Methyh 14(15)-epoxyeicosa-5,8,11-trienoic acid
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MS of methyl-14(15)-EET. Mass ion 263 resulted from the 
cleavage of the C15-C16 bond.
2.5.5: Selective 5(6)-EET synthesis _ ,
TTTe products from selective epoxidation of AA were
examined using TLC with a solvent of ether/hexane/acetic
acid (30:70:1). Previously synthesised 5(6)-EET and AA
were used as standards. Although some unreacted AA
remained no 5(6)-EET was detected in the mixture.
2.3.4: HPLC Separation
4 minutes after sample injection onto the column a 
non-radiolabel led peak with high UV absorbance was 
detected corresponding to 3-chlorobenzoic acid, the polar 
breakdown product of the oxidising agent. The appearance 
of this peak was used as a marker to initiate collection 
of the eluate. Radiolabelled peaks were collected after 
30ml, 50ml, 60ml, 122ml, 144ml and 198ml. Although none 
of the eluted compounds were positively identified the 
peak at 198ml was substantially greater than all the rest 
and was presumed to be residual AA. Only poor resolution 
of the peaks at 50ml and 60ml and also at 122ml and 144ml 
was achieved.
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2.4; DISCUSSION
2.4.1; Synthesis and Separation of the EETs
The ratio of EETs produced by non-selective 
epoxidation of AA (79:37;33:4) differed from that 
achieved by Oliw et a l . (1982). The much reduced yield of
the 5(6)-isomer is probably due to the harsher separation 
procedure followed here. The double TLC development 
required for optimal separation was probably instrumental 
in the poor yield due to the increased exposure of the 
EETs to the atmosphere and possibly water. This resulted 
in the loss of some of the synthesised EETs, especially 
the 5(6 )-regioisomer.
The low conversion of AA to EET could have been 
improved by reacting an increased amount of mCPBA, 
however a compromise was required between low conversion 
and the possible loss of EETs by further epoxidation. The 
increased molar proportion of mCPBA found to be suitable 
here in comparison to that used by Oliw et al. (1982) was 
probably due to chemical degradation of the oxidising 
agent during storage.
2.4.2; Identification of the EETs
As no standard EETs were readily available for GC-MS 
analysis, the spectra obtained for the reaction products 
could only be compared with those published by Oliw et
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al. (1982). However, the two sets of spectra were
sufficiently similar to identify the products as the 
EETs. The 5(6)-EET was instantly recognisable by the 
characteristic peak at m/sl43. The other isomers were 
deduced by carefully examining a host of individual MS 
characteristics. The absence of a mass ion at m/s334 was 
undoubtedly due to the harsh ionisation technique
utilised by this system. The identification of the
compounds separated by TLC was confirmed by 2D-TLC.
2.4.3: Selective 5(6 )-EET Synthesis and HPLC Separation
The failure to synthesise 5(6)-EET by selective 
epoxidation was probably due to the difficulties and 
uncertainties encountered in preparing the potassium 
triiodide. The chemical composition of the KI 3  solution 
prepared was not confirmed so the efficiency of the 
initial reaction was unknown. Further attempts to 
overcome these difficulties were not undertaken due to 
time restraints.
Incomplete resolution of the EETs achieved by HPLC 
could have been rectified by compositional manipulation 
of the mobile phase. However, as the maximum sample size 
which could be applied to the column at any one time was 
limited, further scrutiny of the system was not 
justifiable. To permit sufficient product to be separated 
in a reasonable time would have required regular use of a 
preparative HPLC column, access to which was not
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available.
Although not ideal for the large scale production of 
EETs, non-selective epoxidation of AA and separation of 
the products by TLC provided a sufficient supply to meet 
experimental requirements.
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CHAPTER 3: SMOOTH MUSCLE PHARMACOLOGY OF THE EETs
3.1s INTRODUCTION
The basic structure of arteries consists of three 
distinct layers: the tunica adventitia, the tunica media 
and the innermost layer the tunica intima. In addition 
there is a single layer of endothelial cells lining the 
vessel lumen. Vascular smooth muscle accounts for the 
tunica media, the fibres being arranged circularly around 
the lumen. Vascular resistance is determined by smooth 
muscle tone, especially in the arterioles. The degree of 
contracture of vascular smooth muscle is controlled both 
neuronally and by local hormones. Noradrenergic 
activation results in vasocontriction (except in 
skeletal vessels where cholinergic activation induces 
relaxation). 'Local hormones', including AA-metabolites, 
induce both contraction and relaxation (see below).
The endothelial cell lining, invariably only one cell 
thick, prevents contact between blood cells (including 
platelets) and the underlying tissue thereby preventing 
thrombus formation. In addition to its anti-thrombotic 
role, the endothelial lining has recently been implicated 
in the control of vascular tone by the release of 
endothelium derived relaxing factors (reviews: Furchgott, 
1983, 1984; DeFeudis, 1985).
Respiratory smooth muscle tone is also controlled by 
both neuronal and hormonal stimuli. Parasympathetic
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release of ACh is resposible for contraction, whilst 
pre-synaptic a-adrenoceptor stimulation by sympathetic 
innervation reduces the para-sympathetic control.
/?3-adrenoceptors located on the smooth muscle surface 
may be stimulated by circulating adrenaline. Metabolites 
of AA are also known to induce smooth muscle responses 
(see below).
Both cAMP and cGMP have been identified as second 
messengers in the relaxant responses of smooth muscle. 
Stimuli responsible for the activation of adenylate 
cyclase are now known to be different from those which 
activate guanylate cyclase, although the physiological 
effects of both processes have many similarities.
Agents inducing relaxation in various smooth muscles, 
including vascular and respiratory preparations, are
known to stimulate an increase in cyclic GMP levels which 
correlates well with observed relaxation. Furthermore, 
the elevation in cGMP preceeds smooth muscle relaxation. 
Amongst the relaxant agonists found to elevate cGMP 
levels are EDRF, the nitrovasodilators and the atrial 
natriuretic factors (Ignarro et al., 1986; Waldman et 
al., 1984; 1985).
Ulhile the precise mechanisms involved are still 
unknown, elevation of cGMP is accompanied by the
activation of cGMP—dependent protein kinases (Forstermann 
et al., 1986). Activation of kinases results in the
phosphorylation of several cellular proteins, the pattern
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of which is consistent thoughout the range of guanylate 
cyclase activating agents (Rapaport et al., 1982; 1983; 
Draznin et a l . , 1983; 1986). Dephosphorylation of myosin 
light chain, demonstrable during smooth muscle 
relaxation, has also been observed as a result of cGMP 
synthesis suggesting the activation of phosphoprotein 
phosphatases (Draznin et al., 1983; 1986).
Increased levels of cGMP have also been associated 
with reduced cytosolic calcium levels (Johnson & Lincoln, 
1985). Furthermore, elevated cGMP levels activate 
membrane C a ^ - A T P a s e  which could pump calcium directly 
from the cytosol (Popescu et a l ., 1985) however direct
activation of Ca^^-ATPase by cGMP-dependent protein 
kinase has not been demonstrated (Lincoln et a l ., 1988). 
Such reductions in cytosolic calcium were hypothesised as 
possibly leading to reduced activity of Ca^^-dependent 
myosin light chain kinase, dephosphorylation of myosin 
light chain and hence relaxation (Lincoln et al., 1988).
Alternatively, calcium release from internal stores by 
inositol trisphosphate (Yamomoto & Breemen, 1985) may be 
reduced due to inhibition of phosphoinositide hydrolysis 
by cGMP (Lewis et a l ., 1988).
During periods of tonic contraction cytosolic free 
calcium levels are found to revert to basal levels 
(Bradley & Morgan, 1987). In this case increased cGMP 
levels have been proposed to reverse contraction by the 
inhibition of diacylglycerol (DAG) formation from 
phosphoinositides (Lewis et a l ., 1988). Elevated levels
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of DAG are observed during prolongued smooth muscle 
contraction (Griendling et al., 1986) and DAG stimulation 
of protein kinase C is considered to be responsible for 
extended periods of smooth muscle contraction (Forder et 
al., 1985).
In vasculature, /3-adrenergic stimulation (Lefkowitz et 
al., 1983) or exposure to PGI= (Ignarro & Kadowitz, 1985) 
stimulates adenylate cyclase which converts ATP to cAMP. 
Once formed, cAMP activates a cAMP-dependent protein 
kinase resulting in the phosphorylation of smooth muscle 
proteins. However the phosphorylation profile is 
different from the case of elevated cGMP levels. As with 
cGMP, the actual mechanism linking raised cyclic 
nucleotide levels to smooth muscle relaxation are 
undetermined although a similar scheme of kinase 
activation and protein phosphorylation are known to be 
associated with cAMP increases.
The biological activity of AA-metabolites in vascular 
and respiratory models is well documented. The responses 
observed, either contraction or relaxation, are dependent 
upon the species and tissue examined and even on the 
muscle tone immediately prior to exposure to eicosanoid. 
Prostanoid receptors with structural specificity to the 
individual PGs have been identified and standard 
nomenclature determined (e.g. DP, EPX , EP2 , EP3 , FP, IP & 
T P ) . Receptors DP, EP 2  and IP have cAMP as their effector
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pathway, whilst receptors E P * , EP3 , FP and TP have 
IP3 /DAG as their effector pathway. EP 3  receptor 
stimulation may also mediate its effects via decreasing 
cAMP levels (TIPS, 1990). Of interest is the presence of 
EP receptor subtypes with opposing actions in guinea-pig 
trachea, see section 3.6.lb (Dong et a l ., 1986).
Prostaglandins Ea , D= and I3  are known to relax the 
aorta, whilst PGF2 m , TXA= and the LTs induce 
constriction. In the guinea-pig trachea however PGE= is 
relaxant, whereas PGI 2  is without direct effect although 
it may oppose the effects of other constrictor compounds. 
Again PGF=», TXA 2  and the LTs are constrictor (Moncada et 
al., 1980; Messina et al., 1976).
Epoxyeicosatrienoic acid-induced relaxation has been 
reported in the rat caudal artery and intestinal 
microvasculature (Carroll et al., 1987, 1988; Procter et 
al., 1987). The relaxant properties of 5(6)-EET in the 
caudal artery were attributed entirely to its further 
metabolism through eyelo-oxygenase (Carroll et al., 
1987). This chapter describes EET-induced smooth muscle 
responses in a large blood vessel, the rat aorta, and in 
respiratory smooth muscle using the guinea-pig trachea. 
Cyclo-oxygenase and lipoxygenase involvement in 
EET-induced responses were also investigated, together 
with the role of cyclic nucleotides in EET-induced 
relaxation.
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3.2: RAT ISOLATED AORTA
Male Wistar rats (330-370g) were killed by a blow to 
the head, the thoracic aorta removed and cleaned of 
adherent fat and connective tissue. Circular smooth 
muscle strips approximately 3mm wide were prepared and 
mounted in 10ml jacketed organ baths containing Krebs 
buffer at 37°C. Where required, de-endothelialisation of 
the aortic strips was achieved, before mounting in the 
organ bath, by rolling a cotton bud soaked in Krebs
solution across the intimal surface several times. After
mounting in the organ bath, the initial tension was
adjusted to 2g and 45-60 minutes was allowed for the
tissue to equilibrate.
Following cumulative dosing with PE a dose giving 
approximately 807. of maximal contraction was chosen to 
induce tissue tone. The integrity of the endothelium of 
each strip was ascertained using a dose of ACh known to 
give a maximal relaxation in strips with a preserved
endothelium. Only tissues showing an 807 or greater
relaxation to ACh (expressed as a percentage of maximal 
NaNP-induced relaxation) were assumed to have an intact 
endothelium. The success of de-endothelialisation of the 
strips was also confirmed using ACh and NaNP. Only
tissues giving a full NaNP-induced response whilst 
showing no relaxation to ACh were utilised as denuded 
preparations.
Relaxant dose-response curves by both intact and
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de-endothelialised rat aortic strips to the four EETs 
were constructed by cumulative dosing. These responses 
were expressed as a percenage of the maximal NaNP-induced 
relaxation determined at the end of each dose-response 
curve. In addition, the effect of pre-incubation of 
intact and denuded aortic strips with 3xlO-,feM 
indomethacin or lxlO-,bM NDGA prior to EET addition was 
evaluated.
The involvement of cyclic GMP in the EET-induced 
responses was ascertained by pre-incubating the tissue 
with the selective cGMP phosphodiesterase inhibitor M&B 
22,948. The effects of M&B 22,948 on PE-, ACh-, NaNP- and 
isoprena 1 ine-induced responses were also investigated for 
control purposes.
3.3 i GUINEA-PIG ISOLATED TRACHEA
Male Dunkin Hartley guinea-pigs (500-700g) were killed 
by a blow to the back of the head, the trachea carefully 
removed and placed in ice-cold Krebs solution. After 
removal of adherent tissue, opened rings approximately 
3mm wide were prepared and mounted in 10ml jacketed organ 
baths under an initial tension of 3 g . The Krebs solution 
was maintained at 37°C and gassed with 57. C0 2  / 957. 0= . 
The bathing fluid was changed every 20 minutes and a two 
hour equi 1 ibration period allowed.
The sensitivity and responsiveness of the tracheal 
strips to ACh was ascertained by adding the drug to the
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organ bath cumulatively and recording the responses 
obtained. A dose of ACh giving a submaximal response 
(approximately 807. of maximum) was identified and used 
throughout the experiment to induce tone.
A parallel set of experiments were carried out using 
tracheal strips from the same guinea-pigs which were 
exposed to either 3xlO-,£,M indomethacin or lxlO-<foM NDGA 
throughout to inhibit eyelo-oxygenase or lipoxygenase 
activity respectively. A submaximal dose of ACh giving a 
comparable response to that in untreated tracheal strips 
was used to pre-contract the tissues.
EET-induced tracheal responses were examined by 
cumulative addition of each EET to the organ bath. A dose 
of NaNP known to give maximal relaxation in tracheal 
strips was added after the EETs to induce the maximal 
possible relaxation. The EET-induced relaxation was 
expressed as a percentage of this NaNP response.
Additions of methanolic drug solutions were kept below 
3 microlitre, previous experiments indicating that such 
additions had no effect on tissue viability.
For statistical analysis Student's t-test for unpaired 
observations was used. When P was smaller than 0.05 
values were considered to be significantly different.
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3.4; RESULTS: RAT THORACIC AORTA
3.4.1; Control Responses
Preliminary investigations utilised male Wistar rats
weighing 220-280g. Although reproducible dose-response 
curves to PE, ACh and NaNP were obtainable, sub-maximal 
PE-induced contracture was often poorly maintained. 
Following PE-induced contraction intact tissues commenced 
phasic relaxation and contraction (Fig. 3.1a). This 
phenomenon was observable in aorta taken from rats up to 
330g in weight. In de-endothelialised preparations 
however these spontaneous relaxations were not observed. 
Above 330g the aortic preparations were found to maintain 
a stable sub-maximal tone to PE (Fig. 3.1b).
During tissue equilibration the basal tension of the
tissue decreased to between 0 . 8  and 1 .2 g after 
approximately 45 minutes. PE induced a dose-dependent
contraction of rat aortic strips in the range of 3xl0-s> 
to 3xlO-,toM in intact strips and 10-c? to 10_<£>M in denuded 
strips (Fig. 3.2). EC»o values for PE-induced contraction 
of intact and denuded strips were 2.5 + 0.1 x 10”eM
(n=17) and 7.3 + 0.4 x 10“^ (n=14) respectively,
representing nearly a 3 fold increase in sensitivity
following de-endothelialisation. A sub-maximal dose of 
lO-^M was used to induce a sustainable tissue tone in 
intact strips, and 3xlO-eM in denuded preparations.
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Time
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F IGURE 3 . 1 i
Typical trace demonstrating the unstable PE-induced 
contracture (lxlO“‘7’M) observed in aorta taken from rats 
of body weight less than 330g.
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F I G U R E  3 . l b
Typical trace demonstrating a stable PE-induced 
contracture readily obtained in aorta taken from rats of 
body weight greater than 330g. Rats with a body weight of 
350g were used routinely.
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De-endothelialised aortic strips were significantly more 
sensitive to PE (P<0.05). NaNP induced relaxation in the 
range of 10-iO to lO-^M with EC»o values of 1.6 + 0 . 1  x 
10-‘9M (n=15) and 1.8 + 0.2 x lO-^M (n = 15) for intact and
denuded preparations respectively (Fig. 3.3). 
NaNP-induced relaxations were not significantly altered 
by de-endothelialisation (P>0.50).
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PE-induced contraction of rat thoracic aorta
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F I G-U RE 3 . 2
PE-induced contraction of rat thoracic aorta. Cumulative 
addition of PE induced contraction of rat thoracic aorta 
in the presence and absence of an intact endothelium. In 
intact aorta, PE induced contraction with an ECso value 
of 2.5 + 0.1 x 10-8M (n=17). In aorta denuded of
endothelial PE induced contraction with an ECso value of
7.3 + 0.4 x 10-QM (n=14).
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NaNP-induced relaxation of rat thoracic aorta
% Relaxation 
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F  I  G - U  R E  3  . 3
NaNP-induced relaxation of rat thoracic aorta. Cumulative 
addition of NaNP induced relaxation of rat thoracic aorta 
to the same degree both in the presence or absence of the 
endothelium. NaNP induced relaxation with ECso values of
1.6 + 0.1 x 1O-0M (n=15) in intact aorta and 1.8 + 0.2 x 
10-9 (n=15) in aorta denuded of an endothelial lining.
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3.4.2; EET-induced Relaxations of Rat Aorta
In intact aortic strips (Fig. 3.4), 5(6)-EET induced
relaxations in the range 3x10“** to 3xlO“7rM with an ECso 
of 3.9 + 0 . 6  x 10“eM (n = 4 ). 8(9)-, 11(12)- and 14(15)-EET 
were roughly equipotent whilst being less potent than 
5(6)-EET at inducing relaxation. 8(9)-, 11(12)- and
14(15)-EET were relaxant in the range 10-<s> to 3xlO“ ®M 
with EC»o values of 5.2 + 0.7 x 10-<foM (n=4), 6.7 + 0.2 x 
10“AM (n=3) and 8.6 + 0.2 x 10—<foM (n=3) respectively. The 
5(6)-EET was significantly more potent than the other 
EETs (P<0.0001).
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EET-induced relaxation of intact aortic strips
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F IOURE 3 . 4
EET-induced relaxation of rat thoracic aorta with an 
intact endothelium. Cumulative addition of the EETs 
induced dose-dependent relaxations of rat aorta. 5(6)-EET 
induced relaxation with an ECso value of 3.9 ±_ 0.6 x 
10~BM (n=4). 8(9)- 11(12)- and 14(15)-EET induced
relaxation with ECso values of 5.2 + 0.7 x 10-®M (n=4), 
6.7 + 0.2 x 10-6M (n=3) and 8.6 + 0.2 x 10-BM (n = 3)
respectively.
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3.4.3; Endothelial Cell Involvement in EET-induced
Relaxation of Rat Aorta
Figure 3.5 shows a representative relaxant response to 
5(6)-EET in (a) an intact aortic strip and (b) a denuded 
aortic strip.
In de-endothelia1ised strips (Fig. 3.6), the 
5(6)-isomer was again the most potent, inducing
relaxation in the range 10~e to 10“,S»M. The mean potency 
of 5(6)-EET in aortic strips with a disrupted endothelial 
cell lining was reduced in comparison to intact strips 
(ECso value 8.2 + 1.8 x 10“eM (n=4) c.f 3.9 + 0.6 x 10~eM
(n=4) in intact strips), however the change was not
statistically significant (P = 0.08). The 8(9)-, 11(12)-
and 14(15)-EETs were again relaxant in the range 10-<b to 
3xlO“sM and their ECso values were comparable to those in 
intact preparations (8(9)-EET, 4.7 + 1.7 x 10_<£,M (n=3); 
11(12)-EET, 6.5 + 0 . 2  x 10“*M (n=3); 14(15)-EET, 8.9 +
0.8 x 10_<fcM (n=3 ) ) . The 5(6)-EET was still significantly 
more potent than the other EETs (P<0.001). The potencies 
of 8(9)-, 11(12)- and 14(15)-EETs in de-endothelialised 
strips did not differ significantly from that in intact 
strips (P>0.45). Relaxant responses to the EETs are 
expressed as a percentage of maximal NaNP-induced
relaxation.
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5(6)-EET 
(Log conc. M)Tension
/Nfl>
Tension
*(9>
1.0-
1.0-
0.5-0.5-
(mins)
F I G U R E  3 . 5
Respresentative traces of 5(6)-EET-induced relaxation of 
rat thoracic aorta a) with an intact endothelial lining 
and b) denuded of endothelium.
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EET-induced relaxation of de-endothelialised aortic strips
% relaxation
80 -
60 -
Log cone, 
-V(M)
e 5(6)-EET ■ 8(9)-EET •  11(12)-EET a14(15)-EET
F7 I G U R E  3 . 6=>
EET-induced relaxation of rat thoracic aorta denuded of 
an endothelial lining. Cumulative addition of the EETs 
induced a dose-dependent relaxation of rat aorta. The 
potency of the 5(6)-isomer was reduced by the removal of 
the endothelium whereas the potency of the other EETs was 
unaffected. 5(6)-EET induced relaxation with an ECso 
value of 8.2 + 1.8 x 10“SM (n=4). 8(9)- 11(12)- and
14(15)-EET induced relaxations with ECso values of 4.7 +
1.7 x lO-^M (n=3), 6.5 + 0.2 x 10-^M (n=3) and 8.9 + 0.8 
x 10“AM (n=3) respectively.
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3.4.4; Effects of Indomethacin and NDGA on EET-induced
Relaxation of Rat Aorta
Exposure of aortic strips to 3xlO_<f*M indomethacin
reduced the relaxant responses induced by 5(6)-EET (Fig. 
3.7). 5(6)-EET-induced relaxation of intact aortic strips 
in the presence of indomethacin was observed between
10_eM and 10_AM with an ECso of 7.5 + 1.0 x 10~eM (n=4), 
this compared to 3.9 + 0.6 x 10~eM in untreated strips 
demonstrating a significant reduction in potency
(P<0.02). Pre-incubation with indomethacin had no
significant (P>0.45) effect on 8(9)-, 11(12)- and
14(15)-EET induced relaxation. EC»o values for 8(9)-, 
11(12)- and 14(15)-EET were 4.5 + 1.6 x 10“*M (n=4), 6.7
+ 0.7 x 10_,4’M (n=4) and 8.5 + 0.8 x 10“^M (n=4)
respectively. Neither the PE-induced contraction or the 
ACh-induced relaxation were altered in the presence of 
3xlO-AM indomethacin.
5(6)-EET induced relaxations in de-endothelialised 
aortic strips was also attenuated by 3xlO-<bM
indomethacin. 5(6)-EET-induced relaxation of de-endo-
thelialised strips pre-incubated with indomethacin was 
observed between l O ^ M  and 10-®M (EC»o value 1.2 + 0.3 x 
lO-^M (n=4)). Pre-incubation of de-endothelialised rat 
aortic strips with indomethacin again had no significant 
effect (P>0.50) on the relaxant responses observed with 
8(9)-, 11(12)- and 14(15)-EET (ECso values; 5.1 + 0.9 x
10-^M (n = 4 ), 6.4 + 0 . 5  x 10-^M (n=4) and 8.1 + 1.1 x
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Effect of indomethacin on 5(6)-EET-induced relaxation of aortic strips
% relaxation
1001
Log conc.
"7, (M)
•  Intact, No indomethacin ■ Denuded, No indomethacin 
•  intact, 3pM indomethacin ▲ Denuded, 3pM indomethacin
x cbljf?e; 3  . ^
EET-induced relaxations of rat thoracic aortic strips in 
the presence and absence of indomethacin. The potency of 
5(6)—EET in both intact and de—endothelia1ised aortic 
strips was reduced by pre-incubation of the aortic strips 
with 3x 10-<faM indomethacin. ECso values were 3.9 + 0.6 x 
10~BM (n=4) in intact untreated aorta, 7.5 + 1.0 x 10“eM
(n=4) in intact indomethacin treated aorta, 8.2 + 1.8 x
10_SM (n=4) in de-endothelialised untreated aorta and 1.2 
—  0.3 x 10-<bM (n=4) in de—endothe 1 ia 1 ised indomethacin
treated aorta.
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10-^M (n=4) respectively).
Exposure of intact aortic strips to l x l O ^ M  NDGA had 
no significant effect (P>0.20) on EET-induced relaxations 
(Fig. 3.8). 5(6)-EET was again relaxant in the range
3xiO-s>M to 3xlO~‘7’M with an ECao value of 3.1 + 0.7 x 
10~eM (n=4). The other three EETs were relaxant in the
range lxlO“*»M to 3xlO“*M (ECso values were 4.8 + 0.8 x 
10“*M for 8(9)-EET; 5.9 + 0.6 x 10“*M for 11(12)-EET and
7.7 + 1.1 x lO-^M for 14(15)-EET. All n=4).
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EET-induced relaxation of aortic strips in the presence of NDGA
% relaxation
100T
20 “
Log conc. 
~ ’ (M)
•  5(6)-EET ■ 8(9)-EET « 1 1(12)-EET A14(15)-EET
F" I G U R E  3 - 0
Effect of NDGA on EET-induced relaxation in rat aortic 
strips with an intact endothelial lining. Pre-incubation 
with lxiO-<feM NDGA had no significant effect on 
EET-induced relaxation. EC»o values in the presence of 
NDGA were 3.1 + 0.7 x 10-eM (n=4), 4.8 + 0.8 x 10_<feM
(n=4), 5.9 + 0.6 x 10~*M (n=4) and 7.7 + 1.1 x 10“*M
(n=4) for 5(6)-, 8(9)-, 11(12)- and 14(15)-EET
respectively.
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3.4.5; Effect of M&B 22.948 on EET-induced Relaxations of 
Rat Aorta
Pre-incubation of intact rat aortic strips with
3xlO-AM M&B 22,948 for 5 minutes prior to the addition of
PE significantly (P<0.001) attenuated the contractile
response observed (Fig. 3.9). PE-induced contraction, in
the presence of M&B 22,948 was observed in the range of
3xlO~eM to 3xiO~AM with an EC»o value of 1.7 + 0 . 1  x
10-^M (n=6) (c.f. ECso of 9.8 + 0.7 x lO-^M (n=6) in the
absence of M&B 22,948). ACh- and NaNP-induced relaxant 
responses were both augmented by pre-incubation with M&B
22,948. In the presence of M&B 22,948, ACh induced 
relaxation in the range lxl0_loM to lxlO~'7M with an EC»o 
value of 3.1 + 0.7 x 10“** (n=6) (c.f. 1.7 + 0.3 x 10“®M
(n=6) in the absence of M&B 22,948; P<0.002) (Fig. 3.10), 
and NaNP induced relaxation in the range Ixl0-XXM to
3xlO-eM with an EC»o value of 7.0 + 0.8 x 10” iO (n=6)
(c.f. 2.0 + 0.2 x 10-**M (n=6) in the absence of M&B
22,948; P<0.001) (Fig. 3.11).
Due to the relaxatory effect of M&B 22,948, exerted 
through its augmentation of EDRF in intact aortic strips, 
subsequent investigations utilised de-endothelialised 
strips. Relaxations of de-endothelialised strips induced 
by 8(9)-, 11(12)- and 14(15)-EET were significantly
(P<0.002) augmented in the presence of M&B 22,948 (Fig. 
3.12). The 5(6)-EET-induced response was unaltered 
(P>0.90), relaxation being observed in the range 3xlO_<?M
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to lxlO-^M with an ECso value of 7.8 + i.8 x 10“eM (n=4) 
(c.f. 8.5 + 1.6 x 10_eM (n=4) in the absence of M&B
22,948). 8(9)-, 11(12)- and 14(15)-EETs induced
relaxation in the range l O ^ M  to 10~®M with ECso values 
of 1.2 + 0.3 x 10-*M (n=4), 1.8 + 0.2 x 10-*M (n=4) and
1.6 + 0.2 x 10-,£»M (n=4) respectively (c.f. 5.9 + 0.9 x
10-<bM (n = 4 ) , 6.5 + 0.7 x 10_<t>M (n=4) and 7.2 + 1.0 x
10“*»M (n=4) respectively in the absence of M&B 22,948).
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Effect of M&B22,948 on PE-induced contraction of rat aortic strips
% contraction
Log conc.
— 7 (M)
■ 3pM M&B22,948e No M&B22,948
F - X G U R E  3 . 9 ?
Effect of M&B 22,948 on PE-induced contraction of rat 
thoracic aortic strips with an intact endothelial lining. 
The potency of PE was decreased following pre—incubation 
of the tissues with M&B 22,948. In the absence of M&B
22,948, PE induced contraction with an EC»o of 9.8 + 0.7 
x 10-^M (n=6). In the presence of M&B 22,948 the EC»0 for 
PE-induced contraction increased to 1.7 + 0.1 x 10_7rM 
(n = 6 ).
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Effect of M&B22,948 on AChHnduced relaxation of rat aortic strips
% relaxation
1001
Log conc. 
“ I  (M)
- 1 1
■ 3pM M&B22,948e No M&B22,948
F I G U R E  3 - 1 0
Effect of M&B 22,948 on ACh-induced relaxation of rat 
thoracic aortic strips with an intact endothelial lining. 
The potency of ACh was increased following pre—incubation 
of the tissues with M&B 22,948. In the absence of M&B
22,948, ACh induced relaxation with an EC»c> of 1.7 + 0.3 
x 10-eM (n=6). In the presence of M&B 22,948 the ECSo for 
ACh-induced relaxation decreased to 3.1 + 0.7 x 10-I?M
(n = 6 ) .
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Effect of M&B22,948 on NaNP-induced relaxation of rat aortic strips
% relaxation
1201
Log conc. 
(M)
-10-12
■ 3pM M&B22,948# No M&B22,948
X G U R E  3 . ±  ±
Effect of M&B 22,948 on NaNP-induced relaxation of rat 
thoracic aortic strips with an intact endothelial lining. 
The potency of NaNP was increased following 
pre-incubation of the tissues with M&B 22,948. In the 
absence of M&B 22,948, NaNP induced relaxation with an 
of 2.0 + 0.2 x 10_,?M (n=6). In the presence of M&B 
22,948 the ECs© for NaNP-induced relaxation decreased to
7.0 + 0 . 8  x 10-loM (n=6).
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Effect of M&B22,948 on EET-induced relaxation of rat aortic strips
% relaxation 
ieei
Log conc. 
(M)-10
•  5(6)-EET ■ 8(9)-EET •11(12)-EET A14(15)-EET
 Control
F^IGLJRE 3 - ±  2
Effect of M&B 22,948 on EET-induced relaxation of rat 
thoracic aortic strips denuded of endothelium. The 
potencies of 8(9)-, 11(12)- and 14(15)-EETs were
increased following pre-incubation of the tissues with 
M&B 22,948, however the response to 5(6)-EET was 
unaltered. The ECS«:> values for the individual EETs in the 
presence of M&B 22,948 (c.f. absence of M&B 22,948) were: 
for 5(6)-EET 7.8 + 1.8 x 10“eM (c.f. 8.5 + 1.6 x 10~eM);
for 8(9)-EET 1.2 + 0.3 x 10-^M (c.f. 5.9 + 0.9 x 10“*M); 
for 11(12)-EET 1.8 + 0.2 x 10-^M (c.f. 6.5 + 0.7 x
10-^M); and for 14(15)-EET 1.6 + 0.2 x lO—^M (c.f. 7.2 +
1.0 x 10-^M). n=4.
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3.5; RESULTS: GUINEA-PIG TRACHEA
3.5.1: Control Responses
After two hours a stable basal tone of approximately 1 
to 1.5g was reached. Tracheal strips exposed to 
indomethacin throughout the equilibration period 
continually decreased in tone finally aquiring a resting 
tension of approximately lg (Fig. 3.13a). However 
tracheal strips not exposed to indomethacin initially
demonstrated a reduction in tone for approximately 40
minutes, followed by an increase in tone to a final 
resting tension of approximately 1.5g (Fig. 3.13b).
Drug induced tension was developed in the tissue using 
ACh concentrations greater than 10~'7’M (Fig. 3.14). A 
maximal response to ACh was not achieved as exposure to 
ACh concentrations greater than 10-3M rendered the tissue 
less responsive to subsequent drug applications. A 
suitable sustainable submaximal tone of 2g was induced by 
3xlO_<feM and lxlO~*M ACh in the presence and absence of 
indomethacin respectively. The increase in sensitivity of 
the tracheal strips to ACh-induced tone was significant 
at the higher concentrations (P<0.05). NaNP-induced 
relaxations were obtained in the range 10“,PM to 10~3M,
with EC»o values of 2.0 + 0.5 x 10_,f»M (n=7) and 3.0 + 0.6
x 10-^M (n=S) for control and indomethacin treated
tissues respectively (Fig. 3.15). In the presence of 3uM
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indomethacin the maximal NaNP-induced relaxation was
significantly less than in tissues not treated with
indomethacin (P<0.03). Maximal relaxation with no
indomethacin was 100.4 + 10.3% as opposed to 75.6 + 2.4%
in the presence of indomethacin.
-84-
Tension (g)
Time 
* (mins.)40 80
F I G U R E  3  - :L3«=3i
Representative trace showing the continual decrease in 
basal tone of guinea-pig isolated tracheal rings 
throughout equilibration in the presence of indomethacin. 
The final basal tone of tracheal rings incubated with 
indomethacin was always less than that of untreated 
rings.
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A
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 ^Time
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F I G U R E  3  - 1  3  t>
Representative trace showing an increase in basal tone 
during equilibration of guinea-pig isolated tracheal 
rings in the absence of indomethacin. This increase 
characteristically occured after 40 minutes.
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ACh-induced contraction of guinea-pig trachea
Tension (g)
Log conc. 
~~! (M)TT T TT T
▲ No hdomethacin e 3pM indomethacin
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ACh-induced contraction of guinea-pig tracheal rings in 
the presence and absence of 3xlO_,feM indomethacin. 
Exposure of the tracheal rings to indomethacin increase 
the magnitude of response observed to ACh. EC»0 values 
for ACh-induced contractions were not calculated as 
maximal responses could not be obtained without causing 
lasting desensitization to the preparations.
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NaNP-i nduced relaxation of guinea-pig trachea
% Relaxation
Log conc. 
(M)T T
▲No indomethacin •  3pM indomethacin
F I G U R E  3 . 1 5
NaNP-induced relaxation of guinea-pig tracheal rings in 
the presence and absence of 3xlO-,s,M indomethacin. 
Exposure of the tracheal rings to indomethacin decrease 
the magnitude of response observed to NaNP. EC00 values 
for NaNP-induced relaxation were 2.0 + 0.5 x 10~*M (n=7)
in the absence of indomethacin and 3.0 + 0.6 x 10_AM
(n=8) in the presence of indomethacin.
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3.5.2; EET-induced Relaxation of Guinea-pia Trachea
All four EETs induced a dose-dependent relaxation in 
guinea-pig tracheal strips (Fig. 3.16). 5(6)-EET induced 
a dose-dependent relaxation in the range 10“'7’M to 3xiO"“°M 
with an EC30 value of 1.3 + 0.5 x 10”AM (n=8). The
5(6)-EET was significantly more potent then the other 
three EETs (PC0.01). 8(9)-, 11(12)- and 14(15)-EET were 
roughly equipotent and induced relaxation in the range 
10-°M to 3xlO-*M. The EC3o values for 8(9)-, 11(12)- and 
14(15)-EET were 7.3 + 0.4 x 10“®M (n=5), 2.8 + 1.6 x
10~*M (n=5) and 6.4 + 0.3 x 10“®M (n=4) respectively.
Maximal relaxation observed with 3xlO~*M 5(6)-EET was 
only 60.67. + 5.0% of maximal NaNP-induced relaxation.
Maximal relaxation observed with the other three isomers 
at a concentration of 3x10”^  to lxl0*“3M was 
approximately 80-100% of maximal NaNP-induced relaxation.
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EET-induced relaxation of guinea-pig tracheal rings (No indomethacin)
% relaxation
Log conc. 
“ L <M)
e 5(6)-EET ■ 8(9)-EET •  11(12)-EET ▲ 14(15)-EET
F I G U R E  3 _ 1
EET-induced relaxation of guinea-pig tracheal rings. All 
four EET-isomers induced a dose dependent relaxation of 
trachea. 5(6)-EET was more potent than the other isomers 
and induced relaxation with an EC3o of 1.3 + 0.5 x 10_AM 
(n=B). ECb o values for the 8(9)-, 11(12)- and 14(15)-EETs 
were 7.3 + 0.4 x 10-®M (n=5), 2.8 + 1.6 x 10~®M (n=5) and
6.4 + 0.3 x 10-*M (n=4) respective1y .
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3.5.3s Effects of Indomethacin and NDGft on EET-induced
Relaxation of Guinea-pig Trachea
Figure 3.17 shows a representative relaxation response 
of a guinea-pig tracheal strip to 5(6)-EET in (a) the 
absence of indomethacin and (b) the presence of 
indomethacin.
Exposure of the trachea to 3xlO“^M indomethacin 
reduced the potency of 5(6)-EET (Fig. 3.18). In the 
presence of indomethacin 5(6)-EET induced relaxation in 
the range l x l O ^ M  to 3xlO“<q’M with an ECso value of 4.3 + 
0.6 x 10“*M (n=4). 8(9)-, 11(12)- and 14(15)-EET induced 
relaxation in the range lxlO-=kM to 3xlO“^M and had EC»o 
values of 1.4 + 0.3 x 10“'*M (n=3), 1.2 + 0.3 x 10“*M
(n=3) and 9.9 + 1.8 x 10- *M (n=3) respectively (Fig.
3.19). 8(9)-, 11(12)- and 14(15)-EET induced relaxations
in the presence of indomethacin were not significantly 
different from that in the absence of indomethacin 
(P>0.30). In the presence of indomethacin the maximal 
5(6)—EET induced relaxation (76.3/C + 4.0/C) was comparable 
to that induced by the other three EETs.
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5(6)-EET 
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->Time
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Representative traces of 5(6)-EET-induced relaxation of 
guinea-pig isolated tracheal rings in the a) absence of 
indomethacin and b) presence of indomethacin.
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5(6)-EET-induced relaxation of guinea-pig tracheal rings (±3pM indomethacin)
% relaxation
60-
Log conc.
“I (M)
■ 3pM indomethacin•  No indomethacin
F I G U R E  3 _ 1 ©
5(6)-EET-induced relaxation in the presence and absence 
of indomethacin. Direct comparison of the two 
dose-response curves highlights the reduced potency but 
increased efficacy of the 5(6)—isomer following exposure 
of tracheal to indomethacin.
-93-
EET-induced relaxation of guinea-pig tracheal tags (+3uM indomethacin)
% relaxation
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Log conc. 
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e 5(6)-EET ■ 8(9)-EET •  11(12)-EET a 14(15)-EET
X G U R E  3 . 1 ^
EET-induced relaxation of guinea-pig tracheal strips in 
the presence of 3xlO-,!bM indomethacin. All four
EET-isomers induced a dose dependent relaxation of 
trachea. The potency of 5(6)-EET was reduced in the 
presence of indomethacin, EC»0 = 4.3 + 0.6 x 10“®N (n=4). 
The responses to the other EETs were unaltered by 
indomethacin, EC»0 values for the 8(9)-, 11(12)- and 
14(15)-EETs were 1.4 + 0.3 x 10“*M (n=3), 1.2 + 0.3 x
10-AM (n=3) and 9.9 + 1.8 x 10-®M (n=3) respectively. The 
degree of relaxation to 8(9)-, 11(12)- and 14(15)-EET was 
reduced in the presence of indomethacin.
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Exposure of guinea-pig tracheal strips to lxlO“*M NDGA 
had no significant effect (P>0.20) on EET-induced 
relaxations (Fig. 3.20). 5(6)-EET induced relaxation in 
the range lxlO-^M to 3xlO_59M with an ECso value of 9.7 +
1.1 x lO-^M (n=4). The other three EETs were relaxant in 
the range lxlO“®M to lxlO“3M (EC90 values were i.O + 0 . 1  
x 10“*M for 8(9)-EET, 9.5 + 1.6 x 10-®M for 11(12)-EET
and 9.5 + 1.5 x 10“*M for 14(15)-EET. All n=4).
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EET-induced relaxation of guinea-pig trachea in the presence of NDGA
% relaxation
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Effect of NDGA on EET-induced relaxation in guinea-pig 
tracheal rings. Pre-incubation with lxlO-^M NDGA had no 
significant effect on EET-induced relaxation. ECso values 
in the presence of NDGA were 9.7 + 1.1 x 10-^M (n=4), 1.0
+ 0.1 x 10-^M (n=4), 9.5 + 1.6 x 10“*M (n=4) and 9.5 +
1.5 x 10~*M (n=4) for 5(6)-, 8(9)-, 11(12)- and
14(15)-EET respectively.
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3.5.4; Effect of M&B 22,948 on EET-induced Relaxation of
Guinea-pig Trachea
Pre-incubation of guinea-pig tracheal strips with 
3xlO-<4,M M&B 22,948 for 5 minutes prior to the addition of 
ACh had no effect on ACh-induced contractions. Although 
NaNP-induced relaxations were augmented by M&B 22,948 
the increase in potency was not significant (P=0.06), 
EC9o value for NaNP-induced relaxation in the presence of 
3xlO-*M M&B 22,948 was 4.7 + 0.8 x 10~^M (n=4) (c.f. 1.3
+ 0.4 x 10-AM (n=4) in the absence of M&B 22,948) (Fig.
3.21). 8(9)-, 11(12)- and 14(15)-EET induced relaxations
of guinea-pig tracheal strips were significantly 
(P<0.002) augmented in the presence of M&B 22,948, 
however 5(6)-EET-induced relaxation was not significantly 
(P > 0 .20) altered (Fig. 3.22). 5(6)-EET-induced relaxation 
in the range Ixl0-,?’M to 3xl0“®M with an ECSo of 2.0 + 0.4 
x 10_<£>M (n=4) (c.f. 1.4 + 0.6 x 10“*M (n = 4 ) in the
absence of M&B 22,948). 8(9)-, 11(12)- and 14(15)-EETs 
induced relaxation in the range lxl0“<bM to 3xl0-4M with 
ECso values of 4.9 + 0.7 x 10“SM (n=4), 3.5 + 0.8 x
10~*M (n=4) and 3.7 + 1.2 x 10_ *M (n=4) respectively
(c.f. 1.3 + 0.2 x 10-^M (n=4) for 8(9)-EET; 1.2 + 0.2 x
10“*M (n = 4 ) for 11(12)-EET and 9.2 + 0.9 x 10~*M (n=4)
for 14(15)—E E T ).
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Effect of M&B22,948 on NaNP-induced relaxation of guinea-pig trachea
% relaxation 
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Effect of M&B 22,948 on NaNP-induced relaxation of 
guinea-pig tracheal rings. The potency of NaNP was 
increased following pre-incubation of the tissues with 
M&B 22,948. In the absence of M&B 22,948, NaNP induced 
relaxation with an EC»o of 1.3 + 0.4 x 10“^M (n=4). In
the presence of M&B 22,948 the EC00 for NaNP-induced 
relaxation decreased to 4.7 + 0.8 x iQ-^M (n=4).
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Effect of M&B22,948 on EET-induced relaxation of guinea-pig trachea
% relaxation
Log conc. 
7 ,  (M)
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Effect of M&B 22,948 on EET-induced relaxation of 
guinea-pig tracheal rings. The potencies of the 8(9)-, 
11(12)- and 14(15)- EET-isomers was increased following 
pre-incubation of the tissues with M&B 22,948. The 
response to 5(6)-EET was unaltered. The ECso values for 
the individual EETs in the presence of M&B 22,948 (c.f. 
absence of M&B 22,948) were: for 5(6)-EET 2.0 + 0.4 x
10-^M (c.f. 1.4 + 0 . 6  x 10-^M); for 8(9)-EET 4.9 + 0 . 7  x
10-*M (c.f. 1.3 + 0.2 x 10“*M); for 11(12)-EET 3.5 + 0.8
x 10-®M (c.f. 1.2 + 0.3 x 10“*M); and for 14(15)-EET 3.7
+ 1.2 x 10-*M (c.f. 9.2 + 0.9 x 10“»M). n=4.
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3.6; DISCUSSION
3.6.1a; Aortic Responses
The observation that aortic strips with an intact 
endothelial lining, taken from rats with a body weight of 
less than 300-330g, were not capable of maintaining a 
stable PE-induced contracture was not further 
investigated. Some indication of the possible cause was 
demonstrated by the ability of de-endothelialised strips 
to maintain a steady contraction to PE. This would 
suggest the participation of the endothelium and possibly 
EDRF. A similar observation was reported by Ignarro et 
al., (1987). Small branches of unrubbed bovine 
intrapulmonary arteries and veins were less able to
maintain a steady level of sub-maximal PE-induced 
contraction than larger branches. Ignarro et a l . (1987)
suggested that the larger endothelium:smooth muscle ratio 
found in smaller vessels could be responsible. 
Alternatively, in this case, the greater age of the
larger rats must also be considered. The ability of the 
endothelial lining to release EDRF may be impaired with 
age.
Consistent with the theory of a basal release of EDRF
(Griffith et al. 1984; Martin et al., 1985) is the
difference in responses to PE observed in intact and 
de-endothelialised aortic strips. These differences were 
evident in strips taken from the same area of the same
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aorta. Such a basal release is also suggested by the 
reduced sensitivity of intact aortic strips to PE in the 
presence of M&B 22,948 (see later).
3.6.lbs Tracheal Responses
The differences in basal tone, ACh-induced contraction 
and NaNP-induced relaxation between tracheal rings in the 
presence and absence of indomethacin are probably a 
result of spontaneously-released eicosanoids. The 
involvement of eicosanoids in indomethacin potentiation 
of agonist-induced contractions in guinea-pig tracheal 
preparations has been described by Orehek et al., (1975). 
The reduction in basal tone was suggested to be a result 
of decreased PGF2m synthesis (Orehek et a l . (1975), such
a basal release being supported by the observations of 
Tschirhart et al., (1987). Furthermore, attenuation of 
ACh-induced contractions at low doses by indomethacin was 
also observed. Alternatively, basal tone may result from 
the action of PGEa on EPa. receptors (Dond et a l . , 1986) 
stimulating the IP3/DAG pathway. The eicosanoid 
responsible for opposing agonist-induced contraction has 
been identified as PGEZ (Orehek et a l ., 1975), in this 
case PGE2 would exert its effects through the stimulation 
of the EPa receptor. Furthermore Orehek et al. (1975) 
demonstrated that these alterations in contractile and 
relaxant responses were not simply a consequence of 
differences in initial resting tension. Whilst the
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potentiation of histamine-induced contractions of 
guinea-pig tracheal strips by indomethacin or 
de-epithelialisation is readily acknowledged, such 
potentiations of ACh-induced contractions have also been 
reported (Flavahan, 1985; Holryod, 1986; Murlas, 1986).
Lipoxygenase-derived products are acknowledged to be 
responsible for the hyper— reactivity of tracheal 
preparations treated with indomethacin or other 
eyelo-oxygenase inhibitors. Various lipoxygenase 
inhibitors have been shown to reverse the potentiating 
effects of indomethacin on contractile agonists (Mitchell 
1982a, 1982b, 1982c, 1984). However leukotriene-induced 
contracture is believed to be of minor importance in 
comparison to inhibition of prostaglandin-induced 
relaxation (Jones et a l ., 1988).
The reduced relaxation of guinea-pig tracheal strips 
induced by NaNP following pre-incubation with 
indomethacin observed here contrasts with the inability 
of de-epithelialisation to reduce the potency of 
nitroglycerin reported by Goldie et a l . (1986). Both
relaxants exert their effects by stimulation of guanylate 
cyclase so similar results would have been expected. Of 
probable significance is the lack of effect of 
de-epithelialisation on ACh-induced contraction described 
by Goldie et a l . (1986). The discrepancies observed with
the nitrovasodilators are probably an extention of the 
differing results obtained with ACh and could demonstrate 
some fundamental experimental variance.
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3.6.2a: EET-induced Relaxations in the Aorta
The discovery of a cytochrome P4»o pathway for AA,
producing a series of EETs, raises the question as to
their role in the control of smooth muscle activity.
Vasodilation has been demonstrated to 5(6)-, 8(9)- and 
11(12)-EET in the rat intestinal microcirculation 
(Procter et a l ., 1987). In addition, during the course of 
this investigation, two further reports of EET-induced 
vasoactivity have been published (Carroll et a l . 1987, 
1988). Utilising the rat tail caudal artery, Carroll et 
al ., demonstrated 5(6)-EET to be vasorelaxant, the
observed activity being eyelo-oxygenase dependent. No 
vascular response was observed for the 8(9)-, 11(12)- and 
14(15)—EETs.
In contrast to the findings of Carroll et al. (1987), 
all four EETs proved to be relaxant in the rat thoracic 
aorta. This discrepancy may be due to the use of
different vascular preparations (the tail being a heat 
loss organ in the rat). Alternatively, the other EETs may 
have proved vasorelaxant in the caudal artery at
concentrations greater than 2xlO~AM. The 5(6)-isomer 
proved to be approximately 100 times more potent than the
other isomers in the aorta. The greater potency of
5(6)-EET in the aorta is in accordance with the results 
observed in the intestinal microcirculation (Procter et 
al., 1987).
-103-
3,6.2b: EET-induced Relaxation in the Trachea
All four EETs were found to relax guinea-pig tracheal 
smooth muscle. Again the 5(6)-isomer was approximately 
100 fold more potent than the other three epoxides, the 
potencies of which did not differ significantly in either 
tissue. However there were some important differences 
between EET-induced relaxations in tracheal and aortic 
preparations. The concentration of all four EETs required 
to induce relaxation in the trachea were 10 to 100 fold 
greater than in the aorta. Furthermore the maximal 
relaxation to 5(6)-EET in trachea was only 607. of maximal 
relaxation (NaNP-induced), whereas in the aorta 1007 
relaxation to 5(6)-EET was observed. 8(9)-, 11(12)- and
14(15)-EETs induced relaxations greater than 807 with 
respect to NaNP.
The greater potency of the 5(6)-EET in both aortic and 
tracheal preparations may be a result of its further 
conversion to a compound of greater potency. Indeed the 
8,11,14 triene conformation preserved in 5(6)-EET 
following arachidonate epoxidation is known to be 
essential for eyelo-oxygenase substrates. This 
configuration is not preserved in the 8(9)-, 11(12)- and 
14(15)-isomers. Indeed, Oliw (1984) has demonstrated the 
metabolism of 5(6)-EET by eyelo-oxygenase to 
prostaglandin epoxy-endoperoxides and to epoxy-PGE* and 
epoxy-PGFi.. The implications of further eyelo-oxygenase
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and lipoxygenase conversions in EET-induced responses 
will be discussed later.
3.6.3: Endothelial Cell Involvement in EET-induced
Relaxations of Rat Thoracic Aorta
Attenuation of the 5(6)-EET-induced response by the 
process of de-endothelialisation further supports the 
idea of conversion of 5(6)-EET to a compound with 
increased relaxant potency and would appear to locate 
this process to the endothelium. Preservation of the NaNP 
response militates against smooth muscle damage being the 
cause of the reduced relaxant effect. This was further 
supported by the absence of any alteration in 8(9)-, 
11(12)- and 14(15)-EET-induced responses.
The fact that following de-endothelialisation the 
potency of 5(6)-EET did not revert back to the position 
of the other EETs may be explained by: 1) a small amount 
of endothelium, sufficient to maintain some conversion of 
5(6)-EET, remained intact, 2) 5(6)-EET conversion may
also take place in the smooth muscle.
In the rat caudal artery (Carroll et al., 1988), 
de-endothelialisation almost totally abolished 5(6)-EET- 
induced relaxation. This result differs from those 
reported here, the ECso in denuded vessels was only twice 
that in intact preparations. This may demonstrate a 
greater role for the endothelial lining in 5(6)-EET— 
induced relaxation of the caudal artery than in thoracic
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aorta.
3.6.4a; Effect of Indomethacin and NDGft on Aortic
Relaxations Induced by the EETs
Exposure of aortic strips to 3xlO-tf*M indomethacin 
reduced the potency of 5(6)-EET to a similar degree as 
did the process of de-endothelialisation. Exposure to 
indomethacin had no inhibitory effect on 8(9)-, 11(12)- 
and 14(15)-EET induced responses. The reduced potency of 
5(6)-EET in the presence of indomethacin suggests that a 
eyelo-oxygenase product of 5(6)-EET may contribute to the 
relaxant effects noted. Exposure to indomethacin was also i 
reported to inhibit 5(6)-EET induced relaxation of the 
rat caudal artery (Carroll et al., 1988). The findings 
reported here in part agree with the proposal by Carroll 
et al., (1988) that the activity of 5(6)-EET requires an 
intact endothelium and further metabolism through cyclo— 
oxygenase. However, in the aorta 5(6)-EET also has a 
direct action of its own.
The inhibitory effect of indomethacin proved to be 
additive to that of de-endothelialisation. The 
concentration of 5(6)-EET required to induced relaxation 
in de-endothelialised aortic strips exposed to 
indomethacin was nearly the same as that of the other 
three EETs. The additive effects of both these treatments 
suggests that in isolation each treatment was not 
sufficient to completely block eyelo-oxygenase activity.
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Further investigations utilising a higher concentration 
of indomethacin (say lxlO“*M) with or without de-endo­
thel ia 1 isation may reduce the potency of 5(6)-EET to that 
of the other EETs. Alternatively 5(6)-EET be acting 
through a mechanism additional to eyelo-oxygenase which 
is located in the endothelium.
In accordance with the findings of Carroll et al. 
(1988), lipoxygenase inhibition by NDGA had no effect on 
5(6)-EET induced relaxation. Furthermore, exposure to 
NDGA had no effect on the relaxations induced by the
other EETs. These findings would indicate that the
lipoxygenase pathway plays no role in EET-induced 
responses in vascular tissue.
3.6.4b: Effect of Indomethacin and NDGA on Tracheal
Relaxations Induced by the EETs
Exposure of the trachea to indomethacin had a more 
pronounced inhibitory effect on the 5(6)-EET-induced 
relaxant response than observed in rat aorta. In contrast 
to the slight decrease in potency of 5(6)-EET in intact 
aorta, the potency of 5(6)-EET in trachea was reduced, 
becoming similar to that of the other EETs. The differing 
ability of indomethacin to attenuate 5(6)-EET-induced 
responses in aorta and trachea may be due to the 
different protocols used. Continual exposure to
indomethacin in the tracheal rings could have reduced 
eyelo-oxygenase activity more effectively than the 5
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minute pre-incubation allowed in the aortic strips. 
Continual exposure of the aortic preparations to
indomethacin may attenuate 5(6)-EET responses to the same 
degree observed in tracheal rings.
The maximal response to 5(6)-EET in the trachea was 
increased in the presence of indomethacin. However in 
contrast, although the potencies of 8(9)-, 11(12)- and
14(15)-EET were not altered in the presence of
indomethacin, the maximal responses observed were reduced 
by as much as 157.. This reduction in maximal relaxation 
to 8(9)-, 11(12)- and 14(15)-EET in the presence of
indomethacin may be explained by the blockade of release 
of an inhibitory eyelo-oxygenase product by the
epithelium (Butler et al., 1987). The increased response 
(but decreased potency) of 5(6)-EET in the presence of 
indomethacin supports the idea of two components to the 
5(6)-EET response acting by different mechanisms. In the 
presence of indomethacin 5(6)-EET could act through the 
same mechanism as the other EETs, probably a direct 
action on the smooth muscle. De-epithelialised tracheal 
rings exposed to indomethacin would probably show similar 
responses to all four EETs.
From the work of Oliw (1984) the most likely product 
of 5(6)-EET metabolism by eyelo-oxygenase capable of 
inducing relaxation in the trachea would be epoxy-PGEi. 
This correlates well with the findings of Coleman and 
Kennedy (1980) on the relaxant activity of PGEX in 
pre-contracted guinea-pig trachea. PGEi was found to be
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relaxant over the same dose range as that identified for 
5(6)-EET, the half maximal concentration for PGE* being 
4.8xlO_?,M compared to 1.3xlO~AM for 5(6)-EET. Furthermore 
the maximal relaxation observed with both PGEx and 
5(6)-EET in ACh-precontracted guinea-pig trachea is 60% 
in both cases. However, there is no direct evidence 
regarding the potency of epoxy-PGEj. in tracheal 
preparations.
As with aortic preparations, the involvement of the 
lipoxygenase pathway in EET-induced responses was 
militated against due to the absence of an effect with 
lxlO-^M NDGA. The lack of any effect of NDGA on 
ACh-induced precontraction and NaNP-induced relaxation is 
of some interest. As previously discussed (section 3.6.1) 
in addition to an inhibitory eyelo-oxygenase product, the 
trachea has been shown to release a bronchoconstrictor 
lipoxygenase product (Mitchell, 1982a,b,c,d, 1984). 
However it should be noted that a reduction in 
ACh-induced response following exposure to NDGA was not 
observed, although exposure to indomethacin did increase 
the ACh-response. Furthermore in the presence of 
inhibitory eyelo-oxygenase products the leukotrienes play 
only a minor role (Jones et al., 1988). As a result any 
small change which may occur following lipoxygenase 
inhibition would be masked by the dominant cyclo- 
oxygenase effect. Exposure of indomethacin-treated 
tracheal rings to NDGA may indeed reverse the potentiaion 
of the ACh- and NaNP-induced responses. Alternatively the
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concentration of NDGA utilised here may have been too low 
to produce any significant effects. However previous 
reports have shown ixlO“<feM NDGA to effectively inhibit 
lipoxygenase activity in guinea-pig tracheal preparations 
(Yen, 1981; Burka, 1985; Chand et al., 1986).
3.6.5a; Effect of M&B 22.948 on Aortic Relaxations
The involvement of cGMP in aortic preparations was 
investigated utilising the cGMP-specific phospho­
diesterase inhibitor M&B 22,948 (Weishaar et al., 1986). 
3xlO-tf,M of M&B 22,948 was observed to reduce the potency 
of PE in contracting aortic strips. Furthermore 
cGMP-phosphodiesterase inhibition was also found to 
augment the relaxant properties of ACh and NaNP. An 
understanding of the mechanism of action of EDRF readily 
explains these observations. As previously discussed, 
intact aortic strips release a basal level of EDRF
(Griffith et al. 1984; Martin et al., 1985). Both EDRF-
and nitrovasodilator— induced relaxations have been
associated with increases in cGMP, and inhibition of cGMP 
formation and catabolism have also been shown to reduce
and augment, respectively, such relaxant responses 
(Molina et al., 1987). Investigation of the role of cGMP 
in EET-induced relaxations would have been complicated by 
the basal release of EDRF. For this reason EET-induced 
relaxation was investigated using aortic strips denuded 
of their endothelial lining. Pre-incubation with M&B
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22,948 potentiated the relaxation induced 8(9)-, 11(12)- 
and 14(15)-EET, but not to 5(6)-EET. This would suggest 
cGMP is not involved in the 5(6)-EET relaxatory mechanism 
but is important to the actions of the other EETs. 
However further investigation into the endothelial- 
dependent component of 5(6)-EET-induced relaxation may 
show a cAMP-dependence. The use of selective inhibitors 
of cAMP-phosphodiesterase such as Amipazone or MDL 17,043 
(Weishaar et a l ., 1986) would be useful in evaluating 
such a role for cAMP.
3.6.5b; Effect of M&B 22.948 on Tracheal Relaxations
Exposure of tracheal preparations to M&B 22,948 prior 
to the addition of the EETs had an identical effect to 
that seen in aortic strips, i.e. augmentation of 8(9)-, 
11(12)- and 14(15)-EET-induced relaxant responses, but 
not the 5(6)-EET-induced response. The absence of any 
effect on ACh-induced contraction indicates that cGMP is 
not of importance in the contractile response. As with 
the aorta, NaNP-induced relaxation was augmented in the 
presence of M&B 22,948. Investigations utilising 
cAMP-specific phosphodiesterase inhibitors would again 
verify any cAMP-dependent component in the 5(6)-EET 
relaxant response.
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CHAPTER 4; ACTION OF THE EETs ON RAT BLOOD PLATELETS
4,1; INTRODUCTION
Platelets constitute an essential component of
haemostasis which follows the disruption of the blood 
vessel wall. Aggregation of blood platelets forms a white 
thrombus which acts as the target for blood clot
formation.
Stimulation of platelets by agonists, including 
thrombin, collagen, platelet aggregating factor (PAF), 
serotonin, vasopressin, arachidonic acid, dihomo-y-
linolenic acid, endoperoxide and thromboxane analogues, 
is associated with, and thought to proceed via PLC
hydrolysis of inositol phospholipids (Siess, 1989).
Receptor stimulation is believed to be linked to 
PLC-activation by guanine nucleotide-binding proteins 
(Haslam & Davidson, 1984; Brass et al., 1986). Conclusive
information identifying the precise G-proteins
responsible and the exact mechanisms involved has not 
been resolved. Activation of platelets by epinephrine and 
ADP appears to differ from other agonists, the mechanisms 
being uncertain.
Activation of PLC is known to be independent of 
intracel lular Ca2'4' (Billah & Lapetina, 1982b; Simon et 
a l ., 1984). Furthermore increasing intracellular Ca2+
levels by ionophores does not stimulate PLC (Imai & 
Nozawa, 1982; Rittenhouse-Simmons, 1981; Rittenhouse,
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1984). PLC activity results in the formation of inositol 
1,4,5-trisphophate (IP3 ) and 1,2-diaylglycerol (DAG) 
(Rittenhouse-Simmons, 1979; Billah & Lapetina, 1982b).
□nee liberated, DAG stimulates protein phosphorylation 
through the activation of protein kinase C (Nishizuka, 
1984). Furthermore, increased levels of DAG are known to 
be necessary for granule secretion and exposure of 
fibrinogen receptors essential for aggregation (Shattil & 
Brass, 1987).
Increased IP3 results in an increase in cytosolic 
calcium levels. Release from the dense tubular system is 
widely believed to account for the increase (Berridge & 
Irvine, 1984), however calcium release from Ptdlns 4,5-P= 
upon hydrolysis would also be sufficient to account for 
the observed rise in cytosolic Ca22"* (Billah & Lapetina, 
1982c). Increased levels of cytosolic Ca22"" are essential 
for platelet functioning; including shape change, 
secretion and fibrinogen receptor function (Siess, 1989). 
As a result, factors altering the level of cytosolic 
calcium would undoubtedly affect the aggregabi1ity of 
blood platelets.
To this end, cAMP inhibition of platelet activity is 
well documented (see Haslam et al., 1978). Inhibition of 
platelet function by cAMP is considered to be mediated by 
a reduction in cytosolic Ca2+ levels by an inhibition of 
PLC (Billah et al., 1979; Imai et a l ., 1983).
Alternatively, increased levels of platelet cAMP, in the 
presence of a protein kinase, may reduce cytosolic Ca22""
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levels, and inhibiting platelet function, by stimulating 
calcium uptake into the dense tubular system 
(Kaser— Glanzmann et a l ., 1977).
Inhibition of PLC hydrolysis of Ptdlns 4,5P2 is 
proposed as the mechanism by which cGMP inhibits 
stimulus-induced increases in cytosolic Ca2**" levels 
(Brass & Laposata, 1987; Nakashima et al., 1986).
Metabolites of arachidonic acid can both stimulate or 
inhibit platelet activation. The prostaglandin endo- 
peroxides, G2 and H2 , as well as thromboxane A2 stimulate 
platelet aggregation. PGI2 , PGD2 , PGEX , 12-HPETE and 
12-HETE, on the other hand, increase levels of platelet 
cAMP and inhibit platelet aggregation.
Two reports describing eyelo-oxygenase inhibition by 
8(9)-, 11(12)- and 14(15)-EET (Fitzpatrick et al. 1986, 
1987) also demonstrated inhibition of AA-induced washed 
platelet aggregation by 8(9)-, 11(12)- and 14(15)-EET. 
The anti-aggregatory activity of these three epoxy­
isomers as well as 5(6)-EET against ADP- and 
thrombin-induced aggregation are described here, together 
with results of cyclic nucleotide manipulation on 
EET-induced inhibition.
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4.2: PREPARATION AND INCUBATION OF PLATELETS
Five 9ml aliquots of blood were taken from five 
separate Wistar rats using plastic syringes containing 
lml of trisodium citrate, to prevent clotting, giving a 
final citrate concentration of 0.387.. The whole blood was 
centrifuged in plastic tubes at 220g for twenty minutes. 
The supernatant was re-centrifuged at 220g for 10 minutes 
to remove any remaining red or white blood cells. The 
supernatant (platelet rich plasma, PRP) was removed 
without disturbing the buffy coat. If required, the PRP 
was then centrifuged at 1300g for 15 minutes to sediment 
the platelets. The platelet pellet was resuspended in a 
small volume (approximately 5ml) of lOmM HEPES-Tyrodes 
(pH 7.35) by gently aspirating the solution repeatedly 
with a plastic pasteur pipette. The resultant platelet 
suspension was finally diluted to 600,000 platelets/mm3 
+ 107.. A Coulter Thrombocounter was utilised to ascertain 
the platelet count.
Platelet aggregation was investigated using 0.5ml 
aliquots of washed platelets or PRP in a Payton 
Aggregation Module (37°C, stirred at 500rpm). Changes in 
optical transmittance, indicating platelet aggregation, 
were recorded on a BBC SE120 chart recorder (chart speed 
lcm/minute). The platelets were allowed to equilibrate in 
the aggregometer for two minutes both in the presence and 
absence of the epoxyeicosatrienoic acids. Volumes of 
added drugs were kept below 0.01ml to avoid possible
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dilution effects. The effects of the EETs on both ADP- 
and thrombin-induced platelet aggregation in washed 
platelets, and on ADP-induced aggregation in PRP were 
investigated. Furthermore, anti-aggregatory effects of 
prostacyclin, PGE* and sodium ni troprusside (NaNP) on 
washed platelets were also examined as positive controls.
The possibility of in situ metabolism of the EETs was 
investigated by pre-incubation of the platelets for 30 
seconds with either indomethacin (3xiO-,£»M) or NDGA 
(lxlO-tf*M) prior to the addition of EET.
Cyclic nucleotide involvement in platelet responses to 
the EETs, PGI= and NaNP were evaluated. 0.5ml aliquots of 
platelet suspension were pre-incubated for 30 seconds 
with either papaverine or M&B 22,948. A submaximal dose 
of EET, PGI= or NaNP was then introduced into the 
platelet suspension and the response compared to that in 
the absence of papaverine or M&B 22,948.
Unless otherwise stated, for statistical analysis 
Student's t-test for unpaired observations was used. When 
P was smaller than 0.05 values were considered to be 
significantly different.
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4.3; DETERMINATION OF EET AND PGI^ HALF-RESPONSE TIMES
Blood was taken from Wistar rats as above and the 
platelets separated by the same procedure. For the 
purpose of determination of half-response time, the 
platelets were diluted to 750,000 platelets/mm3 +107.. The 
greater concentration of platelets in this instance 
allowed 0.1ml of Hepes-Tyrodes to be added to the 
aggregometer cuvette prior to the platelet suspension, as 
incubation medium for the test compounds. On addition of 
0.4ml of the platelet suspension, the final platelet 
count would be 600,000 platelets/mm3 +10% as used above.
Doses of the test compounds (EETs and PGI2 ) giving 
100% inhibition of platelet aggregation were added to the 
Hepes-Tyrodes at 37°C. After a predetermined time had 
elapsed (0-180 seconds for PGI = and 0-25 minutes for EET 
determinations), 400ul of platelet suspension was 
introduced to the cuvette followed by the dose of ADP 
known to give 100% aggregation.
By observing the time-dependent decrease in 
anti-aggregatory activity of the test compounds a 
biological half-response time could be calculated.
In addition an approximate chemical half-life was also 
determined from the half-response time results. This was 
achieved utilising the linear portion of a dose-response 
curve (between 30% and 70% of observed maximal 
responses). The concentration giving 70% inhibition of 
platelet aggregation was determined from the individual
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inhibitory dose/response curves, and the respective time 
for this response from the half-response/time plots noted 
(time 1). The expected inhibitory response that would be 
observed for half this concentration of drug was also 
determined from the individual inhibitory dose/response 
curves. The time after which this response would be 
observed was extrapolated from the half-response/time 
plot (time 2). By subtracting time 1 from time 2 an 
approximation of the time taken for 507. chemical 
decomposition could be determined.
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4.4; RESULTS
4.4.1; Effect of ADP and EETs on Platelet Rich Plasma
Aggregation of platelet rich plasma (PRP) was induced 
by ADP in the range 4xlO_AM to 3xlO-*M (EC»0 1-3 + 0 . 1  x 
10-®M (n=7)) (Fig. 4.1). The time taken for complete
aggregation was less than two minutes. A concentration of 
3xlO~®M ADP was sufficient to maintain peak aggregation 
for longer than 1 minute.
All four epoxyeicosatrienoic acids were found to 
inhibit platelet aggregation in PRP (Fig. 4.2). The 
5(6)-isomer was significantly (P<0.001) more potent an 
inhibitor of aggregation than the remaining three 
isomers. Inhibition of PRP aggregation by 5(6)-EET was 
observed in the range lxlO~*»M to 3xlO“®M ( ICso 1.4 + 0.1 
x 10“®M (n = 4 )). The 8(9)-, 11(12)- and 14(15)- isomers
inhibited ADP-induced aggregation of PRP in the range 
Ixl0-=M to 2xlO-*M (ICso values of 8.2 + 0.6 x 10-°M
(n=4), 5.7 + 0 . 3  x 10-*M (n=4) and 5.7 + 0.5 x 10“SM
(n=4) respectively). Inhibition of ADP-induced 
aggregation by 8(9)-, 11(12)- and 14(15)-EET showed no
significant variation between the isomers (P>0.05).
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ADP-induced aggregation of platelet rich plasma. 0.5ml 
aliquots of PRP at 37°C were aggregated by ADP in the 
range 4x10“* to 3xiO-»M (ECso of 1.3 + 0.1 x 10-*M).
Values are expressed as a mean + SEM (n=7).
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EET-inhibition of ADP-induced PRP aggregation
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EET-inhibition of ADP-induced aggregation of platelet 
rich plasma. 0.5ml aliquots of PRP were pre-incubated
with EET for 2 minutes at 37°C prior to the addition of 
ADP. All four EETs inhibited aggregation at micromolar
concentrations. ICso values were 1.4 + 0.1 x 10_®M for
5(6)-EET, 8.2 + 0.6 x 10~®M for 8(9)-EET, 5.7 + 0.3 x
10“®M for 11(12)-EET and 5.7 + 0.5 x 10"®M for
14(15)-EET. Values are expressed as a mean + SEM (n=4).
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4.4.2; Effect of ADP. Thrombin and EETs on Washed
Platelets
ADP was found to be nearly ten fold more potent in 
inducing aggregation of washed platelets than PRP (Fig. 
4.3). Aggregation was observed between 3xlO“'7’M and 
3xlO“*M ADP (ECso 4.8 + 0 . 1  x 10“^M (n=10)). Thrombin-
induced aggregation of washed platelets was observed 
between 0.05 and 0.85 NIHunits/ml (ECso 0.349 + 0.019
NIHuni ts/ml (n=8)) (Fig. 4.4).
EET inhibition of ADP-induced aggregation in washed 
platelets was 10-fold greater than in PRP. Inhibition of 
ADP-induced platelet aggregation by 5(6)-EET was observed 
between lxlO-^M and 2xiO~*M (ICso value 4.2 + 1.0 x 10"7 
(n=4)) (Figure 4.6). 5(6)-EET was significantly more 
active (P<0.005) than 8(9)-, 11(12)- and 14(15)-EET which 
were roughly equipotent (P>0.60), inhibiting aggregation 
in the range lxl0-*M to 2xlO~*M. ICso values for 8(9)-, 
11(12)- and 14(15)-EETs were 6.6 + 1.9 x 10“*M (n=3), 6.7 
+ 2.0 x 10-* (n = 3 ) and 5.7 + 1.1 x 10“*M (n=3)
respectively.
With thrombin as the aggregatory agent (Fig. 4.7), 
5(6)-EET was the most potent anti-aggregatory of the four 
isomers (P<0.001), with an effective dose range of 
lxl0-^M to 2xlO“*M (ICso value; 6.7 + 1.9 x 10~^M
(n=4)). The other EET-isomers were approximately 30-100 
fold less potent than 5(6)-EET, inhibiting 
thrombin-induced aggregation in the range 5xlO~*M to
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5xlO“*M. ICso values for the 8(9)— , 11(12)- and
14(15)-EETs were 4.0 + 0.8 x 10~*M (n=3), 2.2 + 0 . 3  x
10~*M (n=3) and 1.6 + 0.5 x 10“®M (n=3) respectively.
Whilst the 5(6)-EET was equipotent at inhibiting both 
thrombin-induced and ADP-induced aggregation (Fig. 4.5), 
8(9)-, 11(12)- and 14(15)-EET were about ten fold less 
inhibitory against thrombin-induced platelet aggregation 
than against ADP.
Examination of the platelet pre-incubation period with 
the EETs revealed the inhibitory effect of the EETs to be 
immediate. Reduction of the pre-incubation period had no 
effect on the degree of inhibition obtained for any 
particular EET- concentration. It was therefore concluded 
that inhibitory doses of EET could be introduced to the 
platelet suspension just prior to the agonist.
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ADP-induced aggregation of washed platelets
% aggregation
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ADP-induced aggregation of washed platelets. 0.5ml
aliquots of washed platelets were aggregated by ADP at 
37°C. ADP induced aggregation in the range 3xl0“'7lvl to 
3xlO-AM (EC»0 of 4.8 + 0.1 x 10-'7’M). Values are expressed 
as a mean + SEM (n=10).
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Thrombin-Induced aggregation of washed platelets
% aggregation
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Thrombin-induced aggregation of washed platelets. 0.5ml 
aliquots of washed platelets were aggregated by thrombin 
at 37°C. Thrombin induced aggregation in the range 0.05 
to 0.85 NIHunits/ml (EC»o of 0.35 + 0.02 NIHunits/ml).
Values are expressed as a mean + SEM (n=8).
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Representative traces of (a) 5(6)-EET inhibition of
ADP-induced washed platelet aggregation and (b) 5(6)-EET 
inhibition of thrombin-induced washed platelet 
aggregation. Readings have been superimposed.
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EET-inhibition of ADP-induced platelet aggregation
% inhibition
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EET-inhibition of ADP-induced aggregation of washed 
platelets. 0.5ml aliquots of washed platelets were 
pre-incubated with EET for 2 minutes at 37°C prior to the 
addition of ADP. All four EETs inhibited aggregation at 
approximately ten fold lower concentrations than observed 
in PRP. IC»o values were 4.2 + 0.1 x l O ^ M  for 5(6)-EET, 
6.6 + 1.9 x 10-^M for 8<9)-EET, 6.7 + 2.0 x lO-^M for
11(12)-EET and 5.7 + 1.1 x 10-^M for 14(15)-EET. 5(6)-EET 
was significantly more potent than the other EETs 
(PC0.01). Values are expressed as a mean + SEM (n=4 for 
5(6)-EET and n=3 for 8(9)-, 11(12)- and 14(15)-EETs).
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EET-inhibition of thrombin-induced platelet aggregation
% inhibition
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EET-inhibition of thrombin-induced aggregation of washed 
platelets. 0.5ml aliquots of washed platelets were 
pre-incubated with EET for 2 minutes at 37°C prior to the 
addition of thrombin. All four EETs inhibited 
aggregation. IC»0 values were 6.7 + 1 . 9  x lO-^M for
5(6)-EET, 4.0 + 0.8 x 10“®M for 8(9)-EET, 2.2 + 0.3 x
10“ for 11(12)-EET and 1.6 + 0.5 x 10-*M for
14(15)-EET. 5(6)-EET was again the most potent of the
EETs. Values are expressed as a mean + SEM (n=4 for 
5(6)-EET and n=3 for 8(9)-, 11(12)- and 14(15)-EETs).
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4.4.3; Effect of Indomethacin and NDGA on EET-inhibition
of Washed Platelet Aggregation
To investigate whether platelet eyelo-oxygenase or 
lipoxygenase enzymes contributed to the EET-induced
inhibition of aggregation, the platelet suspensions were
pre-incubated with either indomethacin or NDGA for 30
seconds prior to EET addition.
The maximal dose of indomethacin or NDGA which could 
be pre-incubated with washed platelets without altering 
the observed ADP-induced aggregation was ascertained. 
Concentrations of 3xlO_AM indomethacin and lxlO-<feM NDGA
could be incorporated into washed platelet suspensions
without attenuating the aggregation induced by ADR. 
Higher concentrations of both compounds were found to
inhibit ADP-induced platelet aggregation.
Figure 4.8 shows representative platelet aggregation 
traces in which 5(6)-EET inhibitory effects are augmented 
by exposure of the platelets to either indomethacin or 
NDGA.
Pre-incubation of the washed platelets with 3xlO_<feM 
indomethacin for 30 seconds at 37°C prior to the addition 
of the EETs potentiated the anti-aggregatory properties 
of the EETs (Fig. 4.9). Mean changes in percentage 
inhibitory activity of the 5(6)-, 8(9)-, 11(12)- and
14(15)-EETs were 15.8 + 11.0 (n=3), 11.3 + 4.2 (n=3), 7.1
+ 3.5 (n=3) and 6.3 + 2.4 (n=3) respectively. Although
the potentiations were found to be consistent they were
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not statistically significant as determined by the 
students t-test of paired data (P>0.10). The maximal dose 
of indomethacin which could be utilised without affecting 
the ADP-induced response was not sufficient to completely 
block AA-induced platelet aggregation.
Pre-incubation of the washed platelets for 30 seconds 
at 37°C with the lipoxygenase inhibitor NDGA (lxlO“*M) 
also potentiated the anti-aggregatory effects of the EETs 
(Fig. 4.10). Mean percentage changes were 14.7 + 6.2 
(n = 3 ), 5.7 + 1.1 (n=3), 19.9 + 2.9 (n=3) and 9.2 + 1.8
(n=3) respectively. The potentiations were not
statistically significant (P>0.05), as determined by 
Student's t-test of paired data.
Neither indomethacin or NDGA, at the concentrations 
used, had any effect on ADP-induced platelet aggregation.
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Representative traces of indomethacin and NDGA 
augmentation of 5(6)-EET inhibition of ADP-induced washed 
platelet aggregation.
Light transmission
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Effect of indowethacin on EET-inhibition of
RDP-induced platelet aggregation
V. Inhibition
IHDONETHRCIK 
i l  HO INDOHETHRCIN
5(6)-EET 8(9)-EET 11(12)-EET 14(15)-EET
F" I G U R E  ^
Effect of 3xlO-AM indomethacin on submaximal EET 
inhibition of ADP-induced washed platelet aggregation. 
0.5ml aliquots of washed platelets were pre-incubated 
with 3x10”^M indomethacin at 37°C for 30 seconds prior to 
the addition of EET. Following a 30 second pre-incubation 
with a sub-maximal dose of EET the platelets were 
aggregated with ADP. Inhibitory effects of all four EETs 
were augmented in the presence of indomethacin. Mean 
percentage increases in inhibition were 15.8 + 11.0 for 
5(6)-EET, 11.3 + 4.2 for 8(9)-EET, 7.1 + 3.5 for
11(12)-EET and 6.3 + 2.4 for 14(15)-EET. Values are
expressed as a mean + SEM (n=3).
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Effect of HDGfi on EET-inhibition of
RDP-induced platelet aggregation
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Effect of lxlO“*M NDGA on submaximal EET inhibition of 
ADP-induced washed platelet aggregation. 0.5ml aliquots 
of washed platelets were pre-incubated with ixlO-6,M NDGA 
at 37°C for 30 seconds prior to the addition of EET. 
Following a 30 second pre-incubation with a sub-maximal 
dose of EET the platelets were aggregated with ADP. 
Inhibitory effects of all four EETs were augmented in the 
presence of NDGA. Mean percentage increases in inhibition 
were 14.7 + 6.2 for 5(6)-EET, 5.7 + 1.1 for 8(9)-EET,
19.9 + 2.9 for 11(12)-EET and 9.2 + 1.8 for 14(15)-EET. 
Values are expressed as a mean + SEM (n=3).
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4.4.4; Effect of M&B 22,948 on EET-inhibition of Washed
Platelet Aggregation
To obtain some insight into the involvement of cyclic 
nucleotides in the inhibition of platelet aggregation by 
epoxyeicosatrienoic acids, papaverine and M&B22,948 were 
pre-incubated with the platelets prior to the 
introduction of the EETs. PGI2 and NaNP were used as 
positive controls to verify that an adequate 
concentration of phosphodiesterase inhibitor had been 
used to enhance cAMP or cGMP mediated responses.
PGI= was found to be potently anti-aggregatory, 
exceeding 5(6)-EET-induced inhibition 200 fold (Fig. 
4.12). PGI= inhibition of ADP-induced washed platelet 
aggregation was observed between 3xl0-iO to 3xlO_eM with 
an ICso value of 3.5 + 0.4 x 10-,;,M (n=6). NaNP inhibited
washed platelet aggregation in the range 3xlO-AM to 
1x10“3M (ICso 3.9 + 0 . 8  x 10“SM (n=8) (Fig. 4.13).
PGEi was also found to be more potent than 5(6)-EET 
(Fig. 4.11). PGEx inhibited ADP-induced aggregation in 
the range lxl0-,? to 3xl0“7'lvl and had an ICso value of 1.0 
+ 0.5 x 10“SM (n = 4 ).
Pre-incubation of washed platelets with 3xlO-d»M M&B 
22,948 had no significant effect on EET-inhibition of 
ADP-induced platelet aggregation (P>0.10) (Fig. 4.15). 
NaNP-induced inhibition was significantly (P<0.001) 
augmented by the same concentration of M&B 22,948. The 
mean change in NaNP-induced inhibition was 43.0 + 2.17.
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(n=4) compared with the mean changes for 5(6)-, 8(9)-,
11(12)- and 14(15)-EET-induced inhibition of 1.3 + 1.0*/., 
0.5 + 1.6%, 1.3 + 1 . 2 ’/. and 2.0 + 1.07. respectively (all
n=4). ADP-induced aggregations were not effected by 
3xlO-*M M&B 22,948.
Papaverine (3xiO-a»M), a non-selec tive phospho­
diesterase inhibitor, augmented PGI2-inhibition of 
ADP-induced aggregation (Fig. 4.14). The mean change in 
PGIa-induced inhibition was 32.8 + 0.97. (n=4).
EET-induced inhibitions were also augmented by 
papaverine, mean changes for the 5(6)-, 8(9)-, 11(12)- 
and 14(15)-EETs were 31.5 + 1.37., 17.0 + 1.17., 43.3 +
1.7/C and 24.3 + 0.67. respectively (all n=4). The increase 
in inhibitory activity of the EETs and PGIa in the 
presence of 3xlO~"*M papaverine was statistically 
significant P<0.001, (Student's t-test on paired data).
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PGE1 inhibition of ADP-induced platelet aggregation
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PGEi-inhibition of ADP-induced aggregation of washed 
platelets. 0.5ml aliquots of washed platelets were 
pre-incubated with PGEi for 30 seconds at 37°C prior to 
the addition of ADP. PGEX inhibited aggregation in the 
range ixlO-^M to 3xlO“^M ( ICso of 1.0 + 0.5 x 10-eM).
Values are expressed as a mean + SEM (n=4).
R3l2-inhibition of ADP-induced platelet aggregation
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PGI3-inhibition of ADP-induced aggregation of washed 
platelets. 0.5ml aliquots of washed platelets were 
pre-incubated with PGI2 for 30 seconds at 37°C prior to 
the addition of ADP. PGI2 inhibited aggregation in the 
range 3xlO“ioM to 3xlO~eM (ICso of 3.5 + 0.4 x 10-^M).
Values are expressed as a mean + SEM (n=6).
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NaNPHnhibition of ADP-induced platelet aggregation
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NaNP-inhibition of ADP-induced aggregation of washed 
platelets. 0.5ml aliquots of washed platelets were 
pre-incubated with NaNP for 30 seconds at 37°C prior to 
the addition of ADP. NaNP inhibited aggregation in the 
range 3xlO“<s»M to lxlO~3M ( ICso of 3.9 + 0.8 x iO~®M).
Values are expressed as a mean + SEM (n=8).
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Effect of papaverine on prostacyclin- and EET-inhibition
of RDP-induced platelet aggregation
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Effect of 3xlO-,&M papaverine on submaximal EET and PGI2 
inhibition of ADP-induced washed platelet aggregation. 
0.5ml aliquots of washed platelets were pre-incubated 
with 3xlO_tf>M papaverine at 37°C for 30 seconds prior to 
the addition of EET. Following a 30 second pre-incubation 
with a sub-maximal dose of EET or PGIa the platelets were 
aggregated with ADP. Inhibitory effects of all four EETs 
and PGI2 were augmented in the presence of papaverine. 
Mean percentage increases in inhibition were 31.5 + 1 . 3  
for 5(6)-EET, 17.0 + 1.1 for 8(9)-EET, 43.3 + 1.7 for
11(12)-EET, 24.3 + 0.6 for 14(15)-EET and 32.8 + 0.9 for 
PGI2 . Values are expressed as a mean + SEM (n=4).
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Effect of H&B22.948 on NaHP- and EET-inhibition of
flDP-induced platelet aggregation
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Effect of 3xlO-*M M&B 22,948 on submaximal EET and NaNP 
inhibition of ADP—induced washed platelet aggregation. 
0.5ml aliquots of washed platelets were pre-incubated 
with 3x 10-A>M M&B 22,948 at 37°C for 30 seconds prior to 
the addition of EET. Following a 30 second pre—incubation 
with a sub-maximal dose of EET or NaNP the platelets were 
aggregated with ADP. The inhibitory effects of NaNP were 
augmented in the presence of M&B 22,948 whereas the EET 
inhibition was unaltered. Mean percentage increases in 
inhibition were 1.3 + 1.0 for 5(6)-EET, 0.5 + 1.6 for
8(9)-EET, 1.3 + 1.2 for 11(12)-EET, 2.0 + 1.0 for
14(15)-EET and 43.0 + 2.1 for NaNP. Values are expressed 
as a mean + SEM (n=4).
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4.4.5; Determination of EET Half-response Time
Pre-incubation of PGI^ with buffer solution at 37°C 
demonstrated a biological half-response time of 52.0 +
4.9 seconds (n=4) (Fig. 4.16). All anti-aggregatory 
activity was lost after 180 seconds pre-incubation. 
Utilising the data from both the PGI2 dose-response and 
response decay curves an estimated half-life for PGI= of 
31 seconds was obtained (range 26-38 seconds).
Application of the same technique to the EETs 
demonstrated half-response times of 6.3 + 1.3 minutes for 
5(6)-EET; 6.6 + 1.2 minutes for 8(9)-EET; 6.2 + 0.9
minutes for 11(12)-EET and 8.1 + 1.1 minutes for
14(15)—EET (all n=4) (Fig 4.17). The anti-aggregatory 
activity of the EETs was not totally abolished through 
pre-incubation. The minimal anti-aggregatory activity 
observed for 5(6)-EET was 38.0 + 3.3/C (as a percentage of 
maximum aggregation), whilst that for the 8(9)-, 11(12)- 
and 14 (15)-EETs was 29.8 + 2.17., 27.8 + 2.17. and 28.5 + 
1.07. respectively. In order to obtain an indication of 
EET-breakdown, the decay profiles were adjusted so that 
the minimal response was taken as zero (Fig. 4.18). 
Accordingly adjusted half-response times of 2.6 + 0.3, 
3.5 + 0.5, 3.8 + 0.5 and 4.5 + 0.4 minutes for 5(6)-,
8(9)-, 11(12)- and 14(15)-EET respectively were thus
obtained. The approximate 'half-lives' of the 5(6)-, 
8(9)-, 11(12)- and 14(15)-isomers were calculated as 70, 
153, 147 and 230 seconds respectively (ranges; 39-103s,
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110— 197s, 101—195s and 137-324s respectively).
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Half-response time of PGI, in platelet buffer (pH 7.35)
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Decay profile of PGI= anti-aggregatory activity in 
platelet buffer. A maximal inhibitory dose of PGI = was 
pre-incubated in 0.1ml of platelet buffer at 37°C for a 
pre-determined period of time before the addition of 
0.4ml platelet suspension. 30 seconds later a maximal 
aggregatory dose of ADP was added to the platelet 
suspension. All anti-aggregatory activity to PGI2 was 
lost after 3 minutes pre-incubation with buffer. The 
estimated half-life was 31 seconds. Values are expressed 
as a mean + SEM (n=4).
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Half-response time of EETs in platelet buffer (pH 7.35)
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Decay profile of the EET inhibitory activities in 
platelet buffer. A maximal inhibitory dose of EET was 
pre-incubated in 0.1ml of platelet buffer at 37°C for a 
pre-determined period of time before the addition of 
0.4ml platelet suspension. 30 seconds later a maximal 
aggregatory dose of ADP was added to the platelet 
suspension. 607. of the anti-aggregatory activity to 
5(6) -EET and 707. to 8(9)-, 11(12)- and 14(15)-EET
remained after 20 minutes pre-incubation with platelet 
buffer. To obtain an approximation of half-life the 
minima 1 in hi bi tory ac tivity was ad j us ted to 1007.. Va 1 ues 
are expressed as a mean + SEM (n=4).
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Adjusted half-response time of the EETs in platelet buffer (pH 7.35)
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Adjusted decay profile of the EET inhibitory activity in 
platelet buffer. Approximate 'half-lives' for the EETs 
were 70 seconds for 5(6)-EET, 153 seconds for 8(9)-EET, 
147 seconds for 11(12)-EET and 230 seconds for 
14(15)-EET. Values are expressed as a mean + SEM (n=4).
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4.5: DISCUSSION
4.5.1: Choice of Platelet Preparation
The use of washed platelets had several advantages 
over PRP. Due to the increased sensitivity of the washed 
platelets, compared to PRP, smaller quantities of drugs 
and synthetic compounds were required to induce 
responses, so reducing the demand on resources. This was 
undoubtedly true for the epoxyeicosatrienoic acids 
considering the arduous preparation and low resultant 
yields. Also by excluding plasma proteins from the 
platelet suspension, thrombin could be readily utilised 
as an aggregatory agent. Also, by avoiding the use of 
PGI= in platelet preparation, the isolated platelet 
suspension could be used immediately rather than having 
to stand for several hours for the PGI = activity to 
dec 1ine.
The 10-fold increase in responsiveness to ADP of the 
platelets following resuspension in Ca2+-free 
HEPES-Tyrodes was probably due to the absence of plasma 
proteins and enzymes found in PRP which could bind or 
metabolise the pro- and anti-aggregatory agents used. In 
the cases of the EETs, the apparently reduced potency may 
be due to epoxide hydrolase in PRP preparations (Chacos 
et a l ., 1983).
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4.5.2; H a 1f-response Time Determination
The responsive nature of washed platelets to both 
agonists and inhibitors of platelet function highlighted 
their suitability in the determination of biological 
stability of the EETs in aqueous conditions. 
Authentication of the technique, using PGI= as test 
compound, indicated it to be accurate giving an aqueous 
half-life for PGI = of 31 seconds. However, in order to 
obtain a viable estimation of half-life any break-down 
products must be physiologically inactive, indicated by 
the decay profile falling to zero. Unfortunately, the 
analysis of EET-stabi1ity was complicated by the 
anti—aggregatory activity not falling to zero. It must be 
stressed therefore that the instability profile so 
obtained for the EETs can only be used as a guidance to 
their stability in aqueous conditions. Even so, it is 
still reasonable to conclude that the life-time of these 
compounds in physiological fluids is relatively short and 
so could probably act as local mediators of physiological 
responses.
Of interest is the apparent anti—aggregatory activity 
of the degradation products, presumably the DHETs and the 
d5-lactone. Previous publications have indicated some 
biological activity for these compounds in other 
preparations (Capdevila et a l ., 1983).
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4.5.3: Effect of Indomethacin and NDGA on EET-inhibition
of Washed Platelet Aggregation
Fitzpatrick et al. (1986, 1987) demonstrated
micromolar concentrations of 8(9)-, 11(12)- and
14(15)-EETs to be anti-aggregatory in human platelets 
activated by AA. The findings reported here endorse and 
extend these findings to rat platelets stimulated by ADP 
or thrombin. Furthermore, the 5(6)-isomer also proved to 
be anti-aggregatory, this property not being reported by 
Fitzpatrick et al. (1986, 1987).
The greater potency of 5(6)-EET does not appear to be 
due to it's further metabolism by eyelo-oxygenase despite 
being a substrate for this enzyme (Oliw, 1984). Blockade 
of the eyelo-oxygenase pathway by indomethacin augmented 
EET-inhibition by all four isomers. If an 
anti-aggregatory epoxyprostaglandin is responsible for 
the greater potency of the 5(6)-isomer, then an 
attenuation of 5(6)-EET-induced inhibition of aggregation 
would have been observed in the presence of indomethacin. 
However the failure to completely block AA-induced 
aggregation by the concentration of indomethacin used 
would suggest only a partial blockade of eyelo-oxgenase 
activity was achieved. Increasing the pre-incubation 
period with indomethacin may have improved the blockade 
of AA-induced aggregation. Nevertheless, a reduction in 
5(6)-EET potency following a reduction in
eyelo-oxygenase activity would have been observed whereas
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augmentation resulted.
The absence of a significant reduction in inhibitory 
activity following NDGA- and indomethacin-induced 
blockade would suggest that further metabolism via the 
eyelo-oxygenase or lipoxygenase pathways is not 
responsible for the greater potency of 5(6)-EET. Moreover 
the other three EETs also will not act through 
eyelo-oxygenase-dependent mechanisms as they are not
substrates. The anti-aggregatory activity of these EETs
was indeed found to be unaffected by indomethacin. 
Lipoxygenase involvement in 8(9)-, 11(12)- and 14(15)-EET 
inhibition of platelet aggregation is also ruled out as 
the inhibition was not attenuated by NDGA. Thus the
biological activity of the EETs in platelets appears to 
be totally independent of these two pathways.
4.5.4; Effect of M&B 22.948 on EET-inhibition of Hashed 
Platelet Aggregation
Examination of the roles of cyclic nucleotides in the 
EET-inhibition of platelet aggregation indicated the
participation of cAMP but not cGMP. Pre-incubation of the 
platelets with M&B22,948, a specific inhibitor of 
cGMP-phosphodiesterase (Weishaar et a l ., 1986), had no 
significant effect on EET-inhibition of ADP-induced 
aggregation, whilst augmenting inhibition by NaNP. 
Pre-incubation with Papaverine, a non-selective 
phosphodiesterase inhibitor (Kramer & Wells, 1979;
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Weishaar et a l ., 1986), augmented the inhibitory effects 
of both the EETs and PGI= . However, an increased 
inhibition of platelet aggregation following
cAMP-phosphodiesterase inhibition is not surprising 
considering the central role of cAMP in suppressing 
platelet aggregation (Haslam et al., 1978). Furthermore,
the involvement of cAMP in EET-inhibition of platelet 
aggregation is disputed by their inability to increase 
cAMP levels in human platelets (Fitzpatrick et a l .,
1986). The findings that neither eyelo-oxygenase or 
lipoxygenase nor cyclic nucleotides are essential to the 
inhibitory actions of the EETs suggest an independent 
mechanism is operative.
4.5.5; Other Mechanisms to be Considered
Investigations into the biological activity of the 
EETs on human washed platelets by Fitzpatrick et a l . 
(1986) uncovered an anomaly in their apparent mechanism 
of action when compared with other anti-aggregatory
compounds. Normally, the addition of an anti-aggregatory 
agent induces a reduction in the platelet TXB= level 
brought about by an increase in cAMP levels (Malmsten et 
al., 1976; Fitzpatrick & Gorman 1979). Such a response
was not observed with EET-induced anti-aggregatory
effects. However, the phosphorylation of a 40-kDa
platelet protein, another indicator of platelet
activation (Lyons et al., 1975), was reported to behave
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as expected on exposure to the anti-aggregatory EETs 
(Fitzpatrick et al., 1986). This would suggest a 
mechanism by which the EETs could act distally to 
thromboxane synthesis, perhaps as an antagonist at the TX 
receptor. Such receptor inhibition has already been
described for other polyunsaturated fatty acids. 
Antagonism of TX receptors would block the positive 
feed-back loop of TXA= production and halt the 
propagation of platelet aggregation. The changes in
phosphorylation of a 40-kDa protein following 
EET-inhibition of platelet aggregation would suggest its 
involvement distal to TX production. Closer scrutiny of 
this divergence in effects may reveal a mechanism of
action universal to EET-induced responses.
The central role of cytosolic calcium in platelet
activation is well documented (Seiss, 1989). Associated 
with platelet activation is an increase in free cytosolic 
calcium. Of interest therefore is the reported effects of 
the EETs on Ca2+ in anterior pituitary cells (Snyder et 
a l ., 1986), canine aortic smooth muscle and rat liver
microsomes (Kutsky et a l , 1983). Exposure of anterior
pituitary cells to micromolar concentrations of 5(6)-EET 
resulted in an increase in cytosolic calcium levels. 
Similarly, exposure to 14(15)-EET increased Ca="' release 
and decreased active Ca2"*" uptake in canine aortic and rat 
liver microsomes. Such EET-induced effects would appear 
to contrast with their inhibitory effects in human and
-152-
rat platelets, where an increase in cytosolic Ca2-*" levels 
would initiate aggregation. These discrepancies suggest 
primary differences in calcium release mechanisms between 
platelets and other tissues. Furthermore, it may not be
valid to compare the actions of the EETs in an intact
physiological system such as platelets and isolated 
microsomal fractions separated from cellular influence. 
Alternatively, any calcium liberation which may be
induced in platelets could be masked or overcome by the
predominant mechanism responsible for EET anti­
aggregatory activity.
Further investigation into EET-inhibition of platelet 
aggregation is essential if we are to understand their 
inhibitory nature and resolve some of the apparent 
discrepancies between known actions.
-153-
CHAPTER 5; MICROSOMAL SYNTHESIS OF THE EETs
5.1: INTRODUCTION
The synthesis of all four EETs and their corresponding 
diols has been demonstrated utilising microsomes from 
rabbit and rat liver (Oliw et a l ., 1982; Chacos et a l ., 
1982). Furthermore 11,12- and 14,15-DHETs have been 
isolated from rabbit liver and renal cortex (Oliw and 
Moldeus, 1982), 8(9)- and 14(15)-EETs being isolated from 
rabbit whole kidney (Falck et a l ., 1987). However,
although cytochrome P4so monooxygenase has been located 
in many extrahepatic sites including the vasculature 
(Juchau et a l ., 1976; Baird et a l ., 1980; Dees et a l .,
1980; Abraham et al., 1985; Serabjit-Singh et al., 1986), 
the synthesis of EETs by these tissues has not been 
observed. Due to the lability of the EETs, demonstration 
of their syntheses at or near their site of action is 
necessary before concluding any physiological relevance 
in that tissue. For this reason attempts to demonstrate 
aortic microsomal synthesis of the EETs were pursued.
Induction and depletion of cytochrome P4ao has been 
demonstrated to affect some endothelium-dependent 
relaxations. Mono-oxygenase induction by 3-methyl- 
cholanthrene and /?-naphthoflavone caused an increase in 
AA-induced relaxation in rabbit pulmonary artery (Pinto 
et a l ., 1986) and canine coronary artery (Pinto et al., 
1987). Depletion of cytochrome P49o by cobalt chloride
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reduced AA-induced relaxations in both tissues. 
Furthermore, endothelium-dependent ACh-induced
relaxations in the rat superior mesenteric bed were 
augmented by pre-treatment of the rats with 
phenobarbitone (Pb) (Randall & Hiley, 1988), the 
concentration of cytochrome P^so being elevated following 
Pb treatment.
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5.2; METHODS
5.2.1; Preparation. Assessment and Incubation of 
Microsomes from Rat Aorta
The tissue to be examined for EET synthesis was 
removed from the animal and immediately placed in 
ice-cold phosphate buffered saline at pH 7.4. All traces 
of fat and connective tissue were removed and a 50% w/v 
tissue homogenate prepared in cold phosphate-buffered 
saline. The homogenate was centrifuged at 16,000g for 30 
minutes to remove unbroken cells, nuclear, mitochondrial 
and lysosomal debris. The supernatant was re-centrifuged 
at 100,000g for 60 minutes to sediment the microsomal 
protein. The pellet was re-suspended in fresh cold 
phosphate-buffered saline. The entire production of the 
microsomal suspension was carried out on ice or at a 
controlled temperature of 4°C.
The protein content of the microsomal suspension was
assessed using the G-250 dye binding method. In brief, a 
range of protein solutions of known concentration between
O.lmg/ml and lmg/ml were prepared from bovine serum 
albumin (BSA). To 0.1ml of each solution was added 5ml of 
fresh G-250 reagent and after 2 minutes the absorbance 
measured at 595nm. A standard plot was constructed from 
the BSA data. 10 fold serial dilutions of an aliquot of
the microsomal suspension were prepared and processed as
above. The protein content of the suspension could then
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^  \
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be determined by extrapolation from the standard plot.
Aliquots of the protein suspension were incubated with 
25ug/ml l-C3-* AA in the presence of ImM NADPH for 60 
minutes at 37°C. Any products and residual AA were 
extracted using 0.1ml ethylacetate after acidification of 
the microsomal suspension with 0.05ml 0.1M hydrochloric 
acid. The extraction was repeated twice and the organic 
phases pooled.
5.2.2; Effect of P^»c,-Induc tion on AA Metabolism
Three groups of five male Wistar rats, weight 330g to 
370g, were given either B-naphthof1avone (lOOmg/Kg/day
i.p.), phenobarbitone (75mg/Kg/day i.p.) or araclor 1254 
(50mg/Kg/day i.p.) on three consecutive days. In all 
cases the drug was suspended in 2ml olive oil. A fourth, 
control, group was injected i.p. with 2ml olive oil. On 
the fourth day the aortas from all five rats in each 
group were removed, pooled and microsomal suspensions 
prepared as described above. 0.02mg of protein fortified 
with ImM NADPH from each group was incubated with 
radiolabel led AA. The products were separated by TLC to 
11cm from the origin (solvent 35%v/v ethylacetate in 
hexane, containing 0.1% acetic acid), and an 
autoradiograph developed to visualise the metabolites 
formed. The relative product synthesis was estimated 
using an LKB 2202 Ultrascan Laser Densitometer to analyse 
the autoradiograph.
5.2.3: AA Metabolism by Rat Aortic Microsomes
20 male Wistar rats where pre-treated with 75mg/Kg
phenobarbitone on three consecutive days to induce 
cytochrome P^.so monooxygenase. On the fourth day the rats 
were killed and the thoracic aortae were removed. A 
microsomal suspension was prepared as described in
section 5.2.1 and 0.92mg microsomal protein incubated in 
the presence and absence of ImM NADPH as previously
described. Following extraction of the products and
residual AA the samples were methylated and silylated. 
Incubation products were separated using gas 
chromatography as described in chapter 2.
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5.3; RESULTS
5.3.1; Effect of Paso-Induction on Aft Metabolism
Incubation of NADPH-fortified aortic microsomes 
(0.02mg protein) from control rats, with 1-A*C 
radio-label led AA, gave products with Rf values of 0.44, 
0.29, 0.22 and 0.15. Incubation of NADPH-fortified
microsomes (0.02mg protein) from rats treated with 
inducing agents gave products with similar Rf values to 
those obtained from untreated rats. In addition a product 
with an Rf value of 0.36 was produced by NADPH-fortified 
aortic microsomes from rats pre-treated with 
phenobarbitone. This band was not produced in any 
significant quantities by microsomes from rats pretreated 
with 0-naphthoflavone, araclor 1254 or by the control 
group. Furthermore the total product formation, as 
determined by laser densitometry, by microsomes from 
phenobarbi tone treated rats (area = 6. 1/C) was greater
than that produced in the other incubations (area 
3.3-4.1/C). The band at Rf 0.44 also appeared in the 
negative control AA sample subjected to TLC (Figure 5.1). 
Analysis of the autoradiograph using laser densitometry 
clearly indicated the presence of an additional 
metabolite (Fig. 5.2). The relative intensities of the 
bands are summarised in table 5.1 (page 177).
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Autoradiograph following TLC separation showing the 
products of AA metabolism by aortic microsomes from a) 
araclor 1254 treated rats, b) phenobarbitone treated 
rats, c) b-naphthof1avone treated rats and d) control 
rats. Lane e) shows AA breakdown in the incubation 
medium.
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1 —  ^lijVIy ^
irrir*-
.73
i. 90
RUN TIME 2.47
DEFAULT 0
NORMALIZATION METHOD USING AREA
TINE HEIGHT AREA MAREA
0.28 860255 10559882 P 11.9163670
8.55 29353 311915 SP 6.3519807
0.73 104504 1567776 SP 1.7014516
0.8W 115971 1079916 S 1.2186253
0.95 8919 38858 S 0.0438493
1.85 926513 6242907 7.0448135
1.53 4806 5684 P 0.0657376
1.90 987590 41567366 P 46.9067286
2.29 987588 27363367 30.8105066
UAL 88617065 100.0000000
F I G U R E  5  - 2  <E*
Laser densitometer analysis of TLC autoradiograph from 
araclor pretreated rat aortic NADPH-fortified microsomes 
incubated with 1-A*C A A .
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1.35
1.44
2.01
RUN TIME 2.49 
DEFAULT 0
NORMALIZATION METHOD US INS AREA
TIME HEIGHT AREA JiAREA
0.33 752864 6004319 P 8.4103263
0.59 117162 716196 ? 1.0031848
0.73 178043 1591784 P 2.2296321
6.83 180653 1659656 P 2.3247013
0.99 49841 410561 P 0.5750788
1.11 846378 4244607 5.9454752
1.35 147 356 p 0.0064986
1.44 1 146 0.0002045
2.01 988875 37810757 P 52.9620180
2.38 988066 18953842 26.5488880
iTAL 71392224 108.0000000
F I G U R E  5 . 2 b
Laser densitometer analysis of TLC autoradiograph from 
phenobarbitone pretreated rat aortic NADPH-fortified 
microsomes incubated with 1 — A A . The peak at time 0.99 
represents the additional product at Rf 0.36 produced by 
phenobarbitone induced microsomes.
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UTZ
5.59
*3.73
1.97
2.08
RUN TIME 2.48 
DEFAULT 0
NORMALIZATION METHOD USING AREA
TIME HEIGHT AREA HAREA
0.32 882715 9209704 P 11.3586706
0.59 47490 363722 SP 0.4485918
8.73 88815 1186732 SP 1.4636407
0.85 109940 1201809 s 1.4822357
1.02 10888 22421 s 8.0276526
1.13 818898 4543104 5.6093459
1.42 1 1251 p 0.8015429
1.48 1 1069 p 0.0813184
1.97 988893 26874682 p 33.1455450
2.08 988102 20749413 p 25.5910230
2.33 988109 16921919 20.8704320
UAL 81030826 100.0000000
F7 I C3LJF?E: S  - 2 d
Laser densitometer analysis of TLC autoradiograph from 
b-naphthof1avone pretreated rat aortic NADPH-fortified 
microsomes incubated with 1—X*C A A .
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RUN TINE 2.46
DEFAULT 0
NORMALIZATION METHOD USING AREA
TIME HEIGHT AREA 7.AREA
0.29 748379 6138537 P 9.2491346
0.50 36190 207015 S 6.3119162
0.63 128474 1078507 P 1.6250218
0.70 114463 1421895 2. 1424157
1.03 987534 4899109 7.3816479
1. b6 988271 36754704 P 55.3795150
1.91 988266 15869004 23.9103470
ITAL 66368771 100.0000000
I G U R E  5  . 2  cd 
Laser densitometer analysis of TLC autoradiograph from 
control pretreated rat aortic NADPH-fortified microsomes 
incubated with 1 — A A .
- 1 6 5 -
1.98
•7RUN TINE
DEFAULT A
NORMALIZATION METHOD USING AREA
TIME HEIGHT AREA *AREA
G. 17 29376 243864 0.8153787
0.36 183388 2430493 P 8.1533112
0.68 48559 529027 S 1.7746658
0.88 15027 113429 P 0.3305071
1.03 20382 186577 P 0.6258883
1.18 464178 2053181 6.8875694
1.26 8196 10716 S 8.0359477
1.51 27987 557924 P 1.8716932
1.98 988377 23685534 79.4551280
)TAL 29809956 100.0000000
F I G U R E  5 .
Laser densitometer analysis of TLC autoradiograph from AA 
breakdown in the incubation medium over the time period 
of the experiment.
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Table 5.1
Rf values and band intensities from autoradiograph 
assessed by laser densitometry of the products from 
AA-incubation with rat aortic microsomes taken from a 
control group, and groups pretreated with araclor 1254, 
phenobarbitone and b-naphthof1avone (n=l).
araclor PB b-NF CONTROL
Rf •/.Area Rf •/.Area Rf '/.Area Rf XArea
AA 77.72 AA 78. 51 AA 79.61 AA 79.29
0.44 7.04 0.44 5.95 0.44 5.61 0.44 7.38
0.36 0. 58
0.29 1.21 0.29 2.32 0.29 1.48 0.29 2.14
0.22 1 .70 0.22 2.23 0.22 1 .46 0.22 1 .62
0.15 0.35 0.15 1 .00 0.15 0.45 0.15 0.31
5.3.2: AA Metabolism in Rat Aorta
The spectrum of AA-metabo1ites following incubation 
with rat aortic microsomes in the presence and absence of 
ImM NADPH was qualitatively similar. However the quantity 
of a group of products which eluted between 8 and 9 
minutes during gas chromatography (on an OV-1, 12m
capillary column) was greatly increased relative to the 
other metabolites by the addition of InM NADPH to the 
incubation medium (Fig. 5.3). The identities of these 
compounds was not ascertained.
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GC trace of phenobarbitone-induced rat aortic microsomal 
metabolites of AA in a) the presence of ImM NADPH and b) 
absence of NADPH.
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5.3; DISCUSSION
Preliminary investigations into AA-metabolism by rat 
aortic microsomes demonstrated a change in the profile of 
products formed by both Pb-induction and NADPH-
fortification of microsomal suspension. Pre-treatment of 
the test animals with phenobarbitone has been shown to 
preferentially increase the amounts of EETs synthesised 
(Oliw et a l ., 19B2), whilst NADPH is known to be
essential for cytochrome P^.»o activity. Although the 
identities of the metabolites enhanced by Pb-treatment 
and NADPH-fortification were not determined, the results 
would suggest that phenobarbitone-inducible cytochrome 
P 4 9 o activity can be found in rat aorta. Furthermore, 
although the identities of the AA-metabolites increased 
by the presence of NADPH and eluting from the GC-column 
between 8 and 9 minutes were not identified, it is 
interesting to note that the methylated EETs also eluted 
at this time. In order to reach a firm conclusion that 
the EETs are produced in aortic tissue will require the 
isolation and positive GC-MS identification of either the 
EETs or their respective DHETs against standards. 
Chemical synthesis of the DHETs and d5-lactone can be 
achieved from the EETs as described by Oliw and Moldeus
(1982).
To demonstrate the biological importance of these 
compounds in the tissues tested requires evidence of 
their in vivo synthesis. Unfortunately time prevented
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anything more than some basic preliminary investigations 
into this important topic. A detailed examination of 
microsomal AA-metabolites, especially from phenobarbitone 
pre-treated animals, may reveal the DHETs, or in the 
presence of an epoxide hydrolase inhibitor, the EETs.
-170-
CHAPTER 6: GENERAL DISCUSSION AND OVERVIEW
Biological responses to the epoxyeicosatrienoic acids 
appear to be as diverse as those observed for the other 
eicosanoids. This report describes the relaxant 
properties in two separate smooth muscle preparations as 
well as anti-aggregatory actions to all four isomers.
In addition to the intrinsic relaxant actions of the 
EETs, the 5(6)-EET may act via the eyelo-oxygenase 
pathway. This additional feature of the 5(6)-isomer is 
due to its residual B ,11,14-cis-triene configuration 
following cytochrome P4so metabolism of AA. The results 
provided here together with a report by Carroll et al 
(19BB) suggest that epoxyprostaglandins are responsible 
for at least some of the activity induced by 5(6)-EET. It 
is therefore prudent to consider such eyelo-oxygenase 
metabolism when investigating the biological actions of 
this compound. The work of Oliw (1984) identified 
5-hydroxy-PGI a.*, 5-hydroxy-PGI xt. > 5(6)-epoxy-PGFx*,
5(6)-epoxy-PGEx, 5,6-dihydroxy-PGEi and the epoxy-PG
endoperoxides as eyelo-oxygenase metabolites of 5(6)-EET. 
However the conversion of the 5(6)-epoxyendoperoxides by 
thromboxane synthetase has not been demonstrated, such 
possible production of an epoxythromboxane warranting 
investigation. Furthermore secondary conversion of the 
EETs by the lipoxygenase pathway may also have 
implications in the actions of the EETs, although NDGA 
had no effect on the EET-induced responses reported here.
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Glutathione conjugation of the EETs has been described, 
the 14(15)-EET being the preferred substrate of the four 
EETs (Spearman et al., 1985).
Although many interesting results have been obtained 
further investigations are warranted particularly with 
respect to cyclic nucleotides. The effects of the 
cGMP-phosphodiesterase inhibitor, M&B 22,948,
demonstrated the importance of cGMP in the relaxant 
actions of the less potent EETs but not in the 
anti-aggregatory actions of the EETs. In addition, 
experiments with specific cAMP-phosphodiesterase 
inhibitors may disclose cAMP-dependent effects to 
5(6)-EET in smooth muscle. The synthesis of some 
5(6)-epoxyeicosanoids, notably 5(6)-epoxy-PGE* and 
5(6)-hydroxy-PGIxS, and their subsequent bioassay would 
prove informative.
The reported increases in anterior pituitary cell 
cytosolic Ca3"** (Snyder et a l . 1986) and Ca3"" release by
liver and aortic microsomes (Kutsky et a l . 1983) would
appear to be at odds with the relaxant and 
anti-aggregatory activity demonstrated here and elsewhere 
(Carroll et al., 1987, 1988; Procter et a l ., 1987;
Fitzpatrick et al., 1986, 1987). More information
concerning the influence of the EETs on Ca3* mobilisation 
may help unify these variant actions.
Increases in cytosolic calcium were observed in 
LHRH-induced LH release and EET-induced LH-release 
(Snyder et a l . , 1983; 1986). A role for calcium as a
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second messenger in LHRH stimulation of the anterior 
pituitary rather than cAMP or cGMP has been suggested by 
Conn et al., (1981). However it could not be deduced 
whether LHRH or EET simply increased the permeability of 
the anterior pituitary cells to calcium, or induced its 
release from internal stores such as the endoplasmic 
reticulum.
The involvement of calcium as a second messenger 
rather than cAMP has also been implicated in the release 
of prolactin (Thorner et al., 1980). EET-induced 
mobilisation of calcium could account for the stimulated 
prolactin release from GH3 cells following EET exposure 
as described by Cashman et a l . (1987).
Cytochrome P*9o involvement has also been implicated 
in endothelium-dependent relaxations. AA-induced 
endothelium-dependent relaxations have been reported in 
canine coronary and superior mesenteric arteries 
(Furchgott, 1983; Pinto et a l ., 1987), rabbit pulmonary 
artery & thoracic aorta (Singer & Peach, 1983; Pinto et 
a l ., 1986) and rat thoracic aorta (Davies & Williams, 
1984). Cytochrome P^so metabolites of AA have been 
proposed as the mediators of AA-induced endothelium- 
dependent relaxations (Pinto et al. 1986, 1987),
cytochrome P4 so activity having been demonstrated in 
various blood vessels of different species (Juchua et 
al., 1976; Baird et al., 1980; Dees et a l ., 1982).
Cytochrome P*»o activity has been detected both in the 
endothelium (Abraham et al., 1985) and in the smooth
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muscle (Serabjit-Singh et a l ., 1985). Manipulations of 
the cytochrome P4so-dependent pathway were shown to alter 
the endothelium-dependent responses to AA. 3-Methyl- 
cholanthrene (3-MC) and /3-naphthof lavone ( /?-NF) which 
induce cytochrome enhanced AA-induced relaxations
whereas cobalt chloride (CoCl2 ) which is known to deplete 
cytochrome P*»o levels attenuated AA-induced responses 
(Pinto et al., 1986; 1987). ACh-induced endothelium-
dependent relaxations have also been shown to be enhanced 
by inducing cytochrome P4so with phenobarbitone in test 
animals prior to use (Randall & Hiley, 1988). In 
addition, a direct role for cytochrome P4So in 
ACh-induced relaxations has also been proposed (Rubanyi 
and Vanhoutte, 1987).
Arachidonic acid is not the only unsaturated fatty 
acid (FA) capable of inducing endothelium-dependent 
relaxations. However the doses required of the other FAs 
is much greater than that of AA (Cherry et al., 1983; 
Furchgott, 1984). It is interesting to note though that 
the next most potent unsaturated FA, docosahexaenoic 
acid, is also a substrate for cytochrome P*eo metabolism 
(Van Rollins et al., 1984) possibly indicating the 
importance of this pathway. Alternatively endothelium- 
dependent relaxations to other unsaturated FAs could be 
due to an increase in membrane fluidity (see reviews by 
Furchgott, 1983, 1984).
Over the last three years there have been two other 
reports of EET-induced biological activity and a further
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observation of EET synthesis. 5(6)-, 11(12)- and
14(15)-EET and the DHETs have been demonstrated to 
inhibit forskolin- and vasopressin-stimulated osmotic 
water flow in the toad bladder (Schlondorff et al.,
1987). The 5(6)- and 11(12)-isomers were roughly 
equipotent, 14(15)-EET being less so. Increased levels of 
cAMP in the bladder following vasopressin or forskolin 
stimulation were found to be attenuated by the EETs. This 
attenuation of cAMP formation by the EETs was parallelled 
by their ability to decrease water flow across the
bladder. All the effects observed appeared to be 
independent of PG production. Of interest was the ability 
of 11(12)-EET to inhibit cAMP or 8-BrcAMP induced water 
flow, indicating an additional mechanism of action for
this isomer independent of cAMP. The activity of the 
8(9)-isomer was not investigated.
Secondly, incubation of arachidonic acid with
microsomes of bovine adrenal fasciculata cells, in the 
presence of NADPH, resulted in the production of DHETs 
and w-hydroxylation products (Nishimura et a l ., 1989). 
Althought the EETs were not identified in the incubate, 
the appearance of their hydrolysis products suggested 
they were synthesised (Oliw et a l ., 1982). However, only 
the 14(15)-DHET was identified following AA-incubation 
with fasciculata cells, and the (w-1)-hydroxylation was 
not identified in either incubations. Investigation into 
the pharmacological activities of the EETs in the 
fasciculata cells revealed a positive effect on cortisol
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production by all four compounds. Maximal stimulation of 
steriodogenesis was obtained with the 14(15)-isomer at 
micromolar concentrations.
The synthesis of 5(6)- and 8(9)-EET together with a 
host of other oxygenated NADPH-dependent AA-metabolites 
in human isolated epidermal cells has recently been 
described by Holtzman et a l . (1989).
The discovery of a third metabolic pathway for 
arachidonic acid may have many implications. The EETs 
have already been shown to have biological properties, 
the final spectrum of which could be as broad as the 
eicosanoids. Furthermore, due to the inducible nature of 
their synthetic pathway, these cytochrome P4so products 
may take a more prominent role where long term 
administration of P^oo-inducing drugs or environmental 
xenobiotics are concerned.
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APPENDIX 1; REAGENTS. BUFFERS AND EQUIPMENT
Reagents;
Acetylcholine chloride — Sigma 
Adenosine Diphosphate - Sigma 
Arachidonic acid - Sigma
Arachidonic acid - Amersham 
Bovine serum albumin - Sigma 
m-Chloroperoxybenzoic acid - Sigma 
Indomethacin - Sigma
M&B 22,948 - May & Baker Laboratories (Gift)
Reduced Nicotinamide Adenine Dinucleotide Phosphate 
(NADPH) - Sigma 
b-Naphthof1avone - Sigma
Nordihydroguaiaretic acid (NDGA) - Sigma 
Phenobarbitone - Sigma
Phenylephrine HC1 - Koch-Light Labs Ltd 
Prostacyclin - Welcome (Gift)
Prostaglandin Ei - Sigma
SKF525A - Smith, Kline & French Laboratories (Gift) 
Sodium Nitroprusside - BDH 
Thrombin - Sigma
Buf fers;
Coomassie G-250 Dye Binding Reagent:
iOOmg Coomassie G-250 dye dissolved in 50ml of 957. 
ethanol
add 100ml of 857. w/v phosphoric acid 
make to 1 1  with distilled water.
HEPES-Tyrodes:
NaCl 137mM
KC1 2.7mM
NaHC03 
NaH-PCU 
MgCl = 
Glucose 
HEPES
12mM 
0. 4mM
ImM
5. 5mM 
lOmM
Krebs
NaCl
Glucose
NaHCOrs
MgS0^.7H=0
KH3PCU
CaCl2 .6H30
KC1
118.4mM 
11.ImM 
25.OmM 
1 .2mM 
1 .2mM 
2. 6mM 
4. 7mM
-Al-
Phosphate Buffered Saline:
1 1 -9g Na^HPCU.2 H = 0  made to 1 1  with normal saline 
9.1g KH 2 PO 4  made to 1 1  with normal saline 
final sol" —  85.2ml Na^HPQ^.2H=0 sol" : 14.8ml 
KH=PCU sol", pH 
adjusted to 7.4 using HC1 or NaOH.
Equipment:
TLC plates - Watman LK5D channelled silica plates, 
0.25mm thick, particle size 60 Angstrom.
X-ray Photographic plates - Kodak XAR-351
Developing solutions - Kodak fixer
Kodak Dektol Developer
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APPENDIX 2; RESULT TABLES TO ACCOMPANY GRAPHS
Table A3.2: PE-induced contraction of rat aortic strips in the presence and absence of an intact 
endothelial lining.
PE Endothelius i No EndotheliuR
conc. MEAN + SEM (n) ; MEAN + SEM (n)
10-’ 3.3 + 1.4 (14)
3x10“’ 1.7 + 0.9 (17); 23.8 + 4.0 (14)
10-® 22.3 + 2.8 (17); 66.0 + 1.8 (14)
3xl0"8 58.3 + 2.3 (17); 83.8 + 0.5 (14)
io-7 78.7 + 1.2 (17); 91.3 + 0.8 (14)
3xl0-7 89.7 + 0.3 (17); 95.8 + 1.7 (14)
10-* 96.7 + 0.7 (17); 100.0 + 0.0 (14)
3xl0‘A 100.0 + 0.0 (17);
e c 90 2.5 + 0.i x io-8 ; 7.3 + 0.4 x 10-’
Table A3.3: NaNP-induced relaxation of PE pre-contracted rat aortic strips in the presence and 
absence of an endothelial lining.
NaNP EndotheliuR ! No EndotheliuR
conc. MEAN ♦ SEM (n) ; MEAN + SEN (n)
lO-io 3.7 + 1.2 (15)1 3.3 + 0.9 (15)
3xl0-1° 12.0 + 0.6 (is): 10.5 + 1.8 (15)
10"’ 42.3 + 1.8 (15): 38.8 + 3.3 (15)
3x10-’ 72.3 + 1.8 (is); 70.3 + 3.1 (15)
10"8 93.3 + 2.3 (15); 90.5 + 2.7 (15)
3xl0"8 101.3 ♦ 0.9 (is): 97.8 + 1.6 (15)
io-7 104.0 + 0.0 (is): 102.3 + 1.9 (15)
e c 90 1.6 + 0.1 x 10-’ 1.8 + 0.2 x 10-’
Table A3.4: EET-induced relaxation of PE pre-contracted rat aortic strips with intact 
endotheliuR.
EET
conc.
5(6)-EET I 8(9)-EET 
MEAN + SEN (n) I MEAN + SEN (n)
_  _ r i— _
11(12)-EET 
MEAN + SEM (n)
14(15)-EET 
MEAN + SEM (n)
3x10-’
i
11.3 + 3.0 (4) ;
io-8 19.0 + 4.0 (4) ;
3xi0-8 43.3 + 3.5 (4) I
io-7 88.8 + 3.1 (4) I
3xl0-7 98.8 + 1.6 (4) I
io-* ; 17.0 + 2.0 (4) 10.0 + 2.0 (3) 5.7 + 1.5 (3)
3x10“* ; 34.3 + 3.2 (4) 16.3 i  2.3 (3) 13.3 + 1.2 (3)
io-s ; 73.3 + 5.1 (4) 79.0 + 1.0 (3) 56.3 + 0.9 (3)
3x10"* ; 93.0 t  0.9 (4) 
_ _ _ _ _ _ _ _ _ _ _ _ 1_ _ _ _ _ _ _ _ _ _ _ _
99.3 + 3.4 (3) 95.3 + 2.2 (3)
e c 90
J
3.9 + 0.6 x IO"8 I 5.2 + 0.7 x 10~* 6.7 + 0.2 x 10-* 8.6 + 0.2 x 10-*
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Table A3.5: EET-induced relaxation of PE pre-contracted rat aortic strips with no endothelial
lining.
EET 5(6)-EET B(9)-EET 11(12)-EET 14(15)-EET
conc. MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n) MEAN + SEN (n)
io-8 12.0 + 3.9 (4)
3x10-° 27.3 + 7.2 (4)
io-7 56.0 + 7.6 (4)
3xi0"7 84.3 + 2.1 (4)
io-* 97.0 + 2.5 (4) 16.0 + 9.5 (3) 5.0 + 2.1 (3) 1.7 + 1.7 (3)
3xi0-6 36.0 + 9.0 (3) 18.0 + 2.0 (3) 7.7 + 4.4 (3)
io-9 73.0 + 8.0 (3) 80.0 * 1.5 (3) 56.7 + 6-4 (3)
3xl0“9 90.3 + 5.2 (3) 98.0 + 2.1 (3) 98.0 + 4.0 (3)
e c 90 8.2 + 1.8 x 10"8 4.7 t 1.7 x IO"6 6.5 + 0.2 x 10"6 8.9 + 0.8 x IO"6
Table A3.7a: EET-induced relaxation of PE pre-contracted intact rat aortic strips in the 
presence of 3xiO“6M indoaethacin.
EET 5(6) -EET 8(9) -EET 11(12)-EET 14(15)-EET
conc. MEAN + SEM (n) MEAN t SEM (n) MEAN + SEM (n) MEAN + SEM (n)
IO"8 4.0 + 2.6 (4)
3xl0"8 :! 23.3 + 3.4 (4)
io-7 :1 59.5 + 6.2 (4)
3xl0“7 j: 80.3 + 3.6 (4)
IO"6 i: 92.8 + 4.2 (4) 14.0 + 3.0 (4) 9.0 + 3.5 (4) 6.5 + 3.8 (4)
3xio-6 :11 41.0 ♦ 7.3 (4) 20.8 + 4.7 (4) 14.0 + 3.5 (4)
io-9 ;11 71.5 + 6.4 (4) 74.5 + 6.2 (4) 58.0 + 5.8 (4)
3xio-9 :11 95.5 + 4.2 (4) 97.8 + 1.3 (4) 97.0 + 3.0 (4)
e c 80 :
1
7.5 + 1. 0 x 10"8 4.5 + 1.6 x IO"6 6.7 + 0.7 x IO"6 8.5 + 0. 8 x IO"6
Table A3.7b: EET-induced relaxation of PE pre-contracted de-endothelialised rat aortic strips in 
the presence of 3xlO~6M indoaethacin.
EET
conc.
5(6}-EET 
MEAN + SEM (n)
B(9)-EET 
MEAN + SEM (n)
11(12)-EET 
MEAN + SEM (n)
14(15)-EET 
MEAN + SEN (n)
IO"7 11.3 + 3.9 (4)
3xl0"7 24.5 + 6.0 (4)
IO"6 42.5 + 6.8 (4) 19.3 + 7.2 (3) 5.3 + 5.3 (3) 5.0 + 2.6 (3)
3xl0"6 86.0 + 5.2 (4) 29.3 + 5.8 (3) 17.0 + 4.0 (3) 10.7 + 5.3 (3)
IO"9 92.8 + 4.6 (4) 78.0 + 6.7 (3) 77.0 + 6.1 (3) 62.3 + 9.3 (3)
3xl0~9 87.3 + 4.7 (3) 93.0 + 3.6 (3) 96.3 + 3.7 (3)
e c 80 1.2 + 0.3 x 10"6 5.1 + 0.9 x IO"6 6.4 + 0.5 x IO"6 8.1 + 1.1 x IO"6
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Table A3,8: EET-induced relaxation of intact PE pre-contracted rat aortic strips exposed to
lxl0"6M NDGA.
EET 5(6)-EET 8(9)-EET li(12)-EET 14(15)-EET
conc. MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n)
3xi0"9 12.8 + 3.3 (4)
10"8 20.8 + 4.2 (4)
3xl0~® 47.8 + 3.5 (4)
10“ 7 87.5 + 3.3 (4)
3xl0"7 96.3 + 2.1 (4)
10"6 15.0 + 3.6 (4) 15.5 + 2.9 (4) 14.8 + 3.2 (4)
3xi0~6 35.3 + 4.5 (4) 25.5 + 4.9 (4) 23.0 t 4.8 (4)
10"9 73.0 + 4.5 (4) 78.3 + 4.0 (4) 56.3 + 5.5 (4)
3xi0-9 90.3 t 3.0 (4) 94.3 + 1.9 (4) 90.8 + 2.3 (4)
e c 80 3.1 + 0.7 x IO"8 4.8 + 0.8 x 10-* 5.9 + 0.6 x 10'* 7.7 + 1.1 x IO'6
Table A3.9: PE-induced contraction of rat aortic strips with an intact endothelial lining in the 
presence and absence of 3xl0"*M M&B 22,948,
PE
conc.
No M&B 22,948 
MEAN + SEM (n)
3xi0'6 M&B 22,948 
MEAN + SEM (n)
IO” 0.8 + 0.5 (6)
3x10-’ 5.0 + 1.1 (6)
10“8 50.8 + 5.4 (6)
3xl0-8 74.8 + 3.1 (6) 4.5 + 1.3 (6)
io-7 89.0 + 2.0 (6) 35.3 + 2.5 (6)
3xl0-7 95.3 + 1.1 (6) 73.8 + 3.9 (6)
10*A 99.5 + 0.5 (6) 90.0 + 4.4 (6)
3x10“* 98.8 + 1.3 (6)
ECso 9.8 + 0.7 x 10-’ 1.7 + 0.1 x IO'7
Table A3.10: ACh-induced relaxation of PE pre-contracted rat aortic strips with an intact 
endothelial lining in the presence and absence of 3xi0“6M M&B 22,948.
ACh No M&B 22,948 3xl0"4• M&B 22
C
O
conc. MEAN + SEM (n) MEAN + SEM (n)
lO-io 3.8 + 1.9 (6)
3xlO“ 10 11.0 + 2.6 (6)
10-’ 4.8 + 1.5 (6) 18.3 + 4.1 (6)
3x10-’ 10.8 + 2.5 (6) 48.5 + 3.5 (6)
io-8 39.0 + 4.0 (6) 82.5 + 4.1 (6)
3xl0~8 70.3 + 3.5 (6) 93.8 + 2.2 (6)
O
1 91.0 + 1.5 (6) 98.3 + 1.2 (6)
3xl0"7 97.0 + 1.2 (6)
io-* 99.8 + 0.3 (6)
e c 90 1.7 + o.;3 x 10“8 3.1 + 0.
O'1o•»—HXr-
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Table A3.11: NaNP-induced relaxation of PE pre-contracted rat aortic strips with an intact
endothelial lining in the presence and absence of 3xi0"*M MSB 22,948.
NaNP No MSB 22,948 3xl0-< MSB 22 ,948
conc. MEAN + SEM (n) MEAN + SEM (n)
10-“ 1.3 + 0.8 (6)
3x10'“ 6.0 + 1.6 m
lO-io 2.0 + 0.8 (6) 14.0 + 2.1 (6)
3xlO“ 10 13.3 + 1.3 (6) 31.8 + 3.6 (6)
IO"’ 32.5 + 3.8 (6) 64.0 + 3.8 (6)
3x10"’ 70.8 3.1 (6) 88.3 + 2.9 (6)
io-8 94.0 + 2.1 (6) 97.0 + 1.7 (6)
3xl0"8 99.8 + 1.5 (6) 100.8 + 2.3 (6)
IO"7 102.3 + 1.0 (6)
e c 90 2.0 + 0. 2 x 10-’ 7.0 + 0. 8 x IO"10
Table A3.12: EET-induced relaxation of de-endothelialised rat thoracic aortic strips in the 
absence of MSB22,948.
5{6)-EET 
MEAN + SEM (n)conc.
4.3 (4
3.9 (4
2.7 (4
8(9)-EET 
MEAN ♦ SEM (n)
11(12)-EET 
MEAN + SEM (n)
14(15)-EET 
MEAN + SEM (n)
4.3 + 3.3 (4) 1.3 + 0.8 (4
12.8 + 4.6 (4) 4.3 + 2.6 (4) 9.3 + 3.5 (4
35.8 + 4.0 (4) 25.8 + 4.2 (4) 27.3 + 5.0 (4
69.5 + 6.0 (4) 74.3 + 5.9 (4) 64.8 + 6.0 (4
89.8 + 4.1 (4) 94.3 + 2.8 (4) 92.8 + 3.8 (4
i.9 + 0.9 x 10"* 6.5 + 0.7 x 10"* 7.2 + 1.0 x 10--
Table A3.12: EET-induced relaxation of de-endothelialised rat thoracic aortic strips in the 
presence of HSB22,948.
EET
conc.
5(6)-EET 
MEAN + SEM (n)
8(9)-EET 
MEAN + SEM (n)
11{12)-EET 
MEAN + SEM (n)
14(15)-EET 
MEAN + SEM (n)
3x10-’ 6.3 + 2.4 (4)
IO"8 19.0 + 4.4 (4)
3xl0-8 32.0 + 5.9 (4)
IO"7 56.3 + 6.2 (4) 11.5 + 3.7 (4) 3.5 + 2.3 (4) 6.5 + 4.5 (4)
3xl0'7 82.8 + 5.1 (4) 25.5 + 5.0 (4) 13.3 + 2.6 (4) 19.0 + 3.4 (4)
io-* 97.0 + 2.1 (4) 40.8 + 6.7 (4) 23.5 + 4.7 (4) 32.8 + 5.7 (4)
3x10"* 86.5 + 4.2 (4) 80.5 + 4.7 (4) 73.8 + 4.6 (4)
10"s 92.3 + 2.8 (4) 93.3 + 2.5 (4) 91.8 + 3.9 (4)
e c 90 7.8 + 1-8 x IO"8 1.2 + 0.3 x IO"* 1.8 t  0.2 x IO"* 1.6 + 0.2 x 10"*
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Table A3.14: Acetylcholine-induced contraction of guinea-pig tracheal rings in the presence and
absence of 3xlO"*N Indoaethacin.
ACh No Indoaethacin 3x10-'* Indo.
conc. MEAN + SEN ( n) MEAN + SEN ( n)
IO'7 0.22 + 0.04 (11) 0.15 + 0.05 (13)
3xl0“7 0.50 + 0.07 (11) 0.52 + 0.11 (13)
io-* 0.92 + 0.13 (11) 1.22 + 0.18 (13)
3xl0~* 1.37 + 0.20 (11) 2.02 + 0.23 (13)
10“a 1.B3 + 0.25 (11) 2.77 + 0.27 (13)
3x10-* 2.33 + 0.29 (11) 3.42 + 0.30 (13)
io-4 2.88 + 0.39 (11) 3.73 + 0.38 (13)
Table A3.15: NaNP-induced relaxation of guinea-pig tracheal rings in the presence and absence of 
3xlO-‘H Indoaethacin.
NaNP No Indoaethacin 3x10- * Indo.
conc. MEAN +• SEN (n) HEAN + SEN (n)
io-7 5.1 + 0.8 (7)
____
4.6 + 1.1 (8)
10"* 44.9 + 2.7 (7) 29.1 + 2.8 (8)
io-» 93.3 4.4 (7) 68.2 + 2.4 (8)
IO*4 99.7 + 5.1 (7) 74.8 + 2.2 (8)
io-3 100.4 + 4.3 (7) 75.6 + 2.4 (8)
ECS0 2.0 + 0. 5 x 10-*
mmmm 
3.0 + 0.6 x 10-*
Table A3.16: EET-induced relaxation of ACh pre-contracted guinea-pig tracheal rings in the 
absence of 3xlO"*M Indoaethacin.
EET
conc.
5(6)-EET 
HEAN + SEN (n)
B(9)-EET 
MEAN + SEN (n)
11(12J-EET 
HEAN + SEN (n)
14(15J-EET 
MEAN + SEN (n)
IO"7 3.0 ♦ 1.2 (8)
3xl0-7 8.0 ♦ 3.6 (B)
io-* 27.4 + 4.7 (8)
3x10-* 44.8 + 3.7 (8) 13.8 + 8.5 (5)
io-* 55.6 + 5.3 (8) 2.0 + 0.3 (5) 22.8 + 9.3 (5) 5.6 ♦ 1.5 (4)
3x10"* 60.6 + 5.0 (8) 9.6 ♦ 4.3 (5) 30.8 + 7.5 (5) 14.3 + 1.7 (4)
10-* 42.6 + 0.7 (5) 48.0 + 11.0 (5) 46.3 + 1.1 (4)
3xl0-4 93.0 + 12.1 (5) 98.6 + 0.6 (5) 72.5 + 6.5 (4)
io-3 82.5 + 5.5 (4)
EC,0 1.3 + 0.5 x 10-* 7.3 I 0.4 x 10-* 2.8 + 1.6 x 10"* 6.4 + 0.3 x 10-*
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Table A3.17: EET-induced relaxation of ACh pre-contracted guinea-pig tracheal rings in the
presence of 3xl0~6H Indoisethacin.
EET
conc.
5(6)-EET 
HEAN + SEH (n)
8(9)-EET 
HEAN + SEH (n)
11(12)-EET 
HEAN + SEH (n)
14(15)-EET 
HEAN + SEH (n)
10"6 5.3 + 4.0 (4)
3xl0-6 11.3 + 4.9 (4)
10"9 28.0 + 11.9 (4) 7.0 + 4.4 (3) 4.0 + 1.0 (3) 4.0 + 3.1 (3)
3x10"® 32.3 + 2.3 (4) 7.0 + 4.4 (3) 16.3 + 5.2 (3) 11.0 + 2.1 (3)
10-4 63.0 + 3.3 (4) 33.8 + 6.0 (3) 40.0 + 10.5 (3) 35.0 + 7.8 (3)
3xl0-4 76.3 I 4.0 (4) 88.0 + 13.9 (3) 89.3 + 10.7 (3) 54.5 + 13.5 (3)
10"3 69.5 i  11.5 (3)
ECso 4.3 + 0.6 x 10"9 1.4 + 0.3 x 10-4 1.2 + 0.3 x 10“4 9.9 + 1.8 x IO"9
Table A3.20: EET-induced relaxation of ACh-precontracted guinea-pig tracheal rings in the 
presence of lx!0"4H ND6A.
EET 5(6)-EET B(9)-EET 11(12)-EET 14(15)-EET
conc. HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n)
I O " 7 6.8 + 3.2 (4)
3xl0"7 9.3 + 1.9 (4)
10"A 28.8 + 3.4 (4)
3x10"® 43.8 + 6.1 (4)
i o - 9 51.8 + 5.8 (4) 3.5 + 2.9 (4) 14.3 + 2.9 (4) 3.8 + 2.3 (4)
3x10-® 56.0 + 3.6 (4) 11.5 + 4.3 (4) 25.5 + 5.5 (4) 18.3 + 5.1 (4)
I O " 4 48.0 +  5.1 (4) 50.8 + 5.6 (4) 43.8 +  5.4 (4)
3xl0"4 89.5 + 4.3 (4) 96.8 + 3.0 (4) 77.0 + 6.3 (4)
I O ' 5 97.3 +  2.2 (4) 97.8 +  2.3 {4) 84.0 + 5.0 (4)
e c 90 9.7 +  1 . 1  x I O " 7 1.0 + 0.1 x 10~4 9.5 + 1.6 x IO"9 9.5 + 1.5 x 10~9
Table A3.21: NaNP-induced relaxation of guinea-pig tracheal rings in the presence and absence of 
lxlG"*H M B  22,948
NaNF' No H6B 22,948 ! ixl0"6H H&B22,948
conc. HEAN + SEH (n) !
_I
HEAN + SEH (n)
10-’
1
11
_
3.0 + 2.7 (4)
i o - 8 3.8 + 1.8 (4) ! 7.8 + 1.7 (4)
10‘7 6.5 + 2.5 (4) j; 21.3 + 6.4 (4)
10-6 47.5 + 6.5 (4) ! 87.0 + 4.8 (4)
10-9 91.5 + 3.3 (4) !; 96.0 + 2.3 (4)
10-4 98.0 + 2.0 (4) !1i
i_
EC S0 1.3 + o.<
1
4 x 10-* !
i
4.7 + 0.8 x i0“7
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Table A3.22: EET-induced relaxation of ACh-precontracted guinea-pig tracheal rings in the
absence of M&B 22,948.
EET 5(6)-EET 8(9)-EET 11(12)-EET 14(15)-EET
conc. MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n) MEAN + SEH (n)
1G“7 4.5 + 2.1 (4)
3xl0"7 10.8 + 4.1 (4)
<01o—H 26.3 + 4.2 (4)
3x10"* 41.5 + 4.5 (4)
IO"8 52.5 + 3.3 (4) 8.0 ♦ 3.6 (4) 12.8 + 3,1 (4) 3.0 + 1.9 (4)
3xl0~9 58.8 i 2.7 (4) 10.8 + 4.0 (4) 27.3 + 4.7 (4) 10.8 + 6.1 (4)
i o - 4 41.0 + 4.6 (4) 44.0 + 6.0 (4) 47.3 + 4.5 (4)
3xiO“4 92.5 + 5.0 (4) 90.0 + 4.6 (4) 78.8 I 4.9 (4)
10-3 96.5 + 2.9 (4) 96.3 + 2.2 (4) 86.3 + 3.8 (4)
ECao 1.4 + 0.6 x 10-* 1.3 + 0.2 x 10"4 1.2 + 0.3 x IO"4 9.2 + 0.9 x 10"9
Table A3.22: EET-induced relaxation of ACh-precontracted guinea-pig tracheal rings in the 
presence of lxlO"*M M&B 22,948.
EET 5(6) -EET 8(9) -EET 11(12)-EET 14(15)-EET
conc. MEAN + SEM (n) MEAN + SEH (n) MEAN + SEM (n) MEAN + SEM (n)
i o - 7 4.3 ♦ 1.9 (4)
3xl0“ 7 7.0 + 3.4 (4)
10"* 20.5 I 4.0 (4) 5.0 + 2.4 (4) 12.3 + 1.8 (4) 6.3 + 2.8 (4)
3x10"* 39.3 + 4.2 (4) 13.B + 4.8 (4) 19.3 + 4.8 (4) 11.8 + 4.6 (4)
10"8 55.3 + 4.2 (4) 24.5 + 4.7 (4) 33.3 + 5.0 (4) 23.3 + 4.1 (4)
3xl0~s 60.5 + 2.5 (4) 34.0 + 4.6 (4) 46.0 + 4.9 (4) 37.8 + 6.5 (4)
10"4 82.5 + 5.5 (4) 89.5 + 5.5 (4) 76.8 + 2.9 (4)
3xl0‘4 94.0 + 3.5 (4) 97.8 + 2.3 (4) 83.8 + 2.6 (4)
ECao 2.0 + 0. 4 x 10"* 4.9 t 0.7 x 10"9 3.5 + 0.8 x 10"9 3.7 + 1. 2 x 10"9
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Table A4.1: ADP-induced aggregation of rat platelet rich plasua
ADP I Aggregation
conc. HEAN + SEM (n)
4xl0-6 1.5 + 1.2 (7)
8xl0-8 24.8 + 4.1 (7)
1.2xl0-a 45.0 + 3.0 (7)
1.6xl0-3 64.5 + 3.7 (7)
2x10-8 85.5 + 5.0 (7)
3x10-8 98.0 + 2.0 (7)
ECso 1.3 + 0. 1 x IO'9
Table A4.2: EET inhibition of rat platelet rich plassa aggregation induced by ADP
EET 5(6) -EET 8(9) -EET 11(12)-EET 14{15)-EET
conc. MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n) MEAN + SEM (n)
io-6 2.5 + 2.5 (4)
IO"3 28.3 + 4.8 (4) 10.5 + 1.8 (4) 9.5 4.6 (4)
.5x10-8 53.3 + 5.3 (4)
2x10-8 78.8 + 4.1 (4)
3x10-8 98.0 + 1.1 (4) 7.0 2.0 (4) 23.0 + 4.9 (4) 26.3 + 3.9 (4)
5x10-8 19.0 + 4.7 (4) 36.5 + 4.8 (4) 42.8 + 4.4 (4)
7x10-8 34.5 + 5.9 (4) 75.3 + 5.4 (4) 60.8 + 5.3 (4)
10"4 61.3 + 2.5 (4) 93.0 + 3.3 (4) 92.5 + 2.9 (4)
2X10-4 90.0 + 4.2 (4) 98.8 + 1.3 (4) 98.5 + 1.2 (4)
ECao 1.4 + 0. 1 x IO'8 8.2 i0. 6 x IO"9 5.7 + 0.3 x IO"8 5.7 + 0.5 x IO"9
Table A4.3: ADP-induced aggregation of rat washed platelets
ADP I Aggregation
conc. MEAN + SEM (n)
3xl0-7 0.8 + 0.5 (10)
4xl0-7 17.8 + 4.2 (10)
5xl0-7 56.8 + 3.6 (10)
7xi0“7 74.0 + 2.5 (10)
IO"4 95.0 + 3.2 (10)
3xl0-6 99.8 + 0.3 (10)
ECso 4.8 + 0. 1 x 10"7
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Table A4.4: Thrombin-induced aggregation of rat washed platelets (conc. in NIH units/sl).
Throib. I Aggregation
conc. HEAN + SEH (n)
0.053 0.5 + 0.5 (8)
0.106 12.3 + 3.1 (8)
0.212 28.3 * 2.7 (8)
0.424 61.8 + 3.4 (8)
0.636 96.5 + 2.4 (8)
0.848 100.0 + 0.0 (8)
ECso 0.349 + 0.019
Table A4.5: EET inhibition of rat washed-platelet aggregation induced by ADP
EET 5(6) -E E T 8(9) -E E T 11(12) -EET 14(15) -EET
conc. MEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n)
lO"7 25.5 + 7.4 (4)
5xl0'7 52.8 + 8.0 (4)
io-4 84.0 + 6.7 (4) 9.7 + 9.7 (3) 7.0 + 7.0 (3) 5.0 + 2.5 (3)
.5x10-* 92.8 + 3.8 (4)
2x10-* 95.8 + 2.4 (4)
5x10"* 33.3 + 12.5 (3) 35.3 + 13.7 131 35.3 + 8.7 (3)
io-9 66.7 + 8.1 (3) 68.0 + 8 .4 (3) 70.0 + 12.5 (3)
.5xl0~9 81.7 + 5.2 (3) 86.7 + 6.3 (3) 76.7 + 0.9 (3)
2xl0'9 88.0 + 6.0 (3) 93.0 + 4.0 (3) 81.0 + 3.0 (3)
ECso 4.2 + 1. 2 x IO"7 6.6 + 1. 9 x 10-* 6.7 + 2. 0 x IO'4 5.7 i 1. 1 x 10‘4
Table A4.6: EET inhibition of rat washed-platelet aggregation induced by Thrombin.
EET 5(6) -E E T 8(9)-EET 11(12) -EET
conc. HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n)
IO"7 1.3 + 0.9 (4)
5xl0"7 39.8 + 13.1 (4)
IO"4 69.5 + 10.5 (4)
l.SxlO-4 81.8 + 6.4 (4)
2xl0-4 100.0 + 0.0 (4)
5xl0-4
IO'9 2.3 + 1-9 (3) 1.0 + 1.0 (3)
2xl0~s 9.3 + 2.3 (3) 37.7 + 7.5 (3)
3xl0’9 37.0 + 8.1 (3) 86.3 + 8.2 (3)
4xl0-9 47.0 + 5.8 (3) 95.0 + 1.0 (3)
5xl0"9 94.0 + 5.0 (3) 97.6 + 1.9 (3)
6xl0-9 96.9 + 1.0 (3)
ECso 6.7 + 1.9 x IO"7 4.0 + 0.8 x 10~9 2.2 + 0.3 x IO"9
14(15)-EET 
HEAN + SEH (n)
3.7
28.7
63.3
87.0
98.0
+ 3.7 (3) 
+ 17.4 (3) 
+ 13.6 (3) 
+ 7.2 (3) 
+ 2.0 (3)
100.0 + 0.0 (3)
1.6 + 0.5 x 10-®
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Table A4.8: The effect of Indoaethacin on EET-induced anti-aggregatory activity.
EET ; 5{6)-EET 
HEAN + SEH (n)
8(9)-EET ! 
HEAN + SEH (n) !
11(12)-EET ; 
HEAN + SEH (n) !
14(15)-EET 
HEAN + SEH (n)
change ! 15.8 + 11.0 (3) 11.3 + 4.2 (3) ; 7.1 + 3.5 (3) ! 18.9 + 2.4 (3)
Table A4.9: The effect of NDGA on EET-induced anti-aggreqatory activity.
EET ! 5(6)-EET { 8(9)-EET ! 11(12)-EET \ 14(15)-EET 
! HEAN + SEH (n) \ HEAN + SEH (n) J HEAN + SEH (n) ; HEAN + SEH (n)
’ i l l< 1 
change ! 43.9 + 6.2 (3) J 17.1 +
f i
1.1 (3) ! 22.9 + 2.9 (3) \ 27.6 ♦ 1.8 (3)
Table A4.ll: PGEi-induced inhibition of rat washed-platelet aggregation induced by
PGEi
conc. HEAN + SEH (n)
10-’ 9.5 + 3.4 (4)
3x10-’ 22.3 + 6.0 (4)
10"8 49.5 + 6.4 (4)
3xl0-8 73.5 + 5.0 (4)
io-7 83.5 + 5.7 (4)
3xl0-7 93.0 t  3.4 (4)
e c 90 1.0 + 0.5 x IO"8
Table A4.12: P6I2-induced inhibition of rat washed-platelet aggregation induced by
P6I2
conc. HEAN + SEH (n)
3xlO-10 5.8 + 0.9 (6)
10-’ 11.5 + 2.1 (6)
3x10-’ 45.8 + 3.4 (6)
6x10-’ 72.5 + 6.0 (6)
10"8 94.3 + 1.4 (6)
3xl0-« 99.8 + 0.3 (6)
EC8o 3.5 + 0.4 x 10"’
Table A4.14: The effect of Papaverine on PSI2-induced anti-aggregatory activity.
EET J P6I2
i1 HEAN + SEH (n)
change 32.8 + 0.9 (4)
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Table A4.13: NaNP-induced inhibition of rat washed-platelet aggregation induced by ADP
NaNP
conc. HEAN + SEH (n)
3x10"* 2.0 + 0.7 (8)
10-9 24.0 + 3.9 (8)
3xl0"9 43.3 + 3.9 (8)
10"4 74.3 + 3.1 (8)
3x10— 4 88.5 + 2.9 (8)
10“3 95.0 + 1.1 (8)
e c 90 3.9 + 0.8 x IO"9
Table A4.15: The effect of H&B 22,948 on NaNP-induced anti-aggregatory activity.
EET ; NaNP
HEAN + SEH (n)
change J 43.0 + 2.1 (4)
Table A4.14: The effect of Papaverine on EET-induced anti-aggregatory activity.
EET
change
5(6)-EET 
HEAN + SEH (n)
31.5 + 1.3 (4)
8<9)-EET 
HEAN + SEH (n)
17.0 + 1.1 (4)
11(12J-EET 
HEAN + SEH (n)
43.3 + 1-7 (4)
14{15)-EET 
HEAN + SEH (n)
24.3 + 0.6 (4)
Table A4.15: The effect of H£B 22,948 on EET-induced anti-aggregatory activity.
EET
change
5(6)-EET 
HEAN + SEH (n)
1.3 + 1.0 (4)
8(9)-EET 
HEAN + SEH (n)
0.5 + 1.6 (4)
11(12)-EET 
HEAN + SEH (n)
1.3 + 1.2 (4)
14(15)-EET 
HEAN + SEH (n)
2.0 + 1.0 (4)
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Table A4.16: Half-response ti*e of P6I? in platelet buffer solution deterained by platelet 
aggregation,
Tiae
(secs) HEAN + SEH (n)
0 100.0 + 0.0 (4)
15 86.0 + 2.1 (4)
30 68.0 + 1.4 (4)
60 43.5 t  4.3 (4)
90 21.5 + 2.0 (4)
120 4.8 + 1.6 (4)
180 0.0 * 0.0 (4)
52.0 * 4.9 secs
Table A4.17: Half-response tiae of the EETs in platelet buffer solution deterained by platelet 
aggregation.
TIHE 5(6) -EET 8(9) -EET 11C12)-EET 14{15)-EET
(ains) MEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n)
1 87.0 * 2.1 (4) 91.5 + 1.6 (4) 90.0 + 2.6 (4) 95.5 + 2.4 (4)
2 78.5 + 3.0 (4) 81.5 + 2.0 (4) 81.8 + 2.7 (4) 89.3 + 2.2 (4)
3 63.0 ♦ 4.4 (4) 68.5 + 3.7 (4) 70.0 + 3.7 (4) 79.5 I 4.2 (4)
5 53.5 + 4.4 (4) 54.0 + 3.8 (4) 54.0 + 4.3 (4) 59.5 + 3.6 (4)
10 39.5 I 2.9 (4) 41.3 ♦ 2.5 (4) 36.8 t 1.5 (4) 44.0 + 3.5 (4)
15 38.0 + 3.3 (4) 32.5 + 1.3 (4) 29.5 + 2.0 (4) 33.3 + 3.2 (4)
20 39.8 ♦ 2.1 (4) 29.8 + 2.1 (4) 27.8 + 0.9 (4) 29.8 + 2.3 (4)
25 28.5 + 1.0 (4)
6.3 ♦ 1 .3 ains 6.6 + 1 .2 ains 6.2 + 0 .9 ains 8.1 + 1 .1 ains
Table A4.18: Adjusted half-response tiae of the EETs in platelet buffer solution
platelet aggregation.
TIHE 5(6)-EET 8(9)-EET 11(12}-EET 14(15)-EET
(ains) HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n) HEAN + SEH (n)
1 79.0 + 3.4 (4) 87.9 + 2.3 (4) 86.1 + 3.6 (4) 93.7 + 3.4 (4)
2 65.3 + 3.8 (4) 73.6 + 2.8 (4) 74.8 + 3.7 (4) 85.0 + 2.9 (4)
3 40.3 + 7.1 (4) 55.1 i 5.3 (4) 58.4 + 5.1 (4) 71.3 + 5.9 (4)
5 25.0 + 7.1 (4) 34.5 + 5.4 (4) 36.3 + 6.0 (4) 43.4 + 5.0 (4)
10 2.4 + 4.7 (4) 16.4 + 3.6 (4) 12.5 + 2.1 (4) 21.7 + 4.9 (4)
15 0.0 + 5.3 (4) 3.8 ♦ i-9 (4) 2.4 + 2.8 (4) 6.7 + 4.5 (4)
20 0.0 + 3.0 (4) 0.0 + 1.2 (4) 1.8 + 3.2 (4)
25 0.0 + 1.4 (4)
2.6 + 0.3 ains 3.5 + 0.5 ains 3.8 + 0.5 ains 4.5 + 0.4 ains
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Table A4.1B: 'Half-life' of the EETs deterained using inhibition of platelet aggregation.
5(6)-EET 8(9)-EET 11(12)-EET 14(15)-EET
70X Resp. Tiael 99 132 138 186
(Range) secs. (84-116) (120-144) (124-154) (160-210)
70% Resp. Conc. 7.8xl0-7 1.1x10-’ l.lxlO"9 1.0x10-’
Ha If-conc. 3.9xl0'7 5.5x10-* 5.5x10"* 5.0x10-*
Half-conc. Resp. 45 37 39 35
Half-conc. Tiae2 169 285 285 416
(Range) secs. (155-187) (254-317) (255-319) (347-484)
Tiae 1 - Tiae 2 70 153 147 230
(Range) secs. (39-103) (110-197) (101-195) (137-324)
Table A4.16: 'Half-life' of P612 deterained using inhibition of platelet aggregation.
P6I2
70% Resp. Tiael 28
(Range) secs. (27-29)
70X Resp. Conc. 5.7x10-’
Half-conc. 2.9x10-’
Half-conc. Resp. 44
Half-conc. Tiae2 59
(Range) secs. (55-65)
Tiae 1 - Tiae 2 31
(Range) secs. (26-38)
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